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EXPRESSION AND FUNCTION OF INFLAMMATION-ASSOCIATED MICRORNAS IN 
TRAUMATIC BRAIN INJURY 
Emily Brooke Harrison, Ph.D. 
University of Nebraska, 2016 
Advisor: Dr. Howard S. Fox., M.D., Ph.D.  
MicroRNAs (miRNAs) are important regulators of gene expression. Many neurological diseases, 
including traumatic brain injury alter expression of miRNAs in the brain. However, the function 
of these molecules in the context of TBI is largely unknown. Here we report multiple potential 
roles for miRNAs in TBI, some of which extend beyond the traditional model of post-
transcriptional regulation, highlighting that these RNA molecules may have broader implications 
for the neurobiology of disease. We found that miR-155 plays an essential role in interferon 
expression after CCI and that miR-155 contributes to TBI induced anxiety, potentially through 
regulation of interferons. Expression of miR-155 was identified in neuronal nuclei, suggesting 
additional roles for miR-155 in the neuronal response to injury that may be outside of traditional 
gene silencing. Similarly, we found that miR-21 was also expressed in neurons. In addition, miR-
21 levels were elevated in extracellular vesicles (EVs). Novel roles have recently been elucidated 
for miRNAs carried in EVs, including stimulation of toll-like receptor 7/8 (TLR 7/8). We 
identified 3 differentially expressed EV-associated miRNAs with motifs known to mediate TLR 
7/8 binding. This suggests that EV-associated miRNAs may act as damage associated molecular 
patterns (DAMPs) in TBI. Overall, we have identified multiple potential roles for miRNA in TBI 
that warrant further study.  
 In other studies we found that neurotrophic cytokines IL-6 and CNTF could elicit both 
Stat3 phosphorylation and miR-21 induction in human neurons, providing a possible mechanism 
for miR-21 induction in many models of neuronal injury. Additionally, we identified disinhibition 
and hyperactivity as chronic phenotypes of a mouse model of TBI. This finding will allow for 
future mechanistic studies of TBI induced impulsivity.  
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Chapter 1: Introduction 
 
The last decade has bought the eye of the public on traumatic brain injury (TBI). TBI has 
been called the signature injury of the wars in Iraq and Afghanistan, with millions of 
veterans suffering a distinctive set of symptoms caused by both penetrating and blast 
injuries [1, 2]. Meanwhile, a major class action lawsuit against the National Football 
league was prompted by the discovery of chronic traumatic encephalopathy in American 
football players. Together these circumstances have heightened public awareness and 
bought to light that even relatively mild brain injuries, such as concussions, can have 
severe consequences.  
In the midst of all the media and public attention, many scientific advances are 
being made in our understanding of the brain and how it responds to injury. One element 
that unifies all TBI from mild to severe is the presence of neuroinflammation. As in all 
types of injury, inflammation plays a reparative role to clear damaged tissue and fight 
potential infection, but excessive inflammation can result in tissue damage and 
dysfunction.  
This work is an investigation into the regulation of neuroinflammation in the 
context of traumatic brain injury. Though several molecular classes coordinate to 
produce an inflammatory response, we have chosen to focus on post-transcriptional 
regulation by microRNAs (miRNAs). Functionally, miRNAs bind to their messenger RNA 
targets reducing production of corresponding proteins. Translational silencing by 
miRNAs is accomplished by complimentary base pairing to target transcripts, typically 
found in the 3’ UTR. Using this mechanism a single miRNA can bind multiple targets. 
These targets can range in the hundreds, making miRNAs powerful regulators of the cell 
proteome. Recent studies in knockout mice have revealed that ablating certain miRNAs 
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can result in impaired or overactive immune function, showing that these molecules are 
critical regulators of the immune response [3]. While the importance of miRNAs in the 
peripheral immune response is increasing recognized, what role they play in the unique 
immune environment of brain injury remains largely unexplored. The overall aim of this 
work was to characterize the regulatory role of inflammation-associated miRNAs in the 
injured brain and determine their effect on brain recovery and cognitive function after 
TBI.  
 
1.1 Traumatic brain injury  
Traumatic brain injury is a leading cause of death and disability worldwide [4]. In 2009, 
the Center’s for Disease Control and Prevention (CDC) estimated that 2.4 million people 
were diagnosed with TBI [5]. This is likely an underestimate as many TBIs, especially 
mild injuries, go unreported. Broadly defined TBI is any injury to the head that disrupts 
brain function. This includes closed head injuries where the head is struck by or against 
an object as well as jolts to the head that cause forward/reverse or rotating movement of 
the brain within the skull. Approximately 75% of TBIs are mild; concussions being 
included in this category [6]. Often mild TBI are left unreported and untreated. However, 
as is now realized with sports concussion, repeated mild TBI can cause motor and 
cognitive deficits. More severe forms of TBI are those that cause skull fractures or result 
from penetration of the brain with an object, such as a bullet. Although the most severe 
injuries are associated with penetration of the brain, diffuse axonal injury can also be 
severe and sometimes fatal.   
The immediate consequences of traumatic brain injury include loss of 
consciousness, hemorrhage, edema, and ischemia. Surgical intervention is sometimes 
required and improvements in surgical techniques and more informed treatment 
guidelines have resulted in increasing survival rates [7]. But still, a diagnosis of TBI was 
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found in 30.5% of injury rated fatalities [6]. Even when patients survive a TBI, the long 
term effects can be disabling. It is estimated that 5.3 million people in the U.S. alone are 
living with TBI associated disabilities including cognitive and psychological dysfuntion 
[8].  
The evaluation of TBI takes many forms and is highly dependent on the timing of 
evaluation. Severity of brain injury in the acute period is traditionally classified by the 
Glasgow comma scale (GCS), which takes into account impairment in speech, motor 
function, and loss of consciousness [9]. Several retrospective studies have called into 
question the reliability of the GCS, yet it is still a common tool for describing the severity 
of TBI [10]. Since the introduction of the GCS in 1974 [9], new technologies, such as 
computed tomography (CT) scans, have allowed for more physiological and reliable 
indicators of injury severity [11]. Other measures are more useful during the in-patient 
rehabilitation, also called the sub-acute phase. The functional independence measure 
(FIM) is most useful during this period. Scores on the FIM range from “complete 
independence to “total assistance” [12]. Another outcome measure with utility during the 
sub acute phase is the Craig handicap assessment and reporting technique (CHART) 
which measures physical independence, cognitive independence, mobility, social 
integration, occupation, and economic self sufficiency [13]. During the chronic phase 
after patients have been discharged the expanded Glasgow outcome scale (GOS) is the 
most commonly used outcome measures in clinical trials [14]. GOS is useful to 
determine positive or negative outcome (Table 1.1). The community integration 
questionnaire (CIQ) is also helpful to determine community integration after TBI [15]. 
One measure that can be useful to span the acute through chronic phases of TBI is the 
disability rating scale (DRS), which includes measures that range from “eye opening” 
and “motor response” to “toileting” and “employability [16].” To determine the 
neuropsychological impairment the composited neuropsychological score (CNPS) is  
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Table 1.1 
  
Glasgow Outcome Scale (GOS) 
1 Good Recovery  Return to normal life and employment. Some deficits, but 
lack of disability 
2 Moderate Disability  Disabled, but independent. Return to work is dependent on 
special arrangements 
3 Severe Disability Dependent on daily support due to mental or physical 
disability or a combination of the two 
4 Vegetative State Unaware with only reflex responses.  
5 Death Self described 
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used. This test measures visuoconstruction and memory, oral fluency, sustained 
attention, and fine motor dexterity [17]. While many of the measures describe here show 
better accuracy then the GOS or measure different aspects of outcome, this is the 
primary measure used for research purposes and clinical trials.  
The physical damage caused by a TBI can be divided into two categories the 
immediate mechanical damage (primary injury) and the events that occur in the wake of 
that primary injury (secondary injury). Primary damage can further be separated into 
focal damage that consists of contusion, laceration, and intracranial hemorrhage and 
diffuse damage resulting from acceleration/deceleration events, including diffuse axonal 
injury. Secondary damage includes ischemia and increased intracranial pressure as well 
as changes in neurochemistry, metabolism, and inflammation that can lead to neuronal 
cell death and dysfunction [18]. After survival of the primary insult any further decrease 
in neurological function or consciousness is due to secondary injury mechanisms. While 
eliminating or reducing primary damage is the goal of preventative efforts, once a 
traumatic brain injury has occurred, little can be done to reduce the primary damage. 
Instead therapeutic efforts are focused on the secondary damage that occurs after TBI. 
However, despite extensive research, there has not been any proven therapeutic 
treatment developed to reduce secondary damage after TBI. Many excellent reviews 
cover in detail the various secondary injury mechanisms [19, 20], but for our purposes 
here, we will focus on inflammation.  
 
1.2.1 Neuroinflammation and TBI 
After TBI there is marked elevation of activated resident glia including microglia and 
astrocytes. Increased cytokines and chemokine release from these resident cells in the 
acute time frame after TBI recruits peripheral immune cells such as neutrophils, 
macrophages, and T cells. Other than perivascular macrophages and resident microglia 
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the brain is normally free of other immune cells, however the damage caused by TBI, 
including disruption of the blood-brain barrier (BBB), allows the infiltration of peripheral 
immune cells. The multicellular response to TBI is described in figure 1.1. As in other 
types of injury, inflammation in TBI plays a dual role [21]. The phagocytic properties of 
microglia, neutrophils and macrophages helps to clear damaged tissue and these and 
other leukocytes reduce the risk of infection. Activated glia, including microglia and 
astrocytes, can also produce neuroprotective and neuroregenerative factors. However, 
the production of inflammatory molecules by infiltrating peripheral immune cells as well 
as glia, including cytokines and chemokines, nitric oxide (NO), and reactive oxygen 
species can also have detrimental effects on neuronal function. Even though both 
negative and positive components are present, generally anti-inflammatory agents 
improve TBI outcomes in animal models [22].  
The front line of the cellular response to TBI is resident microglia. Microglia are 
highly sensitive to even subtle changes in the local environment. For example, microglia 
can be activated by molecules usually confined to the cellular compartment such as 
purine nucleotides [23], as well as neurotransmitters [24], and even changes in ion 
homeostasis [25]. First described by Rio-Hortega in 1932, resting microglia in a non-
pathological brain have a small cytoplasm relative to other cells in the brain and delicate, 
ramified processes. Recent two-photon microscopy experiments have shown that 
microglial processes are constantly moving, surveying the local environment [26]. Upon 
activation microglial morphology rapidly changes, processes become stumpy or “bushy” 
and the cell body can even become amoeboid to the point were it is undistinguishable 
from a peripheral mononuclear cell [27].  
Activation of microglia results in proliferation, migration, secretion of soluble 
factors and electrophysiological changes [22]. Proliferation and migration result in  
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Figure 1.1 
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Figure 1.1 Inflammatory response to TBI. This figure demonstrates the time course of 
inflammation, activation of resident glia and recruitment of peripheral immune cells to the 
lesion site following TBI (A). Within minutes to hours cytokines, damps, and chemokines 
are released from the damaged tissue and neutrophils are recruited to the injury stie (B). 
By 1 day post injury (dpi) neutrophils have invaded the brain tissue and monocytes are 
being recruited to the brain tissue (C). By 3 dpi peripheral monocytes have begun 
differentiation into macrophages and activated microglia and astrocytes are present at 
the lesion site, but the neutrophils are now nearly undetectable (D). At 10 dpi the 
immune response has largely subsided, however activated astrocytes and macrophages 
are still present at the lesion site [28].   
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increased numbers of microglia at sites of injury. Factors secreted by microglia upon 
activation include inflammatory cytokines, proteases, free-radicals and growth factors.  
Primary among microglia-secreted cytokines is IL-1β, which in turn, can induce of 
IL-6 and TNFα in an autocrine and paracrine manner [29]. In addition to glial cells, 
neurons carry receptors for IL-6, TNFα, and IL-1β, which can mediate effects in neurons 
[30, 31]. Although classically neurons are thought to be damaged by inflammatory 
cytokines [32], there is growing evidence that these same cytokines may be necessary 
for neuroprotective and neuroregenerative effects likely in a concentration dependent 
manner [33]. In addition to cytokines, free radicals such as NO are secreted by microglia 
and likewise cause both beneficial and detrimental effects to their neuronal neighbors 
[34]. To add further complexity microglia secrete neurotropic factors such as NGF, 
BDNF, and NT3 [35-37] in addition to proteases, which can clear the damaged 
extracellular matrix but can also exacerbate BBB dysfunction [38].  
Overall, the interaction between neurons and microglia is complex and multi-
faceted. There is no doubt that the conversation is two-sided with neurons signaling 
microglia, which in turn modulate neuronal function [39]. While inhibiting inflammation 
can improve outcomes in brain injury models, the effects of anti-inflammatory agents are 
not specific to microglia [22]. One clue to the balance of microglial effects in 
neuroinflammation is the work of Heppner et al. in experimental autoimmune 
encephalitis, a mouse model of multiple sclerosis [40]. In this study a mice were 
genetically altered to “paralyze” microglial activation. This microglial paralysis repressed 
the development of experimental autoimmune encephalitis. While similar studies are yet 
to be performed in studies of TBI, accumulating evidence suggests a detrimental 
pathological role for microglia in neuroinflammation.   
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Astrocytes also undergo morphological changes and activation, but they have a 
distinctly different role from microglia in CNS pathology. In the non-diseased CNS 
astrocytes control homeostasis of ions, neurotransmitters, water, and blood flow and 
play a role in neural circuit formation. The morphology of protoplasmic astrocytes, the 
type that predominates in the grey mater, consists of short, branched processes in close 
proximity neuronal synapses [41]. Unbranched, fibrous astrocytes are found in the white 
mater and function to maintain mylenated axons [42]. Astrocytes also regulate the BBB, 
completely ensheathing capillaries [43]. Interestingly, astrocytes do not function as 
indepent cells, but are connected in a vast network by gap junctions [44]. The primary 
pathological marker of a reactive astrocyte in neuroinflammatory conditions is the 
increased expression of intermediate glial fibrillary acidic protein (GFAP) [45]. Evidence 
points to mechanical forces as the impetus for astrocyte activation after TBI [46]. The 
activation of astrocytes occurs very early after injury, causing ATP release and 
subsequent microglial activation [47]. However, astrocytes also serve to wall-off inflamed 
tissue from healthy or salvageable tissue by formation of a glial scar [48]. Glial scar 
formation is also required for repairing the damaged BBB after TBI. As important players 
in the synapse, astrocytes also maintain neural circuits and promote synaptic remolding 
after injury [46]. This beneficial effect also has a counter-point in that through their effect 
on synapses after TBI, astrocytes may also promote epileptogenesis [46].  As with 
microglia, astrocytes have duplicitous role in TBI pathology. And again genetic studies in 
mouse models are beginning to elucidate whether these cell types provide net benefit or 
detriment. An elegant genetic study in a mouse model of TBI showed exacerbated tissue 
loss with ablation of reactive astrocytes [49]. All together evidence points to a net 
protective role for reactive astrocytes in TBI. 
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While activation of resident neuroglia occurs almost instantaneously after TBI, in 
the subsequent hours and days peripheral immune cells are also recruited to the site of 
injury. The recruitment of peripheral immune cells is a result of several factors, increased 
permeability of the BBB, secretion of cytokines and chemokines by neural cells, and 
increased expression of adhesion molecules. The integrity of the BBB relies on tight 
junctions between epithelial cells and is reinforced by astrocytic end-foot processes [50]. 
After TBI the BBB is damaged by both primary and secondary injury mechanisms. 
Mechanical forces can affect the physical integrity of the BBB and activation of 
astrocytes can reduce their contribution to the stability of the BBB [51]. The leakiness of 
the BBB allows for infiltration of peripheral immune cells and these cells are attracted to 
the lesion site by cytokines and chemokines secreted by brain resident cells. Primary 
among TBI induced chemokines are CXCL8, CCL2, CXCL12, CXCL10, CX3CL1, and 
CCL5, though this is not a complete list [28]. In addition to permeability and increased 
chememotactic agents, adhesion molecules are upregulated by TBI. Adhesion 
molecules, such as glycoproteins and intergrins are upregulated by cytokines IL-1β, 
TNFα, and IL-6 [52]. Together BBB permeability, chemoattractants and adhesion 
molecules result primarily in recruitment of neutrophils and mononuclear cells, though 
small populations of T cells and natural killer cells call also be detected after TBI [28].  
Neutrophils arrive at the lesion site within 12 hours of injury [53], while peak 
levels of mononuclear cells are found 3 days after injury [54]. Tissue destruction after 
TBI is predominately due to neurotrophils and this cell type causes significant toxicity 
through respiratory burst [55]. However, attempts to block neutrophil accumulation have 
not shown any benefit in animal models of TBI [56-58]. Therefore focus has shifted to 
targeting monocyte recruitment. One chemokine, chemokine receptor target for 
intervention in monocyte infiltration into the brain is CCL2/CCR2. Early studies targeting 
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the CCL2/CCR2 chemokine and receptor axis have shown both histological and 
functional improvements in rodent models and reduced monocyte levels in the brain [59, 
60]. While other chemokine and chemokine receptor systems are altered after TBI in 
humans and in rodent models, their functions in TBI are not well studied. Of note are 
CXCL10 and CCL5, which are elevated after TBI. Both CCL5 and CXCL10 are known to 
play a role in T-cell recruitment, but their importance for TBI pathophysiology is still 
unknown [28].   
 Taken as a whole the immune response to TBI has several distinct elements 
that are highly interconnected. The release of DAMPs together with mechanical shear 
forces disrupts brain homeostasis, this sets off the activation of resident glia which 
secrete a suite of cytokines, chemokines, reactive oxygen species, proteases, and 
growth factors. These factors, particularly chemokines, recruit peripheral immune cells to 
cross the damaged BBB. Once in the brain, these neutrophils, monocytes, T cells and 
dendritic cells assist in clearing damaged tissue and preventing infection, meanwhile 
releasing neurotoxic inflammatory cytokines and reactive species that further exacerbate 
neuronal injury. In rodent models genetically ablating or targeting different molecules or 
cell types within this orchestral production has a variety of effects. Reducing microglial 
activation generally improves outcomes, while inhibiting reactive astrocytes worsens 
them. Inhibiting neutrophil migration and infiltration seems to have little effect, but 
targeting monocyte recruitment reduces neurological deficits. It is evident that 
inflammation following TBI has a large impact on TBI pathophysiology. A clearer 
understanding of the role of individual cell types and molecules in the inflammatory 
response to brain injury may provide potential therapeutic targets for TBI.  
 
1.1.2 Long-term consequences of TBI  
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While therapeutic strategies are currently focused on the acute period after TBI there are 
millions of people in the U.S. alone already living with long-term disabilities related to a 
TBI [8, 61]. A 2008 literature survey by the National Academy of Sciences concluded 
that there was a strong association between moderate to severe TBI and dementia, 
Parkinsonism, endocrine dysfunction, growth hormone insufficiency, depression, anxiety, 
aggression, and social dysfunction [62]. TBI is also associated with an increased risk of 
epilepsy [63]. A moderate to severe TBI increases the odds of developing a psychiatric 
illness 4 fold in the following 6 months [64]. Among psychiatric disorders depression is 
the most common, with estimates that 33% of TBI patients experience depression [65]. 
Moreover, TBI is often associated with aggression, social isolation, and joblessness [66, 
67]. It is likely that these outcomes are linked to increased impulsivity observed in TBI 
patients [68]. While most of the available literature draws strong associations with severe 
and penetrating injuries and subsequent neuropsychological dysfunction we now know 
that repeated mild concussions can also produce increased aggression, motor 
dysfunction, and suicidality, now recognized as chronic traumatic encephalopathy (CTE) 
[69-71]. A handful of recent reports have also identified increased levels of Attention-
deficit/hyperactivity disorder ADHD in both children [72] and adults [73]. There is no 
doubt that TBI can have negative life long consequences which cause great burdens to 
the individual, their families, and society as a whole. However, the pathophysiology 
behind these long-term neuropsychological changes and increased risk of 
neurodegeneration is only beginning to be understood.  
 The pathological hallmark of CTE is progressive tauopathy [71]. Many 
neurodegenerative diseases are considered tauopathies, most prominent among them 
Alzheimer’s disease [74]. One marked difference between Alzheimer’s pathology and 
that of CTE is the localization of tau tangles. While in Alzheimer’s disease these 
pathological features are found concentrated in the hippocampus, in CTE they are found 
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in the sulci, superficial cortical layers, and often in a perivascular arrangement; all points 
of mechanical trauma. Recent work by Johnson et al. Identified tau and amyloid-β 
pathology in post-mortem brains decades after a single TBI [75]. This work suggests that 
tau accumulation may contribute to the cognitive dysfunction and neurodegeneration 
associated with a single TBI, not only repetitive mild TBI as seen in CTE. Aside from tau 
deposition, pathological hallmarks of long-term survivors of TBI are reactive microglia 
and white matter degeneration that persists for as long as 18 years after a single TBI 
[76]. It is unclear whether the inflammatory response causes the white matter 
degeneration, or vise versa and what relationship both may have to tauopathy in 
survivors of TBI.  
Interestingly, inflammation is associated with both neuropsychological 
dysfunction and neurodegeneration outside the context of TBI [77]. It is generally 
accepted that inflammation can cause or exacerbate not only depression, but anxiety, 
and schizophrenia [78-81]. Early studies of the link between inflammation and 
depression after TBI show that inflammatory markers may be associated with risk of 
post-traumatic depression [82, 83]. Further mechanistic and epidemiological studies are 
necessary to understand the link between persistent neuroinflammation and post-
traumatic neuropsychiatric dysfunction. 
 
1.1.3 Modeling of TBI in rodents 
To date there are no drugs proven in clinical trials to ameliorate the effects of TBI. In 
order to discover novel drug targets and test the efficacy of therapeutic approaches pre-
clinical models are necessary. While some models in large mammals such as pigs are 
being developed to better replicate the mechanical features of the human brain, most 
pre-clinical studies are performed in rodents. In general, rodent models replicate 
pathological features of human TBI including reactive glia, peripheral cell infiltration, 
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contusion, edema, hemorrhage, and white matter damage. Rodent models of TBI can 
also recapitulate some of the behavioral and cognitive changes observed in TBI patients. 
One difficulty in any clinical study of TBI is the heterogeneity of injuries found in patients. 
Injuries can be caused by different types of impact with differing amounts of force and be 
localized to different areas of the brain. To represent these diverse injury types a large 
number of animal models have been developed.  
While subtle variations of each model exist four primary models are prominent in 
the field. These are the fluid percussion injury (FPI), controlled cortical impact (CCI), 
weight-drop, and blast models [84]. For the FPI model a craniotomy is performed to 
expose the dura and then a fluid reservoir is placed into the opening and struck with a 
pendulum [85]. The CCI model also employs a craniotomy, but is followed by a 
mechanical impact driven pneumatically or electromagnetically [86]. Relative to the FPI, 
CCI offers more control of injury parameters and thus injury severity. The depth, dwell 
time, and speed of the impact can be controlled with a CCI injury, while only the height 
of the pendulum can be adjusted in the FPI model. One commonality of FPI and CCI is 
the use of both unilateral and bilateral injury models. Interestingly, unilateral injury 
models tend to consistently injure the left hemisphere, most often in the parietal 
sensory/motor cortex. While there does not seem to be any compelling reason for this 
practice, it is standard in the field. Our studies utilized the CCI model to create a 
unilateral injury to the parietal cortex (Fig 1.2) In contrast to FPI and CCI, the weight 
drop model can be either an open or closed head injury. One draw back of this model is 
its use of a gravity driven weight dropped down a guide. Therefore, the mechanical 
parameters can only be altered by changing the height at which the weight is dropped. 
One advantage of this method is the ability to model closed head injury in human 
patients and produce varying degrees of diffuse axonal injury. Blast injury models are  
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Figure 1.2 
  
5 days post TBI 
1 
Craniotomy 
Unilateral injury to 
left sensorimotor 
cortex 
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Figure 1.2 Description of controlled cortical impact (CCI) model of TBI. Mice are 
anesthetized and placed in a sterotactic frame. A craniotomy is performed exposing the 
intact dura. A piston driven by either air pressure or electromagnetic force is used to 
impact the brain. The speed, depth, and dwell time of the piston can be adjusted to 
create different severities of injury. This injury can be either unilateral of bilateral 
depending on placement of the craniotomy. Depending on injury severity CCI causes 
cortical or cortical and hippocampal tissue loss, shown here at 5 days after injury.  
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growing in popularity as these are able to mimic the diffuse axonal injury, changes and 
intracranial pressure, and cognitive deficits seen in human blast trauma [87, 88].  
Although these are the primary models, several lesser-used variations are worth 
noting. The penetrating ballistic-like brain injury is designed to have similar pathology to 
a gunshot wound or other projectiles with high energy and a leading shockwave [89]. 
Additionally a number of mild repetitive injury models have also been devised. One such 
model modified a closed-head weight drop approach, but used repeated mild impacts. 
Even this relatively mild trauma showed both histological and behavioral signs of brain 
damage [90]. The incredible diversity of human TBI is reflected in the many animal 
models of TBI. However, this diversity of models is also problematic for the field. 
Conducting reproducible animal behavior experiments across labs is already difficult 
[91], and in TBI research this issue is compounded by the fact that many labs have their 
own unique injury model. Differences in species and strain, gender, and age all add up 
to a large degree of variation in TBI outcomes. Therefore, finding a pharmacological or 
therapeutic approach that is effective across multiple models presents a high bar for pre-
clinical testing. The benefit of this high diversity is that it more accurately models the 
human condition and will hopefully lead to development of new agents that will prove 
effective in clinical trials. This is the goal of Operation Brain Trauma Therapy (OBTT), a 
consortium consisting of multiple TBI preclinical groups. The goal of this consortium is to 
test the efficacy of agents that have shown promise in pre-clinical testing across a large 
number of models and institutions to identify the most promising candidates for clinical 
trials [92].  
In addition to a large diversity of injury models, there are also a myriad of 
outcome measures used by various laboratories. The main themes among these 
measures are lesion size, motor dysfunction, and cognitive dysfunction (Fig 1.3). Several 
of the injury models mentioned above result in brain tissue loss that can be measured  
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Figure 1.3 
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Figure 1.3. Outcome measures for clinical and pre-clinical testing at different 
phases after TBI. Several outcome measures are available to measure deficits in 
patients after TBI. However, the Glagow Outcome Scale is by far the most common for 
clinical trials. In rodent models of TBI outcome is measured primarily during the acute 
(hours to days) and sub acute (weeks) phases and relies heavily on motor function. Both 
human clinical trials and mouse pre-clinical trials have struggled to show any 
improvement in TBI outcomes. One possible cause is the lack of sensitive outcome 
measures. In rodents, preclinical modeling of the chronic phase is still underdeveloped. 
Developing meaningful outcome measure for chronic TBI in rodents may provide a more 
representative model for the human condition.       
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histologically or by magnetic resonance imaging (MRI). Tissue loss, or lesions, are found 
in the FPI and CCI models and some versions of the weight-drop model, but are absent 
in blast injury. Tissue loss is a result of apoptosis and necrosis of brain tissue as well as 
destruction of tissue by immune cells. In these models, lesion size correlates to 
behavioral deficits [93, 94].  
Behavior assessment can occur anytime spanning the acute, sub acute, and 
chronic phases of TBI and most measures change dynamically within this time frame. 
The neurological severity score or NSS was developed as a counterpart to the Glasgow 
outcome scale, and has several iterations. Generally this is a mix of various motor skills, 
such as the ability to walk on various size beams, startle response, ambulation, hemi-
paresis. Other motor behaviors often used in the literature include beam walking tasks 
and rotarod testing [95]. The most common cognitive test used in TBI models is the 
Morris water maze, though novel-object testing and Barnes maze have also been used 
[96]. While there is a wealth of literature on lesion size, motor, and cognitive function in 
the acute (< 7 d) and sub-acute (7 d-28 d) time period, relatively little is know about the 
persistence of chronic (> 28 d) deficits in rodent models. Also, considering that 
neuropsychiatric dysfunction is linked to TBI, little is known about the presence of 
neuropsychological changes in TBI models, especially in the chronic period. 
Identification of depression, anxiety, impulsivity, or aggressive phenotypes in TBI models 
could not only provide a tool for testing treatment strategies, it would also provide insight 
into the pathophysiology of these conditions. For example, is inflammation related to 
post-traumatic depression? Does white matter degeneration contribute to 
neuropsychiatric dysfunction? Clearly, given the personal and economic burden of TBI 
associated personality changes and neuropsychiatric dysfunction this is an area 
demanding further research.  
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1.2 The biology of miRNAs 
 
The 1990s brought about several landmark discoveries regarding non-coding, 
but functional RNA. Xist RNA was shown to regulate X chromosome inactivation [97] 
and the first long non-coding RNA, murine H19 was discovered [98]. During this time, 
work in C. elegans uncovered that a crucial developmental gene, lin4, encoded a 22bp 
RNA that was responsible for post-transcriptional regulation of mRNA transcripts. Soon 
after several genes exhibiting this pattern emerged and were named microRNA (miRNA) 
for their small size. Lin-4, the first miRNA discovered, shows many features that we now 
understand to be typical of miRNA. Lin-4 regulates lin-14 through anti-sense sequences 
in the 3’ UTR of lin-14, but does not decrease levels of Lin-14 transcript, suggesting that 
it prevents translation without causing mRNA degradation. Also, there are long (60 nt) 
and short (22 nt) gene products, which correspond to different stages of microRNA 
processing.  Since this initial publication more than 28,500 miRNA have been discovered 
in a wide variety of species (miRNbase.org) many, like let-4, are involved in 
development; however, miRNAs are known to regulate many diverse physiological 
processes. The essential nature of miRNAs is highlighted by the fact that mice lacking 
the Dicer enzyme necessary for processing miRNA die at embryonic day 7.5 [99]. 
The transcription and processing of miRNA is complex, and can be regulated at 
many levels.  Some miRNA genes are found within non-coding regions of host-genes, 
while others carry their own promoter sequences. RNA polymerase II is the primary 
polymerase for miRNA transcription. Once a miRNA is transcribed, the primary miRNA 
forms a stem-loop structure, which is cleaved within the nucleus by a multiunit complex 
containing Pasha and Drosha to form an ~70 nt pre-miRNA product [100]. Once 
exported from the nucleus, the pre-miRNA is further processed into its mature form by 
the enzyme Dicer as part of the RNA-induced silencing complex (RISC) loading complex 
(RLC). Aside from Dicer the RLC includes Tar RNA binding protein (TBP), protein 
	   	   	  23 
activator of of PKR (PACT) and Argonaut 2 (Ago2). After cleavage occurs and the 
mature miRNA is formed Dicer, TBP, and PACT dissociate from the RLC, leaving the 
active RISC, which mediates gene silencing [101]. RISC stabilizes the miRNA and helps 
guide it to complimentary sequences on target mRNA molecules. Once bound to its 
mRNA target miRNA induces either degradation or sequestration of the target transcript 
causing a reduction in protein production [102]. A single microRNA is capable of 
targeting hundreds of mRNA and a single mRNA can be targeted by multiple miRNA. 
This creates a highly complex system for regulating the proteome of the cell [103]. While 
this scenario represents the canonical view of miRNA function, the picture becomes 
increasingly complex with further investigation. Reports of miRNA increasing protein 
translation in certain circumstances [104] and regulating transcription in the nucleus 
[105] open the possibility for many nontraditional functions for these molecules. 
The expression of mature miRNA molecules can be regulated transcriptionally or 
at the stage of processing. Transcriptionally, miRNA can be regulated by the promoter 
sequences that control the host gene, or by independent promoters. Often miRNA are 
regulated temporally by negative feedback loops where the transcription factor inducing 
miRNA expression is also targeted by the miRNA. It is increasingly evident that post-
transcription regulation is essential to miRNA biology. Many molecules are known to 
both positively and negatively regulate Drosha, Dicer, and RISC complexes. For 
example, double stranded RNA binding proteins (dsRBP) such as DGCR8 and TRBP 
associate with these complexes and their levels affect the rate of miRNA processing. 
The stability of the miRNA is also regulated. Therefore, some stimuli and developmental 
processes can affect the levels of many microRNA simultaneously [100]. 
Levels of miRNA expression are highly dependent on cell type, creating a type of 
miRNA signature. When a cell transitions from one state to another is also shifts its 
miRNA profile. For example, shifts from a multipotent to a differentiated state are 
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accompanied by corresponding shifts in miRNA levels [106]. The same is true for 
changes in cells as they shift from healthy to diseased, from normal to cancerous [107], 
or from a resting to activated state [108]. In these cases miRNA may be acting to 
effectively shut off protein production of targets that are no longer beneficial for the new 
state of the cell [103]. In this way, one can conceptualize miRNA as important mediators 
of change in the biological world.  
 
1.2.1 Inflammation and miRNAs 
In the immune system, miRNAs are critical regulators of both immune system 
development and activation. Studies of miRNA knock-out mice have revealed roles for 
miRNA in the development of specific immune cell subsets [109]. Additionally 
inflammatory stimuli induce a specific subset of miRNA that can play pro or anti-
inflammatory roles by acting on cytokine signaling pathways. Disturbing the delicate 
balance between these pro and anti-inflammatory functions can on one side disable the 
immune system leaving the organism open to infection or on the other side create 
excessive inflammation leading to autoimmunity. We will cover the relevant inflammatory 
signaling pathways, then delve into their regulation by miRNAs. Subsequent sections will 
discuss the role of miRNAs in the regulation of neuroinflammation. 
The first phase of the innate immune response is recognizing possible 
pathogens. This is accomplished through the use of pattern-recognition receptors 
(PRRs) that recognize unique molecular motifs present in pathogens such as bacterial 
lipopolysaccharides. These molecular motifs are called pathogen associated molecular 
patterns (PAMPS). When PRRs bind PAMPs they alert innate immune cells such as 
macrophages and dendritic cells, inducing an inflammatory response. The most well 
characterized class of PRRs are the Toll-like receptors (TLRs) named after the Toll 
protein of drosophila. TLRs that are expressed both on the surface (TLR1-6 and TLR10) 
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of the cell and in the interior compartment of the endosome (TLR3 and TLR7-9). There is 
a large family of TLRs that can be subdivided into categories based on the type of 
PAMPS they recognize. TLR 1, TLR2, TLR4, and TLR 6 recognize lipids, while TLR3, 
TLR7, TLR8, and TLR9 recognize nucleic acids. Therefore one pathogen can stimulate 
multiple TLRs depending on which PAMPs it expresses. For example a virus expresses 
glycoproteins that can be recognized by TLR2 and TLR4, but also DNA, which 
stimulates TLR9 or RNA, which stimulates TLR3, TLR7, and TLR8. This diverse array of 
PRR/PAMP pairings ensures that there is a robust inflammatory response to a pathogen 
[110]. However, when tissue damage occurs, cells release components that are normally 
sequestered, these are termed damage associated molecular patterns (DAMPs) and 
they can also bind to TLRs. Intracellular protein, DNA, RNA, and nucleotides can all 
serve as DAMPs [111]. This system is the reason that tissue damage causes an 
inflammatory response strikingly similar to a pathogen. Practically speaking tissue 
damage, such as a cut, is often accompanied by an increased risk of infection. This 
association may be the underlying evolutionary reason for ability of PRRs to recognize 
DAMPs. The ability of DAMPs to elicit an immune response is not without drawbacks. 
Recently associations have been made between chronic inflammatory conditions and 
DAMPs. A small list includes arthritis [112], psoriasis [113], atherosclerosis, and 
systemic lupus erythematosus [114], though others are being added with increasing 
frequency. As discussed here, TLR signaling was first characterized in the peripheral 
immune system, but these receptors and signaling pathways are also present in nervous 
system infection and damage [115]. In TBI specifically, TLRs are expressed on both 
resident and invading immune cells, which respond to DAMPs such as heat shock 
protein 70 (HSP70) released from neurons and other damaged cells in the brain [116]. 
Laird et al. showed that the DAMP high mobility group box protein-1 (HMGB1) 
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exacerbates TBI associated edema [117]. Therefore, TLRs and TLR signaling pathways 
show promise as therapeutic targets for TBI.  
 Once a DAMP or PAMP binds to a TLR, one or more adaptor proteins is 
recruited to the intracellular portion of the TLR. The four know adapters are MyD88, 
TRIF, TRAM and Mal. All TLRs are capable of interacting with MyD88, the first adapter 
discovered. Down stream of these adaptor proteins are pro-inflammatory transcription 
factors, primarily NF-κB. MyD88 dependent signaling from TLR2, TLR4, and TLR5 
results in pro-inflammatory gene expression, while TLR7 and TLR9 MyD88 dependent 
signaling specifically induces type I IFN production [110].  
 Profiling studies of miRNA during the immune response has shown that many 
miRNAs are induced by TLR signaling. The primary miRNA induced by TLR signaling 
are miR155, miR-146, and miR-21, but several others have also been cited [118]. The 
expression of these miRNAs seems highly dependent of NF-κB, but changes in miRNA 
processing may be an additional layer of regulation [119]. Once miRNAs are induced by 
TLR signaling they target various levels of the pathway. miRNAs can target TLR 
signaling proteins, transcription factors, regulators, downstream cytokine products, and 
even TLRs themselves. Generally speaking the role of several miRNAs in TLR signaling 
is to provide feed-back inhibition. TLRs stimulate NF-κB, which induces mRNA 
expression. Mature miRNA bind to the mRNA of signaling proteins and transcription 
factors involved in TLR signaling. As proteins are turned over, without active translation 
of target miRNA levels gradually decrease, thereby contributing to the resolution of 
inflammation. Two signaling molecules, IRAK1 and TRAF6, involved in MyD88 
dependent responses are directly targeted by miR-146. Therefore miR-146 expression 
reduces MyD88 dependent TLR signaling [120]. Similarly miR-155 directly targets TAB2, 
an important downstream signaling molecule of TLRs that induces the MAPK pathway 
[121]. Several important downstream transcription factors of TLRs are also targeted by 
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miRNA. CCAAT/enhancer-binding protein-β (C/EBPβ) is a target of miR-155 [122, 123]. 
Alternatively, induction of miR-27b by NF-κB, leads to decreased levels of target 
proliferator-activated receptor-γ (PPARγ). PPARγ is anti-inflammatory and targeting by 
miR-27b would increase inflammatory signaling [124]. Additionally, the transcriptional co-
activator p300 is a target of miR-132 and is required for the induction of anti-viral genes 
[125]. While the general trend is for miRNAs induced by TLR signaling to provide feed-
back inhibition, there are some notable exceptions. Src homology 2 (SH2) domain-
containing inositol-5’-phosphatase1 (SHIP1) is a negative regulator of TLRs and also a 
target of miR-155, a TLR induced gene [126] [127]. Another important target of miR-155 
is suppressor of cytokine signaling 1 (SOCS1). SOCS1 inhibits the function of STAT1 an 
important transcription factor for type I, type II, and type III interferons. The complex 
nature of miRNA regulation of TLR signaling suggests that effects may be cell-type and 
context dependent. A summary of some of the targets and associated signaling 
pathways is shown in figure 1.4. In vivo studies using miRNA knockout mice are 
beginning to show the balance of pro and anti-inflammatory effects in TLR responses. 
Mice deficient in miR-146a have excessive pro-inflammatory responses to LPS causing 
a severe increase in lethality of an intraperitoneal injection of LPS and an autoimmune 
phenotype [128]. Alternatively, miR-155 knockout mice have diminished immune 
responses, which make them more susceptible to various infections [129, 130], but 
causes reduced tissue damage in injury models [131, 132]. Together studies on miR-155 
and miR-146 knockout mice herald a growing appreciation for the importance of miRNAs 
in the innate immune response. What role inflammation-associated miRNAs have in the 
regulation of immune responses in the brain is still being discovered and the expression 
and function of inflammation-associated miRNAs in TBI has not been characterized.  
 
1.2.2 Neuroinflammation and miRNAs 
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Figure 1.4 
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Figure 1.4 Roles for miRNAs in inflammatory signaling pathways. 
A limited diagram of the pattern recognition receptor (PRR) signaling and cytokine 
signaling pathways highlighting the role of miR-155 and miR-146 in modulating the 
immune response. Shown in green are miR-146 and its targets and shown in red are 
miR-155 and its target. Pathogen associated molecular patterns (PAMPs) and damage 
associated molecular patterns (DAMPs) bind to PRRs including the TLR family. TLR 
signaling is dependent on Myeloid differentiation primary response gene 88 (MyD88), 
interleukin-1 receptor-associated kinases (IRAKs), and TNF receptor associated factors 
(TRAFs).  Eventually the cascade initiated by the binding to the PRR induces activation 
of pro-inflammatory transcription factors such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and adaptor protein 1 (AP-1). Activation of pro-
inflammatory transcription factors causes increased gene expression of pro-
inflammatory cytokines and other genes involved in the immune response. Cytokines 
can then bind to their cognate cytokine receptors and induce further signaling cascades. 
Many cytokines receptors are receptor tyrosine kinases which rely on janus kinase (JAK) 
and signal transducer and activator of transcription (STAT) for signal transduction.  The 
expression of miR-146 and miR-155 is also induced by NF-κB. IRAK and TRAF 
molecules are targeted by miR-146 leading to feed back inhibition of the PRR response. 
Alternatively miR-155 inhibits suppressor of cytokine 1 (SOCS1), an inhibitor of STAT1 
activation. Therefore miR-155 promotes the antiviral response induced by STAT1. P 
represents phosphorylation events. IFN, interferon; IL, interleukin; TNF, tumor necrosis 
factor. 
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Considering the widening base of literature on miRNAs in inflammation, comparatively 
less is know about the role miRNAs might play in the unique immune environment of the 
brain. Few reports have highlighted a role for miRNAs both in the activation of resident 
glia calls and the recruitment of immune cells to the brain. Cardoso et al. found that miR-
155 is induced by LPS in microglia [133], similar to what had been shown in  
macrophages [134]. They also validated that SOCS1 was a target of miR-155 in 
microglia and that miR-155 inhibition decreased levels of pro-inflammatory cytokines 
secreted by microglia. Additionally miR-155 increased levels of iNOS and contributed to 
the toxicity of microglial supernatants on cultured neurons. In vivo experiments on the 
superoxide dismutase 1 (SOD1) model of amyotrophic lateral sclerosis (ALS) ablating 
miR-155 restored aberrant microglia and prolonged survival [135]. Interestingly, 
Alzheimer’s 3x transgenic model showed upregulation of miR-155. Furthermore, 
induction of miR-155 in astrocytes and microglia treated with Aβ fibrils was mediated by 
C-Jun. Increased miR-155 in transgenic mice also correlated with a decrease in SOCS1 
levels [136]. Yet another study on alcohol induced neuroinflammation showed increased 
levels of miR-155 in the brain; in TLR4 knockout mice miR-155 was not induced. In miR-
155 knockout mice alcohol induced TNFα, CCL2, and Pro-1L-1β were decreased. In 
another report of miR-155 in neuoroinflammation, miR-155 was shown to regulate the 
alpha synuclein induced inflammatory response in a model of Parkinson’s disease [137]. 
Together these studies suggest a pro-inflammatory role for miR-155 in 
neuroinflammation, likely through inhibition of SOCS1 in microglia. Interestingly miR-155 
is important for inflammation induced deficits in neurogenesis. Microglial activation is 
balanced by two miRNAs. Expression of miR-155 polarizes microglia to an activated 
phenotype, while miR-124 promotes a resting phenotype. The expression of miR-124 is 
brain specific. Ponomarev et al. showed that in experimental autoimmune encephalitis, 
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an animal model of multiple sclerosis, miR-124 levles were decreased. Additionally, 
inhibiting miR-124 in microglia resulted in an activated phenotype [138]. However, 
studies in post-mortem brains from multiple sclerosis patients found increased levels of 
miR-124 in demyelinating hippocampi which targeted AMPA receptors. More functional 
studies are needed to understand the role of miRNA in regulation of microglial activation. 
It is possible that miRNAs like miR-124 may play alternative roles in different neural cell 
types, complicating the understanding of their overall role in the brain. Interestingly, 
although miR-155 is a known regulator of the peripheral immune response, miR-124 is 
brain specific, highlighting the fact that there may be important differences between 
miRNA regulation of the peripheral immune system and neuroinflammation.  
 Although microglia are the primary immune cells of the brain, astrocytes also 
become activated by an immune challenge. In astrocytes miR-146 is induced by pro-
inflammatory cytokines and serves as a negative feedback mechanism to lower the 
levels of pro-inflammatory cytokines. Levels of miR-146 correlated negatively with 
protein expression of IRAK-1 [139]. Work by Tarassishin et al. also points to a role for 
miR-155 in astrocyte responses [140]. As in most other cell types, miR-155 in astrocytes 
is pro-inflammatory and causes down regulation of SOCS1. In summary, both miR-146 
and miR-155 have roles in regulating the inflammatory response to astrocytes and these 
roles reflect their function in the peripheral immune response. Interestingly, miR-21 is 
also involved in the astrocytic response to injury, promoting hypertrophy after spinal cord 
injury [141]. The body of research on miRNA regulation of the astrocytic response to 
injury is still very small. Whether additional research will identify unique miRNA involved 
in the astrocytic response remains to be seen. 
 In addition to regulating the inflammatory response of glial cells, a small number 
of reports have also identified roles for miRNAs in the recruitment of peripheral immune 
cells. In one study TNFα induced expression of miR-17 and miR-126. These miRNAs 
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targeted adhesion molecules E-selectin and ICAM1 respectively. Reduction in E-selectin 
and ICAM1 by miR-17 and miR-126 lead to decreased endothelial adhesion of 
neutrophils [142]. This suggests an interesting feedback loop that self-limits the 
recruitment of neutrophils to sites of injury or inflammation. Neutrophils are recruited to 
the brain after TBI [28], so miRNAs that regulate this process may be relevant to TBI. In 
the periphery it has been shown that CCL2 is  also target for miR-126, affecting 
macrophage recruitment [143]. If miR-126 regulated CCL2 in the brain, it may be a 
mechanism for reducing monocyte recruitment and subsequent inflammation. Overall, it 
is clear that miRNAs do have roles in neuroinflammation. As in the peripheral immune 
response miR-155 acts as a proinflammatory miRNA, while miR-146 has an anti-
inflammatory effect. However, the neural immune response is not identical to that of the 
periphery and involves additional players, such as miR-124. While knowledge about 
miRNA regulation of neuroinflammation is still sparse, it is a growing area of research 
that holds promise for enhancing our understanding of neuroinflammation. 
 
1.3 TBI and miRNAs 
At this time, 6 miRNA profiling experiments have been performed in animal models of 
TBI [144-149]. While all of these studies identified changes in miRNA after TBI, the 
specific model and time course of each study varied. Consequently there was very little 
agreement on miRNA expression between the studies. Additionally, most did not 
perform any functional studies of miRNA in TBI. One notable exception has been the 
emerging functional role for miR-21 in TBI. Elevated expression of miR-21 was found in 
four of the profiling experiments [144, 145, 147, 148]. Redell et al. showed that levels of 
miR-21 targets PDCD4 and Tiam1 showed an inverse relationship with miR-21 
expression after TBI [150]. In an in vitro model of TBI, primary cortical neurons exposed 
to scratch injury exhibited elevated levels of miR-21, which had a neuroprotective effect. 
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Increasing miR-21 decreased PTEN, a negative regulator of the Akt cell survival 
pathway [151]. Additionally, increasing levels of miR-21 in TBI using an miR-21 agomir 
improved motor and cognitive function as well as reducing lesion size. Increasing miR-
21 reduced apoptosis and increased angiogenesis likely through regulation of the Akt 
pathway [152]. Expression of miR-21 also increased BBB integrity [153]. These studies 
point to a critical neuroprotective role for miR-21 in TBI. Interestingly, both exercise and 
aging affected the expression of miR-21 after TBI. For example, aged mice show 
decreased induction of miR-21 and increased levels of targets PTEN, PDCD4, TIMP3, 
and RECK [154]. This suggests that decreased miR-21 induction during aging may 
contribute to worse prognosis for TBI recovery with increasing age. Conversely exercise 
improves TBI outcomes, which is associated with increased levels of miR-21. Altogether 
miR-21 seems to be a promising target for improving TBI recovery. However, the 
delivery and pharmacokinetic properties of miRNA remain challenging, so future work on 
miR-21 in TBI will need to take into account these factors. 
 While the function of other miRNAs in TBI has not yet been evaluated, some 
factors do alter miRNA expression after experimental TBI. For example hypothermia 
increases levels of miR-874 and miR-451 [155]. Given that hypothermia is protective 
after TBI [156, 157], these temperature sensitive miRNA may play a role in the beneficial 
effect of hypothermia on TBI outcomes. Interestingly, two miRNAs are upregulated in 
mitochondria after TBI. These were miR-223 and miR-155, both of which have known 
roles in inflammation [158].  
 Another area of active research regarding miRNA and TBI is the search for 
biomarkers. The TBI field is still in need of novel biomarkers, preferably ones that are 
unique to TBIs, which are commonly accompanied by peripheral injuries, and can predict 
TBI outcomes [159].  Early studies indicate that serum levels of miR-16, miR-92a, an 
miR-765 can predict both mild and severe TBI in human patients [160]. Studies in a rat 
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model of blast induced TBI identified increased levels of let-7i in both the CSF and in 
serum, suggesting that let-7i is a likely candidate for further biomarker studies in blast 
induced TBI. 
 Though the functional roles of miRNA in TBI are just beginning to be uncovered, 
miR-21 is a striking example of a miRNA that can alter TBI outcomes. Profiling 
experiments have shown that miRNA levels are altered by TBI in mouse models, but the 
function of these miRNAs in TBI is largely unknown. Functional experiments on miRNA 
in TBI could lead to a better understanding, not only of the pathophysiology of TBI, but 
also the importance of miRNAs in neurological disorders.  
 
1.4 Overview 
TBI is a prominent health concern, with a large burden on society. The effects of TBI on 
an individual can be devastating and life long. Even in the absence of physical or 
cognitive disability, neuropsychological impairment can result in social exclusion and 
joblessness. Many recent advances in trauma care have improved survival and TBI 
outcomes. However, despite significant efforts in TBI research, no pharmacological 
strategies have been proven to provide therapeutic benefit after TBI. There is an urgent 
need for identification of new drug targets that could alter TBI outcomes.  
 Inflammation plays a critical role in TBI pathophysiology. The activation of 
resident glia by DAMP released from damaged tissue and the recruitment of peripheral 
immune cells to the brain provides many possible levels of therapeutic interventions. 
One class of molecules that has an important regulatory role in both neuroinflammation 
and peripheral immune responses are miRNAs. These post-transcriptional regulators 
can serve to augment or restrict the inflammatory response. Levels of miRNAs are 
altered following TBI and at least one miRNA has been shown to alter TBI outcomes in 
animal models. Further studies on the role of miRNAs, and inflammation-associated 
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miRNAs in particular, will further our understanding of TBI, neuroinflammation, and 
miRNA function and could provide novel therapeutic targets for TBI.  
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Chapter 2: Materials and Methods 
 
2.1 Animals: Mouse strains used are described in Table 2.1. Mice were fed ad libitum 
and housed with a 12 hour light-dark cycle. All procedures and protocols were approved 
by the Institutional Animal Care and Use Committee of the University of Nebraska 
Medical Center and conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals. 
 
2.2 Controlled cortical impact (CCI): CCI surgery was similar to previous reports [161, 
162]. For all experiments seven to nine week-old male mice were anesthetized using 
inhaled isofluorane. For long term behavioral studies (Chapter 7) mice were injected IP 
with 3 µg buprenorphine for analgesia before surgery. For all experiments mice were 
given 3.75 µg bupivacaine SC at the incision site prior to surgery for analgesia. Once 
anesthetized the head of the animal was shaved and placed in a Kopf stereotactic head 
frame. During surgery anesthesia was maintained with 2% inhaled isofluorane. An 
incision was made in the scalp and a 4-mm trephine was used to mark the skull 1 mm 
from the midline midway between lambda and bregma  on the left side. A drill was then 
used to create a craniotomy. The impact was delivered by a Precision Systems and 
Instrumentation TBI-0310 (Fairfax Station, VA) at a 45° angle from the midline. For all 
injuries the speed was set to 3.5 m/s with a dwell time of 200 ms. In order to represent 
different injury severities different depths of injury were used 0.5 mm (moderate) or 1.0 
mm severe. After injury a 4 mm square of Surgicel (Johnson & Johnson, Dallas) was 
placed over the injury site, the removed skull was replaced and adhered with dental 
cement. The wound was closed with tissue clips and mice were placed on a warming 
pad until they regained sternal decumbency. For sham controls craniotomy was 
performed, but no impact was delivered. Naïve animals were not exposed to surgery,  
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Table 2.1 Information regarding mouse stains 
 
  
Mouse  Strain Supplier Background  Controls Origin  
Wild type C57Bl/6 Charles River, 
Wilmington 
C57Bl/6 Na Na 
miR-155 
KO 
B6.Cg-
Mir155tm1.1Rsky/J  
Jackson Laboratory, 
Bar Harbor  
C57Bl/6 C57Bl/6 Rajewsky 
[163] 
miR-21 
KO 
129S6-
Mir21tm1Yoli/J 
Jackson Laboratory, 
Bar Harbor 
C57Bl/6 and 
129S 
WT littermates 
or offspring of 
WT littermates 
Li 
[164] 
miR-21 
knock-out 
first 
Mir21atm1Mtm 
 
Jackson Laboratory, 
Bar Harbor  
Mixed Na McManus 
[165] 
FLP  ROSA26::FLPe 
knock in 
Jackson Laboratory, 
Bar Harbor 
C57Bl/6 Na Raines and 
Wilson 
[166] 
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drugs, or anesthesia. For long-term experiments (Chapter 3) sham, moderate, and 
severe animals were administered 3 µg buprenorphine every 8-12 hours for 48 hours 
post surgery. Animals were randomly chosen for each condition. 
 
2.3 Collection of hippocampal tissue for RNA and protein isolation: Animals were 
sacrificed at the indicated times by isofluorane overdose followed by decapitation. Brains 
were removed from the skull and the left and right hippocampi dissected. Samples were 
frozen in liquid nitrogen and stored at -80°C until RNA isolation was performed. One mL 
Trizol (Life Technologies, Carlsbad) was added to each hippocampus and samples were 
homogenized at RT for 5 sec. RNA and protein were then purified as described below. 
 
 2.4 RNA and protein isolation: Tissue or cells were homogenized in Trizol (Life 
Technologies, Carlsbad), followed by addition of 200 µL of chloroform to each sample. 
Samples were shaken and incubated at RT for 2 min, and centrifuged for 15 min at 
12,000 x g at 4°C. The aqueous phase was removed and RNA was precipitated with 
isopropanol. To pellet RNA samples were centrifuged for 10 min at 12,000 x g at 4°C. 
The supernatant was removed and pellets were washed with 75% EtOH. After air drying 
the RNA pellet was resuspended in RNase free water and analyzed by NanoDrop 8000 
(Thermo, Waltham) to determine purity and concentration. To isolate protein the phenol 
phase above was used. First 300 µL of 100% EtOH was added to precipitate DNA and 
sample was centrifuged 5 min at  7,500 x g and 4°C. The supernatant was then removed 
and stored at -80°C until protein isolation was performed. 2 mL of 0.3 M GuHCl in 95% 
EtOH was added and the sample and incubated fro 20 min at RT then centrifuged at 
7,500 x g for 5 min at 4°C. The protein pellet was washed three times in GuHCL and 
once with 100% EtOH then air dried and resuspended in 4% SDS, 100 mM Tris/HCL, 
0.1 M DTT pH = 7.6. Samples were sonicated and centrifuged at 10,000 x g for 10 min 
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at 4°C. Protein samples were stored at -80°C. Protein quantification was performed with 
Pierce 660 nm protein assay (Thermo, Waltham) according to manufacturers directions. 
 
2.5 cDNA synthesis and real time PCR: For miRNA qPCR TaqMan MicroRNA and 
Gene Expression Assays (Thermo, Waltham) were used for cDNA synthesis and real 
time PCR according to manufacturers instructions. For mRNA cDNA synthesis 
SuperScript III Reverse Transcriptase (Life Technologies, Carlsbad) was used according 
to manufacturers directions. TaqMan Gene Expression Assays (Thermo, Waltham) were 
used for qPCR fro mRNA. To normalize gene expression snRNA U6 and GAPDH were 
used for miRNA and mRNA analyses respectively. Real time PCR and Ct determination 
was performed using a One Step StepOne Real-Time PCR System (Thermo, Waltham). 
Fold change was calculated using the delta-delta Ct method. (2 ^ -((CtmiRNA – CtU6)exp -
(CtmiRNA – CtU6)control )) or (2 ^ -((CtmRNA – CtGAPDH)exp -(CtmRNA – CtGAPDH)control )). A minimum 
of three biological replicates was used for all experiments. Values are reported as the 
mean ± SEM. Statistical analysis was determined using Ct values or fold change where 
appropriate. For experiments with multiple variables statistical analysis was performed 
using two-way ANOVA, test statistic .05 followed by Bonferroni post hoc testing. For 
experiments with more than two conditions one-way ANOVA was used, test statistic .05, 
followed by Dunnett’s Multiple comparison test. When comparing two conditions a 
student’s T-test was used, test statistic, .05. Matching was used where appropriate when 
samples were obtained from the same donor or the same animal.  
 
2.6 SDS-PAGE and Western Blot: Protein samples were loaded onto a 4-12% bis-tris 
gel and transferred to a nitrocellulose membrane using a semi-dry transfer. The 
membrane was blocked and incubated overnight at 4°C with primary antibodies (see 
table 2.2 for antibody sources and concentrations). After washing secondary antibodies  
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Table 2.2 Antibody information 
 
Antigen Manufacturer Host species Dilution 
For immunostaining  
Iba1 Wako Rb 1:500 
GFAP Dako Rb 1:500 
MAP2 (for ICC) Sternberger Ms 1:1000 
MAP2 (for IHC) Abcam Ckn 1:1000 
Synaptophysin Synaptic Systems Ms 1:1000 
SMI-32 Sternberger Ms 1:1000 
SOX2 Millipore Rb 1:1000 
Nestin Millipore Ms 1:1000 
For Western  
P-STAT3 (Y705) Cell Signaling Rb  1:2000 
STAT3 Millipore Rb 1:1000 
PTEN Cell Signaling Rb 1:1000 
P-Akt (Ser 473) Cell Signaling Rb 1:1000 
Akt 1/2/3 Santa Cruz  Rb 1:1000 
SOCS1 Thermo Rb 1:1000 
Caspase 3 Cell Signaling  Rb 1:1000 
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were incubated for 1 hour at RT. For peroxidase secondary antibodies ECL substrate 
was used to develop the membrane, imaging and analyses was performed using a 
Carestream Imaging system (Carestream, Rochester). For secondary antibodies labeled 
with infrared dyes, imaging and analysis was performed with an Odyssey Imaging 
System (LI-COR, Lincoln). Significance was calculated using a student’s T-test, test 
statistic .05. 
 
2.7 Histology on formalin fixed paraffin embedded tissue: Animals were sacrificed at 
indicated times after injury. Brains were removed and fixed in 4% paraformaldehyde. 
overnight, paraffin embedded, and cut into 5-µm slices using a microtome. Before 
staining slides were warmed to 60°C for one hour then allowed to cool. Slides were 
cleared with xylene then dehydrated through graded ethanol washes.  
 
2.7.1 Luxol fast blue staining: After hydration to 95% ethanol slides were stained with 
filtered 0.1% Luxol fast blue in a solution of 0.5% acetic acid at 60°C overnight. The next 
day slides were rinsed in 95% ethanol followed by distilled water then differentiated in 
0.05% lithium carbonate for one min and 70% ethanol for 1 min. Slides were 
counterstained with 0.5% cresyl violet for 30 min at 60°C, rinsed in distilled H2O, and 
differentiated in 95% ethanol for 5 min. Coverslips were mounted using Cytoseal 
(Thermo, Waltham). Slide scanning was performed by the UNMC tissue sciences facility 
using a Ventana’s Coreo Au Slide Scanner at 40x magnification.  
 
2.7.2 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL): 
ApopTag Peroxidase In situ apoptosis detection kit (Millipore, Temecula) was used for 
TUNEL staining according to manufacturer’s directions in conjunction with TSA plus 
cyanine 5 kit (PerkinElmer, Waltham). Briefly, hydrated slides were treated with 20 
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µg/mL proteinase K, then terminal deoxynucleotidyl transferase (TdT) was used to 
transfer digoxigenin (DIG) labeled nucleotides onto fragmented DNA. The tail of DIG 
labeled nucleotides was then detected using an anti-DIG antibody conjugated to 
peroxidase. A TSA plus cyanine 5 kit (PerkinElmer, Waltham) was used to develop the 
fluorescent stain. Coverslips were mouned onto slides using prolong Gold Antifade 
Mountant with DAPI (Life Technologies, Carlsbad) and imaged using a Zeiss 
Observer.Z1 microscope. 
 
6.7.3 Immunohistochemistry: Staining was performed as described by Yelamanchili et  
al. [167]. Tissue was hydrated with a graded alcohol series. Antigen retrieval was 
performed with citrate buffer pH 6 at 90° C for 40 min and washed. Tissue was blocked 
in a solution of 1% BSA and 3% NGS in PBS, and incubated with primary antibody 
overnight at 4°C. Primary antibodies used are described in Table 2.2. The following day 
tissue was washed with TBS and incubated with 3% H202 in PBS for 10 min. After 
thorough washing tissue was incubated with anti-Rabbit secondary labeled with a 
peroxidase enzyme (ImmPRESS, Vector labs, Burlingame) for one hour, rinsed, and 
developed with DAB Plus substrate system (Thermo, Waltham) for 10 min. Tissue was 
then washed with TBS, stained with haematoxylin, and dehydrated. Coverslips were 
mounted with cytoseal (Thermo, Waltham).    
 
2.7.4 In situ hybridization: In situ hybridization procedure was similar to that described 
by Chaudhuri et al. [168] Care was taken at all steps to avoid RNase contamination and 
solutions were all made with Diethylpyrocarbonate (DEPC) treated water. Tissues were 
first cleared with xylene and hydrated with a graded ethanol series, and then citrate 
antigen retrieval was performed. To crosslink miRNA and improve stability, tissue was 
treated with 0.16 M ethylcarbodiimide (EDC) in 0.13 M 1-methylimidazole, 300 mM NaCl 
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pH 8.0. After several washes, tissue was incubated in hybridization buffer (50% 
deionized formamide, 10 mL Tris-HCl, .25% SDS, 1 x Denhardt’s solution, 600 mM 
NaCl, 1 mM EDTA and 200 µg/mL yeast tRNA) at 37°C. Afterwards, tissue was 
hybridized with 5’ and 3’ digoxin labeled locked nucleic aced probes (Exiqon,Vedbæk) at 
a concentration of 4 pM per 100 µM overnight at 37°C. Tissues were then washed with 2 
x and .2 x saline sodium citrate buffer at 42°C. To quench endogenous peroxidase 
tissues were treated with 3% H2O2 in PBS for 10 min. After thorough washing tissue was 
blocked with 1% bovine serum albumin (BSA) and 3% goat serum in phosphate buffered 
saline (PBS). Tissues were incubated at 4°C overnight with anti-digoxigenin-POD, Fab 
fragments (Roche, Basel) at a concentration of 1:100. In experiments where dual 
immunohistochemistry and in situ hybridization were used antibodies to cell-type specific 
markers were included in the overnight incubation. Antibodies used were MAP2 (Abcam, 
Cambridge) (1:1000), GFAP (Dako, Brasschaat) (1:500) and Iba1 (Wako, Kampenhout) 
(1:500). Corresponding Alex Fluor secondary antibodies (Invitrogen, Carlsbad) were 
incubated for one hour. Afterwards the peroxidase signal was amplified using the TSA 
plus cyanine 5 (PerkinElmer, Waltham). Tissues were stained with DAPI and coverslips 
mounted with proLong Gold Antifade Mountant with DAPI (Life Technologies, Carlsbad) 
and imaged using a Zeiss Observer.Z1 microscope. 
 
2.8 Cryosectioning: At indicated times after injury animals were anesthetized with 
isofluorane followed by transcardial perfusion. First animals were perfused with PBS with 
2.5% sucrose. Then animals were perfused with 4% paraformaldehyde (PFA), 2.5% 
sucrose, and PBS. After perfusion brains were post-fixed in 4% PFA with 2.5% sucrose 
in PBS. After 24 hours brains were transferred to 30% sucrose and stored at 4°C until 
they sunk, ~3 days. Brains were frozen using 2 methyl butane on dry ice and stored at -
80°C until they were sectioned on a cryostat. A 4 mm coronal section, including the 
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injury site was sectioned into 50 µM slices and every fifth section was collected in 0.1 M 
phosphate buffer.  
 
2.9 Fluoro-Jade C staining: Free-floating cryosections were mounted on gelatin coated 
slides and air dried overnight. Slides were incubated in .06% potassium permanganate 
followed by .0001% Fluoro-Jade C (Histochem, Jefferson) and .0001% DAPI (Sigma, St. 
Louis) in 1% acetic acid. Tissue was then dried in a 60°C oven and incubated in zylene 
for 1 min, then coverslips were mounted with DPX (Sigma, St. Louis). A Zeiss 
Observer.Z1 microscope was used for imaging. Three slices between bregma -2.5 and -
1.5 were imaged for quantification. For cortex three images were taken in the boundary 
zone for each slice. For the hippocampus each of the three slices per slide images were 
taken of the dentate gyrus, CA3, and CA1 regions. Fluorojade C positive cells were 
counted using Image J[169] by a blinded observer. The average number of fluorojade 
positive cells per slice is reported. Significance was calculated using a student’s T-test, 
test statistic .05. 
 
2.10 Immunohistochemisty: Free-floating cryosections were incubated with 3% H2O2 
to quench endogenous peroxidase. After thorough washing sections were blocked with 
10% NGS + 0.3% TX in PBS. Tissues were incubated with Iba1 (Wako, Kampenhout) (1:500) 
in 0.3% TX +3% NGS in PBS at 4°C overnight. ImmPRESS HRP Anti-Rabbit IgG (Vector labs, 
Burlingame) was used as a secondary and DAB Plus substrate system (Thermo, Waltham) was 
used for developing. Sections were then mounted on gelatin-coated slides, allowed to dry 
overnight, incubated in xylene for 1 min, and mounted with cytoseal (Thermo, Waltham). 
Slides were imaged using a light microscope at 100 x magnification. Images were 
quantified using Image J [169] to calculate the percent area covered by Iba1 staining in 
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the hippocampus and cortex. Student’s t-test was used to calculate significance, test 
statistic of .05.  
 
2.11 Behavioral testing: Mice were allowed to acclimate to the testing room for 30 min 
prior to any behavioral testing. All testing was performed between the hours of 10:00 and 
16:00 by a single technician. Whenever possible testing was arranged so that the least 
stressful tests were done first to reduce confounding factors. Values are reported as the 
mean ± SEM. For experiments with multiple variables statistical analysis was performed 
using two-way ANOVA, test statistic .05 followed by Bonferroni post hoc testing. For 
experiments with more than two conditions one-way ANOVA was used, test statistic .05, 
followed by Tukey’s post hoc testing. When comparing two conditions a student’s T-test 
was used, test statistic, .05.  
 
2.11.1. Rotarod: Testing of mice on the accelerating rotarod apparatus was performed 
with or without training before injury. A seven cm rotarod was used. For testing in the 
acute to sub-acute phase, mice were trained on the rotarod for 3 days, injury then 1, 3, 
5, and 7 days post injury. For testing in the chronic phase testing was performed without 
training on 3 consecutive days. On the first day of training (acute phase) or testing 
(chronic phase) mice were allowed to habituate to the rotarod apparatus for 5 min prior 
to the first trial. For all studies the rotarod apparatus was set to accelerate from 0-35 rpm 
in 2 min, testing was stopped after 2 min. Mice were tested 3 times a day and allowed to 
rest for a minimum of 30 min between tests. The latency to fall was detected by weight-
based sensors and recorded. The average latency to fall for three trials was averaged 
for each day. Procedure was similar to that performed by O’Connor et al.[170]  
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2.11.2. Elevated zero maze: The behavior of mice in an open field maze (34 cm inner 
diameter, 46 cm outer diameter, on 4 braced legs 40 cm off the ground) was recorded 
for 6 minutes. Between trials the equipment was cleaned with 70% EtOH. Testing was 
similar to that described in Heisler et al [171]. 
 
2.11.3. Open field: individual mice were placed into a white 50 x 50 x 38 cm arena and 
their behavior was recorded for either 20 min for testing in the chronic phase or for 10 
min for acute phase testing. The arena was cleaned with 70% EtOH between trials. 
 
2.11.4. Novel object: Novel object testing was performed in the same 50 x 50 x 38 cm 
white arena as used for open field testing. Novel object testing was always performed 
after open field testing so that mice would be acclimated to the arena. First the mouse 
was placed into the arena with two identical objects placed in different corners and 
recorded for 5 min. Second, the mouse was moved back to its home cage for an interval 
of 3 hours. Third, the mouse was placed back into the arena, but one of the two identical 
objects was replaced with a novel object. Again the exploratory behavior of the mouse 
was recorded for 5 min. Before the first round of testing and between each round, both 
the objects and arena were cleaned with 5% acetic acid followed by water to reduce the 
scent of previous test subjects. 
 
2.11.5. Social interaction: Experimental mice were matched with a same-sex 
conspecific of similar size. The experimental mouse and then the test mouse were 
placed in opposite corners of a neutral cage with clean bedding. The interactions 
between the two mice were recorded for 20 min. Bedding was replaced and cage 
cleaned with 70% EtOH between each trial. A blinded observer recorded duration of time 
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spent in proximity as well as frequency of proximity, genital sniff, face sniff, chase, 
wrestle, and tail rattle using Stopwatch software (Georgia State University). 
 
2.11.6. Tail suspension: Mice were suspended from the tail from a 1.2 cm diameter 
metal bar 30 cm off the table for 6 min and their behavior recorded. Time spent mobile 
versus immobile was scored by a blinded observer using Stopwatch software (Georgia 
State University). Procedure was similar to that reported by Heisler et al.[171] 
 
2.11.7. Neurological Severity Score Testing. Mice were tested 3 days post injury as 
described in Flierl et al. [172]. Mice were scored on their ability to perform the described 
tasks. Inability to complete the task resulted in a score of one. These scores were added 
together to give the neurological severity score [87] with a maximum score of 10. For the 
beam walking component the mice were placed on a platform connected to another 
platform by a 3 cm beam and given three min to cross to the opposite platform. Failure 
to do so resulted in a score of 3. If the mouse successfully crossed the first beam, it was 
replaced with a second beam, this time of 2 cm width. If the mouse was not able to cross 
the 2 cm beam it was given a score of 2. If the mouse was able to cross the 2 cm beam, 
the beam was replaced by a 1 cm beam. Failure to cross this beam resulted in a sore of 
1. Ability to cross all three beams resulted in a score of 0.  
 
2.12 Human NPC and Neuronal culture: Cells were obtained from UNMC tissue core 
facility. This work is in accordance with IRB and ESGRO guidelines, approval number 
546-11-ES. Culture conditions were similar to reported previously [173]. Cells were 
plated either in suspension with growth factor rich medium to generate human neural 
progenitor cell (hNPC) cultures or on poly-D-lysine coated plates with neuronal medium 
for human neuronal cultures (hNeu). Both culture were grown at 37°C, with 5% O2 and 
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5% CO2 in a humidified incubator Media components are listed in Table 2.3. For 
neuronal cultures, media was half exchanged every 3-4 days. For hNPC, media was 
changed every other day. NPC cultures were characterized by immunocytochemistry for 
NPC markers Nestin (Millipore, Billerica) and Sox2 (Millipore, Billerica). To verify 
multipotency neurospheres were dissociated and plated onto Matrigel (Corning, Corning) 
coated coverslips, then cultured in a minimal media of X-VIVO-15 (Lonza, Basel)  and 
N2 (Life Technologies, Carlsbad) for 14 days, presence of astrocyte marker GFAP 
(Dako) and neuronal marker MAP2 (Sternberger) was verified by immunocytochemisty. 
For comparison of hNPC and hNeu, RNA was isolated from NPC after 7 div and neurons 
after 14 div. Neurons were treated with 10 ng/mL of IL-6 or CNTF at 13 div. and 
harvested 24 hours later for RNA purification. For measurement of P-STAT3 hNeu were 
treated with 10 ng/mL IL-6 or CNTF for 0, 15, or 30 min on div 14. For inhibitor 
experiments hNeu were treated with 1 µM Stattic (Sigma, St. Louis) 30 min prior to 
cytokine treatment, then harvested 24 hours later. Before cytokine or inhibitor treatments 
hNPC were dissociated from neurospheres and plated onto Matrigel (Corning, Corning) 
coated coverslips. To measure STAT3 activation hNPC were treated with 10 ng/mL 
CNTF for 30 min. For inhibitor experiments hNPC were treated with 2.5 µM Stattic or .6 
nM Jak1 inhibitor for 48 hours.  
 
2.13 Mouse NPC and neuronal culture: E14 mouse brains were digested with trypsin, 
mechanically dissociated and plated in suspension culture in growth media for mouse 
NPC culture (mNPC) or on poly-D-lysine coated plates in neuronal media for neuronal 
cultures. Media are listed in Table 2.3. Media was supplemented every 3rd day and after 
7 days neurospheres were harvested for RNA purification. mNeu were grown in vitro 14 
days before harvesting for RNA purification. Both culture were grown at 37°C, with 5% 
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O2 and  5% CO2 in a humidified incubator. Cells were harvested for RNA purification 
using Trizol (Life Technologies, Carlsbad) and stored at -80°C. 
 
2.14 SH-SY5Y culture. SH-SY5Y cells were grown in DMEM/F12 with GlutaMAX 
(Thermo, Waltham) and 10% FBS at 37°C at 5% CO2 in a humidified incubator. For 
differentiation, cells were treated for 4 days with 10 µM retinoic acid. Cells were 
harvested for RNA purification using Trizol (Life Technologies, Carlsbad) and stored at  
-80°C.  
 
2.15 Preparation of hippocampal slices for electrophysiology: Hippocampal slices 
were prepared as reported previously [174]. Four to six-week old male miR-21 KO and 
WT littermates were anesthetized with isofluorane. Brains were quickly removed and 
placed in oxygenated artificial cerebrospinal fluid (ACSF). Components of cutting-ACSF 
(in mM): C5H14ClNO (110.0), NaH2PO3 (1.25), KCl (2.5), MgSO4 (7.0), CaCl2 (0.2), 
C6H7NaO6 (11.6), C3H3NaO3 (3.1),  NaHCO3 (25.0), Dextrose (25.0), equilibrated with 
95% O2 and 5% CO2, osmolarity 310 ± 10. Hippocampi were dissected and 400 µm-
transverse slices were made using a tissue chopper. Hippocampi were placed on a  
mesh support and equilibriated to oxygenated recording-ACSF for at least one hour prior 
to recording. Components of recording-ACSF (in mM): NaCl (125.0), KCl (3.0), CaCl2 
(2.0), MgCl2 (1.2), NaH2PO3 (1.25), NaHCO3 (26.0) and glucose (10.0), osmolarity 300 ± 
10. Before recording, individual slices were transferred to the recording chamber. The 
recording chamber was perfused with recording 30 ± 1°C ACSF at a rate of 2 mL/min.  
 
2.16 Recording of long-term potentiation: Recording was performed as reported 
previously [174]. Constant current stimulation (0.05 Hz, 50–400 µA) was applied to the 
Schaffer collateral-commissural fibers using an insulated bipolar tungsten electrode to  
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Table 2.3 Media for primary neural cultures 
 
Species  Neuron NPC 
Mouse 50% DMEM/F12 w/ GlutaMAX 
50% DMEM 
1x B27 
DMEM/F12 w/ GlutaMAX 
1 x N2 
20 ng/mL bFGF2 
Human  Neurobasal  
1 x B27-AO 
0.5 mM L-Glutamine 
X-VIVO-15 
20 ng/ mL bFGF2 
20 ng/ mL EGF 
10 ng/ mL LIF 
60 ng/ mL N-acetyl cysteine 
1 x NSF1 
1 x N2   
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elicit a field excitatory post-synaptic potential (fEPSP) in the CA1 stratum radium. 
fEPSPs were recorded using glass recording electrodes with a diameter of 2.5 – 5 µm 
and an Axopatch-1D amplifier (Molecular Devices, Sunnyvale). Intensity of stimulation 
was adjusted to generate 50% maximal response. Baseline response was recorded for 
at least 20 min prior to high frequency stimulation (HFS). HFS was 100 Hz, 500 ms 
delivered twice in a 20 s interval. After HFS response was recorded for 40 min to 
determine LTP. Three sweeps were averaged for each recording. Electrical signals were 
filtered at 1kHz and digitized at 3.5 kHz using a Digidata 1320 interface (Molecular 
Devices). Data were analyzed with pCLAMP 10 software (Molecular Devices). The initial 
slope of the fEPSP was determined and the average fEPSP for baseline recordings was 
set as 100. Data expressed as the mean ± SEM.  
 
2.17 Excitotoxicity assays: Hippocampal neurons were isolated from miR-21 KO and 
WT P0 mouse pups as described by Beaudoin et al. [175]. Briefly, hippocampi were 
dissected and digested with .25% trypsin in HBSS for 20 min at 37°C, then washed and 
triturated. Cells were filtered with a 70 µm filter and plated in neuronal media consisting 
of Neurobasal media (Thermo, Waltham), 1x B27 (Thermo, Waltham), and 0.5 mM L-
glutamine. A full media exchange was done 15 min after plating on poly-D-lysine coated 
plates to remove cell debris. 1/3 media exchange was performed every 3-4 days. On div 
13 neurons were treated with NMDA at specified concentrations with 10 µM glycine in  
artificial CSF (1.3 mM CaCl2, 5.4 mM KCl, 140 mM NaCl2, 33 mM glucose, 25 mM 
HEPES acid, pH 7.35) for 30 min at 37°C. After 30 min conditioned media was returned 
to the wells. To determine toxicity alamarBlue (Invitrogen, Carlsbad) and lactate 
dehydrogenase [176] assays were used. 24 hours after treatment positive control wells 
were treated with 2% triton-X for 15 min at 37°C, 100 µL of neuronal medium was 
removed and 50 µL was used for LDH assay using the Cytotoxicity Detection Kit (Roche, 
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Basel) according to manufacturers directions. Percent Cytotoxicity was calculated by 
subtracting the no treatment control from the experimental and dividing by the triton-x 
positive control. For alamarBlue assay 10 µL alamarBlue (Invitrogen, Carlsbad) was 
added to the100 µL remaining in each well. After 2 hours at 37°C fluorescence was 
measured at 540 nm excitation and 590 nm emission for 5s. Percent viability was 
calculated by dividing the fluorescence at 590 of the experimental condition by the no 
treatment control. Values are reported as the mean ± SEM. Statistical analysis was 
performed using two-way ANOVA, test statistic .05. 
 
2.18 Extracellular vesicle isolation: Extracellular vesicles were isolated from brains as 
described previously [177] using a method adapted from Perez-Gonzalez et al. [178]. 
Seven days after injury animals were anesthetized with isoflurane and decapitated. 
Brains were extracted, cerebellum and brain stem were removed and the two 
hemispheres separated. For each sample 4 ipsilateral or 4 contralateral hemispheres 
were pooled. In total 12 mice for each condition were utilized. This resulted in 3 pooled 
samples of each hemisphere from TBI mice and 3 pooled samples of each hemisphere 
from sham surgery controls, for a total of 12 samples altogether. After removal, tissue 
was snap frozen in liquid nitrogen and stored at -80°C. Samples were thawed and 
digested in 20 units/ml papain in Hibernate A (Life Technologies, Carlsbad), enzymatic 
digestion was stopped by addition of cold Hibernate A, and the solution was further 
homogenized by trituration. Tissue fragments were removed by centrifugation and the 
supernatant passed through a series of successively finer filters (40 µm, 5 µm, and 0.2 
µm). Remaining cell fragments were removed by centrifugation and the EV containing 
supernatant was submitted to several PBS washes followed by ultra-centrifugation. A 
sucrose gradient was established using five concentrations of sucrose ranging from 0.25 
M to 2 M. The extracellular vesicle pellet was re-suspended in the middle concentration 
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(0.95 M), inserted into the gradient, and centrifuged at 200,000 × g for 16 hours at 4°C. 
The extracellular vesicle containing central sections of the sucrose gradient were 
removed and re-suspended to a total volume of 30 ml with PBS.  
 
2.19 EV-RNA isolation and sequencing: The suspensions from the EV isolation were 
subjected to ultra-centrifugation to pellet the EV. The pellets were then subjected to 
miRNA extraction using the mirVana miRNA Isolation Kit (Life Technologies, Carlsbad) 
following the manufacturer’s instructions. RNA samples were then sent to LC Sciences 
(Houston) for miRNA sequencing. Venny (http://bioinfogp.cnb.csic.es/tools/venny/) was 
used to create Venn diagrams 
 
2.20 Electron Microscopy: To validate the purity of EV isolation three hemispheres 
from three mice were pooled and snap frozen in liquid nitrogen and stored at -80°C. EV 
isolation was performed as described above and the sample was submitted to the 
University of Nebraska Medical Center Electron Microscopy Core Facility to undergo 
microscopy by a FEI Tecnai G2 Spirit transmission electron microscope.  
 
 
 
 
  
	   	   	  54 
Chapter 3: Expression of inflammation-associated miRNA in a controlled cortical 
impact (CCI) model of TBI 
 
3.1 Background: Neuroinflammation contributes to neurological dysfunction after TBI 
[179]. However, to date clinical trials targeting neuroinflammation in TBI have been 
unsuccessful. Identifying new regulators of neuroinflammation in TBI would provide a 
better understanding of TBI pathophysiology and provide possible therapeutic targets. It 
has recently been discovered that in peripheral immune responses miRNAs play  critical 
role in modulating inflammation [180, 181]. However, the expression of inflammation-
associated miRNA has not been examined in TBI. Several profiling studies have 
examined the expression of miRNA after TBI in various models [144-149], but very little 
is known about the functional role of miRNAs in TBI. Well-known miRNA regulators of 
the immune response, miR-155 and miR-146, miR-223 and miR-21 were all elevated in 
at least one report describing miRNA profiling following TBI; but there is a large degree 
of inconsistency due to differences in models, species, and times after injury [144-149]. 
The aim of this work was to determine whether inflammation-associated miRNAs were 
elevated in our CCI mouse model, characterize their temporal expression after CCI and 
examine their relationship to pro-inflammatory cytokine expression. 
 
3.2 Results: 
3.2.1 Identification of appropriate anatomical region for studies of inflammation-
associated miRNAs 
Before examining miRNA levels a survey of CCI pathology was performed. These 
studies allowed us to determine the temporal profile of glial activation, cell death, 
neuronal degeneration, and axonal injury after TBI. The overall aim was to determine 
appropriate anatomical regions and time points for examination of inflammation-
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associated miRNAs. Many inflammation-associated miRNAs also have roles in 
apoptosis, especially miR-21 [182] and miR-155 [183, 184]. Therefore we wanted to 
identify areas of the injured brain that: 1) lacked significant apoptotic cell death and 
tissue loss, 2) showed robust inflammation and 3) had evident neuronal pathology. To 
achieve this we examined the brains of mice 1, 3, and 7 days after CCI using various 
histological methods.  
In the unilateral model of CCI used for these studies the injury was induced in the 
parietal cortex between lambda and bregma on the left side. The hippocampus is just 
deep to this injury site. To visualize tissue loss and white matter pathology in various 
neuroanatomical regions we performed luxol fast blue staining in conjunction with cresyl 
violet. Luxol fast blue is a myelin stain used to show demyelination and cresyl violet 
stains the Nissl substance, or rough endoplasmic reticulum, found at high concentrations 
as a granular mass in neuronal cell bodies. After both moderate (0.5 mm injury depth) 
and severe (1.0 mm injury depth) CCI there was significant damage to the corpus 
callosum, particularly at 7 days after injury (Fig. 3.1). Severe injury showed a greater 
amount of cortical loss and more hippocampal involvement as well as enlargement of 
the lateral ventricle. Even in craniotomy only controls some cortical tissue loss was 
observed. This is consistent with reports of other groups showing that craniotomy alone 
can induce mild traumatic brain injury [185, 186]. To determine sites of apoptotic cell 
death after CCI terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
was performed. The majority of TUNEL positive cells were found in the cortical boundary 
zone at the edge of the lesion (Fig. 3.2). Combined, the loss of cortical tissue and the 
concentration of TUNEL positive cells in the cortex raised serious concerns for 
examination of inflammation-associated miRNA in this region. Several inflammation-
associated miRNAs also have roles in regulation of apoptotic signaling. Therefore, it 
would be difficult to differentiate these two functions in lesioned cortical tissue. In  
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Figure 3.1 
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Figure 3.1 Anatomical characterization of CCI. Myelin (Blue) and Nissl (Purple) 
staining of mouse brains 1, 3, or 7 days after craniotomy only (Sham), Moderate CCI 
(0.5 mm), and Severe CCI (1.0 mm). Naïve brain is shown for comparison. Staining was 
performed in duplicate, representative images are shown.  
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Figure 3.2 
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Figure 3.2 Apoptotic cell death in the hippocampus and cortex after moderate CCI. 
Staining for apoptotic cells using TUNEL (magenta). DAPI was used to stain the nucleus 
(blue). Images were from ipsilateral hemisphere 1 day after moderate CCI (0.5 mm) in 
the sub regions of the hippocampus (dentate gyrus (DG), CA1, and CA3) and the lesion 
boundary of the cortex. Original magnification 400x.   
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contrast, the hippocampus had barely detectable levels of TUNEL positive cells and did 
not show tissue loss. While lack of tissue loss and apoptotic cells satisfied the first 
criteria, it was also important that the anatomical region used for analyses showed 
evidence of a robust inflammatory response. 
Next, to identify anatomical regions that met the criteria of robust glial activation 
we examined expression of ionized calcium binding adaptor molecule 1 (Iba1) and glial 
fibrillary acidic protein (GFAP) by immunohistochemistry. Reactive microglia were 
identified by increased Iba1 staining and bushy or ameboid morphology (Fig. 3.3). It is 
important to note that activated microglia cannot be differentiated from invading 
mononuclear cells using this method. Increased staining with Iba1 was seen in the 
ipsilateral cortex and hippocampus 1 and 3 days after injury. To identify activated 
astrocytes we used glial GFAP staining (Fig. 3.4). Both protoplasmic astrocytes in the 
cortex and hippocampus and fibrous astrocytes in the corpus callosum showed 
increased GFAP expression. The GFAP staining in the ipsilateral cortex and 
hippocampus was highest 3 and 7 days after injury. Interestingly, GFAP expression was 
also increased in the ipsilateral cortex of craniotomy only animals 1 day after injury, 
suggesting again that craniotomy induces a mild traumatic brain injury. Also striking was 
increased GFAP expression in the contralateral corpus callosum after TBI. Increased 
Iba1 and GFAP staining was seen in both the ipsilateral cortex and hippocampus. 
Contralateral hemispheres also showed some increase in glial activation, however, it 
was much less dramatic. While the cortex of craniotomy only controls showed increased 
astrocyte reactivity, the hippocampus did not. Therefore, both the cortex and 
hippocampus meet the criteria of robust glial response after CCI.  
In addition to changes in glial activation, we wanted to determine regions of 
evident neuronal pathology. Staining of neurons with microtubule associated protein 2 
(MAP2) and synaptophysin revealed loss of these important neuronal markers in the  
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Figure 3.3 Microglial and macrophage activation at various times after moderate 
CCI in the hippocampus and cortex. Staining for Iba1 positive microglia and 
macrophages (green). DAPI was used to stain the nucleus (Blue). Images were taken 
from ipsilateral (IPSI) and contralateral (CONTRA) hemisphere. Mice were sacrificed 1, 
3, or 7 days after moderate CCI (0.5 mm) or 1 day after craniotomy (SHAM) and 
compared to naïve controls. Hippocampus sub regions (dentate gyrus (DG), CA1, and 
CA3) and the lesion boundary of the cortex are shown. Original magnification 400x. 
Staining was performed in duplicate, representative images are shown.   
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Figure 3.4 Astrocyte activation at various times after moderate CCI in the 
hippocampus and cortex. Staining for GFAP positive astrocytes (green). DAPI was 
used to stain the nucleus. Images were taken from ipsilateral (IPSI) and contralateral 
(CONTRA) hemisphere. Mice were sacrificed 1, 3, or 7 days after moderate CCI (0.5 
mm) or 1 day after craniotomy (SHAM) and compared to naïve controls. Hippocampus 
sub regions (dentate gyrus (DG), CA1, and CA3) and the lesion boundary of the cortex 
are shown. Original magnification 400x. Staining was performed in duplicate, 
representative images are shown.   
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injury boundary zone after CCI but not in craniotomy only controls (Fig. 3.5). Interestingly 
CCI increased the expression of both MAP2 and synaptophysin in the cortex and 
hippocampus not directly involved in the lesion (Fig. 3.6) Interestingly, increased 
synaptophysin staining was also seen by Shojo and Kibayashi after fluid percussion 
injury [187]. They concluded that increased synaptophysin staining was due to 
accumulation of synaptic vesicles and corresponded with neurodegeneration. Finally, 
white matter damage was visualized using SMI-32, an antibody that recognizes 
dephosphorylated neurofilament-H and serves as a marker of white matter damage 
[188]. A strong increase in SMI-32 staining was observed in the corpus callosum and 
hippocampal alveus both white matter tracts which are deep to the injury site at all time 
points after CCI, while little to no staining was observed in craniotomy only controls (Fig 
3.7). While not as profound, SMI-32 reactivity was also found in the contralateral 
hemispheres. Interestingly, SMI-32 staining increased from 3 to 7 days in the ipsilateral 
white matter tracts. Other groups have also reported progressive increase in SMI-32 
staining from 3-7 days after CCI [189]. Together with the progressive white matter 
damage at seen at day 7 shown with luxol fast blue staining, increased SMI-32 staining 
at day 7 suggests progressive white matter damage. The combination of white matter 
degeneration and changes in expression of neuronal proteins is sufficient to suggest 
evident neuropathology in both the cortex and hippocampus. Therefore both these 
regions satisfy the third critera for examination of inflammation-associate miRNAs.  
Overall, these data paint a portrait of CCI induced pathology and allowed us to 
determine an appropriate anatomical region for the study of inflammation-associated 
miRNAs. For the study of inflammation-associated miRNAs we proposed that an 
anatomical region meet three criteria: 1) lack significant apoptotic cell death and tissue 
loss, 2) show robust inflammation and 3) have evident neuronal pathology. While both 
the cortex and hippocampus showed increases in activated glia, the cortex was the site 
	   	   	  66 
Figure 3.5 	  
	  	   	  
	   	   	  67 
Figure 3.5 Loss of neuronal markers at the lesion site. Staining for neuronal markers 
MAP2 (red) and Synaptophysin (green). DAPI was used to stain the nucleus. Images 
were taken at the edge of the lesion and the lesion boundary in the injured hemisphere. 
Mice were sacrificed 1, 3, or 7 days after moderate CCI (0.5 mm) or 1 day after 
craniotomy (SHAM). Original magnification 400x. Staining was performed in duplicate, 
representative images are shown.   
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Figure 3.6 
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Figure 3.6. Increase in neuronal markers after moderate CCI. Staining for neuronal 
markers MAP2 (red) and Synaptophysin (green). DAPI was used to stain the nucleus. 
Images were taken from ipsilateral (IPSI) and contralateral (CONTRA) hemisphere. Mice 
were sacrificed 1, 3, or 7 days after moderate CCI (0.5 mm) or 1 day after craniotomy 
(SHAM) and compared to naïve controls. Hippocampus sub regions (dentate gyrus 
(DG), CA1, and CA3) and the lesion boundary of the cortex are shown. Original 
magnification 400x. Staining was performed in duplicate, representative images are 
shown.   
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Figure 3.7 
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Figure 3.7. White matter damage after moderate CCI. Staining with SMI-32, a marker 
of axonal damage (green). DAPI was used to stain the nucleus. Images were taken from 
ipsilateral (IPSI) and contralateral (CONTRA) hemisphere. Mice were sacrificed 1, 3, or 
7 days after moderate CCI (0.5 mm) or 1 day after craniotomy (SHAM) and compared to 
naïve controls. Hippocampus sub regions (dentate gyrus (DG), CA1, and CA3) and the 
lesion boundary of the cortex are shown. Original magnification 400x. Staining was 
performed in duplicate, representative images are shown.   
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of the majority of cell death, tissue loss and neuronal degeneration. In addition, we 
observed progressive white matter damage and increased levels of MAP2 and 
synaptophysin in both the cortex and hippocampus. Therefore, based on our three 
criteria we chose to focus or study of inflammation-associated miRNAs on the 
hippocampus. 
 
3.2.2. Temporal expression of inflammation-associated miRNAs in the 
hippocampus after moderate CCI. 
To determine whether inflammation-associated miRNAs were elevated after TBI and 
examine their temporal profile RNA was extracted from injured (ipsilateral) and uninjured 
(contralateral) hippocampi from the same animal at times spanning the acute and sub-
acute phase after injury and in naïve and sham controls. Levels of miR-155, miR-146a, 
miR-21, and miR-223 were examined by qPCR. These miRNA were chosen based on 
their importance in regulating inflammatory responses and being positively identified in 
at least one profiling study of TBI. Levels of miRNAs examined did not change between 
hemispheres in naïve or sham controls. We found that miR-155, miR-21 and miR-223 
were all elevated after TBI (Fig. 3.8A-C). No change was observed in miR-146 levels 
(Fig. 3.8D). The expression of miR-155 was significantly increased at 1, 3, and 7 days 
after injury between ipsilateral and contralateral hippocampi, and returned to baseline by 
14 days (Fig. 3.8A). Expression of miR-21 showed a complementary trend, only elevated 
significantly at 14 days after injury relative the uninjured hemisphere, but not at 1, 3, or 7 
days (Fig. 3.8B). Expression of miR-223 was significantly elevated in the ipsilateral 
hippocampus only at 1 day after injury relative to the contralateral hemisphere (Fig. 
3.8C). Overall, changes were observed in three of the four inflammation-associated 
miRNA examined, but each showed a distinct temporal profile.  
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Figure 3.8 
	  
	   	   	  74 
	  	  
Figure 3.8 Expression of inflammation-associated miRNAs in the hippocampus 
after CCI. Levels of miR-155 (A), miR-21 (B), miR-223 (C), and miR-146 (D) in the 
ipsilateral (IPSI) and contralateral (CONTRA) hippocampus were measured 1, 3, 7, and 
14 days after CCI by qPCR at 0.5-mm injury depth and in naïve animals and sham 
surgery controls. Data are expressed as fold change relative to naïve mice normalized to 
snRNA U6. The mean ± SEM from three animals are shown. Statistical analysis was 
performed on ΔCt values using a two-way ANOVA, difference between hemispheres 
was significant for miR-155 (p < .0001), miR-21 (p < .001), and miR-223 (p < .05). 
Bonferroni post-hoc tests were performed on each time point, *, P < .05, relative to the 
contralateral hemisphere.  
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3.2.3 Temporal expression of pro-inflammatory cytokines in the hippocampus 
after moderate CCI. 
Increases in pro-inflammatory cytokines after TBI are found in both patients [190] and 
rodent models [191]. To examine the relationship between inflammation-associated 
miRNA and neuroinflammation, we examined the temporal expression profile of pro-
inflammatory cytokines in the hippocampus after CCI. Expression of pro-inflammatory 
cytokines IL-1β, TNFα, and IL-6 were measured in the ipsilateral and contralateral 
hippocampus from the same animal 1, 3, 7, and 14 days after injury and in naïve and 
sham controls. The same RNA samples were used for both miRNA and mRNA analysis. 
Expectedly, levels of proinflammatory cytokines increased in the ipsilateral hemisphere 
after CCI (Fig. 3.9). All the three cytokines examined showed increased levels in the 
ipsilateral compared to the contralateral hippocampi, with peak expression 1 day post 
injury. Both IL-1β (Fig. 3.9A) and IL-6 (Fig. 3.9C) were not elevated in the sham controls 
and did not change 3, 7, or 14 days after injury. In contrast, increase in TNFα expression 
persisted at 3 days after injury (Fig. 3.9B). Additionally, TNFα expression was increased 
in the ipsilateral hemisphere of sham animals. Other groups have also reported 
increased inflammation in sham controls [185, 186]. We also note that the 8-fold 
increase between naïve and the ipislateral sham cortex is only a fraction of the CCI 
induced increase (~60 fold). These data suggest that TNFα is highly sensitive to CNS 
damage and that relative to other cytokines; its increased expression persists for several 
days after injury. The main finding here was an acute increase in gene expression of the 
pro-inflammatory cytokines after TBI.  
 
3.2.4. Correlation between expression of inflammation-associated miRNAs and 
pro-inflammatory cytokines.  
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Figure 3.9
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Figure 3.9 Expression of inflammatory cytokines in the hippocampus after CCI. 
Levels of IL-1β (A), TNFα (B), and IL-6 (C) in the ipsilateral (IPSI) and contralateral 
(CONTRA) hippocampus were measured 1, 3, 7, and 14 days after CCI by qPCR at 0.5-
mm injury depth and in naïve animals and sham surgery controls. Data are expressed as 
fold change relative to naïve mice normalized to GAPDH. The mean ± SEM from three 
animals are shown. Statistical analysis was performed on ΔCt values using a two-way 
ANOVA, difference between hemispheres was significant for IL-1β (p < .0001), TNFα (p 
< .0001), and IL-6 (p < .0001). Bonferroni post-hoc tests were performed on each time 
point, *, P < .05; **, P < .01; ***, P < .001; ****, P < .0001; relative to the contralateral 
hemisphere.  
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In the peripheral immune system levels of miR-155 correlate with expression of IL-1β 
and TNFα suggesting a relationship between these two classes of molecules [192]. To 
examine the relationship between the inflammation-associated miRNA and pro-
inflammatory cytokines after CCI we performed a Pearson’s correlation analysis (Fig. 
3.10). The strongest association was between miR-155 and IL-1β, r = .72 (Fig. 3.10A). 
The second strongest association was found between miR-155 and TNFα (r = .63), 
followed by miR-21 and IL-1β (r = .55). The only cytokine-miRNA pair that did not show 
any correlation was IL-6 and miR-21 (p = .38) (Fig. 3.10B). This was surprising as miR-
21 is known to be induced by IL-6 in the periphery [193]. In summary, there was a clear 
association between inflammatory cytokines and inflammation-associated miRNAs 
indicating that there is a strong relationship between these two classes of molecules.  
 
3.2.5 Localization of miR-155, miR-21, and miR-223 in the brain after CCI. 
To validate qPCR findings that expression of inflammation-associated miRNAs was 
increased after CCI and to further describe their localization in different anatomical 
regions we performed in situ hybridization (Fig. 3.11). Brains from mice 1, 3, and 7 days 
after CCI as well as naïve and sham controls were analyzed. Similar to results from 
qPCR experiments, we found increased levels of miR-155, miR-21, and miR-223 in the 
hippocampus after TBI. We also found increased expression in the boundary zone of the 
cortex. Expression of inflammation-associated miRNAs was not observed in the brains 
of naïve mice. The ipsilateral hemisphere of sham mice was positive for miR-155, but 
not miR-21 or miR-223. The contralateral hemisphere at day 1 and 3 was also positive 
for miR-155 in contrast to qPCR results (Fig. 3.11A). One striking feature of miR-155 
expression was its nuclear localization as evidenced by co-localization with DAPI 
staining of the nucleus. As was seen in qPCR experiments, miR-21 expression was 
more delayed. Of the timepoints examined the highest levels of miR-21 expression were  
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Figure 3.10 Correlation of inflammation-associated miRNAs with expression of 
pro-inflammatory cytokines. Correlation was calculated using ΔCt values for cytokines 
and miRNAs measured from the same hippocampal RNA. Correlation of TNFα, IL-1β, 
and IL-6 with miR-155 (A), miR-21 (B), and miR-223 (C) are shown. Pearson’s r and p 
values as indicated. Thirty-six paired values from 1, 3, 7, and 14 days after CCI at 0.5-
mm injury depth, naïve animals, and sham controls were used to determine correlation. 
Trend line (dashed) based on linear regression.    
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Figure 3.11 	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Figure 3.11 Localization of inflammation-accociated miRNAs after CCI in the 
hippocampus and cortex. Expression of miR-155 (A), miR-21 (B), and miR-223 (C) 
after CCI. Fluorescence in situ hybridization was performed on tissue sections from mice 
1, 3, and 7 days after .05 mm CCI or 1 day after sham surgery. The cortical boundary 
zone and the dentate gyrus (DG), CA1, and CA3 of the hippocampus on the ipsilateral 
(IPSI) and contralateral (CONTRA) hemisphere are shown. Stratum moleculare (M), 
stratum granulosum (G), hilus (H), stratum radiatum (R), stratum pyramidale (P), and 
stratum oriens (O). Nuclei are stained with DAPI are shown in blue; miRNAs are shown 
in magenta. Staining was performed on tissues from two animals and representative 
images are shown. 
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observed at 7 days after CCI. The localization of miR-21 was not nuclear as was seen 
with miR-155. Interestingly, miR-21 expression was high in the laminar layers of the 
hippocampus, regions densely populated with neurons. In the dentate gyrus expression 
of miR-21 was detected in the stratum molecular, which is composed primarily of 
neuronal projections and the stratum granulosum, which contains the neuronal cell 
bodies (Fig. 3.11B). Additionally in the CA1 region the stratum pyramidale is composed 
of pyramidal neurons and shows miR-21 expression as does the stratum radiatum, 
which contains both neuronal projections such as the Schaffer collateral as well as 
interneurons. The expression of miR-223 is unique from both miR-155 and miR-21 in 
that it was only detected at day 3 after injury and predominantly in the ipsilateral 
hemisphere (Fig. 3.11C).  
In summary, the expression of inflammation-associated miRNAs is detectable in 
the hippocampus and boundary zone of the cortex after CCI. As found in qPCR 
experiments miR-155 was expressed at several time points after CCI, in contrast to miR-
21 which showed a delayed expression pattern. As with qPCR miR-223 showed a short 
duration of expression in the acute period. Several differences do exist between qPCR 
and in situ results. For example, miR-155 expression was not increased in sham or 
contralateral hemispheres by qPCR, but was detected by in situ. This could be due to 
sampling differences between these two methods. RNA isolation from the entire 
hippocampus could dilute the expression of miRNA concentrated near the lesion to 
undetectable levels by qPCR. While differences between these two methods exist, both 
showed increased levels of inflammation-associated miRNAs after CCI.  
 
3.2.6. Expression of inflammation-associated miRNAs with increasing injury 
severity in the hippocampus.  
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To gain a better understanding of the interaction between injury severity and expression 
of inflammation-associated miRNA and identify the ideal conditions for functional studies 
of miRNA, we examined the expression of miRNAs after moderate and severe TBI. In 
the CCI model injury severity can be altered by changing injury depth; with increased 
depth leading to increased lesion size and greater cognitive impairment [194]. In order to 
examine the effect of injury severity on the expression of inflammation-associated 
miRNA, levels of miR-21, miR-155, and miR-223 were measured in animals 3 days after 
sham surgery, moderate (0.5 mm depth) CCI, or severe (1.0 mm depth) CCI as well in 
naïve animals (Fig. 3.12). Injury depth was significant for miR-21 (P < .01) and miR-155 
(P < .01), but not for miR-223 based on a two-way ANOVA. Consistent with Fig. 3.1, CCI 
at the 0.5 mm injury depth increased miR-155 at 3 days, but levels of miR-21 and miR-
223 were not increased in these conditions. In contrast, CCI at 1.0 mm injury depth 
increased miR-21, miR-155 and miR-223 levels in the ipsilateral compared with the 
contralateral hippocampus. Given that the expression of all three miRNAs was present 
at 3 days after severe (1.0 mm) CCI, we chose to use this time point and severity for 
functional analysis of inflammation-associated miRNAs.  
 
3.2.7. Targeted expression profiling of cytokines, chemokines, and growth factors 
at 3 days after CCI.  
One area of interest for functional studies of inflammation-associated miRNAs is their 
ability to regulate the downstream expression of cytokines, chemokines, and growth 
factors after TBI. Based on the data above, 3 days after severe CCI was chosen as the 
ideal conditions for examining miRNA function. In moderate CCI, expression of TNFα 
was significantly elevated 3 days after CCI in the ipsilateral hemisphere, but IL-6 and IL-
1Β were not. To determine whether cytokine expression was a measurable outcome at 3 
days after severe TBI we measured inflammatory cytokine expression in animals 3 days  
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Figure 3.12 Expression of inflammation-associated miRNAs in the hippocampus 
after moderate and severe CCI. Levels of miR-155 (A), miR-21 (B), and miR-223 (C) in 
the ipsilateral (IPSI) and contralateral (CONTRA) hippocampus were measured 3 days 
after CCI by qPCR at 0.5-mm injury depth, 1.0-mm injury depth and in naïve animals 
and sham surgery controls. Data are expressed as fold change relative to naïve mice 
normalized to snRNA U6. The mean ± SEM from 3-4 animals are shown. Statistical 
analysis was performed on ΔCt values using a two-way ANOVA, Injury severity was 
significant for miR-155 (p < .01) and miR-21 (p < .01), but not miR-223. Bonferroni post-
hoc tests were performed on each time point, *, P < .05, ***, P < .001 relative to the 
contralateral hemisphere.  
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after sham surgery, moderate (0.5 mm depth) CCI, or severe (1.0 mm depth) CCI as 
well in naïve animals. In addition we broadened the list of signaling molecules to include 
other cytokines, chemokines, and growth factors important in neuroinflammation. 
Cytokines IL-1β and TNFα, as well as chemokine CXCL10 were increased 3 days after 
CCI (Fig. 3.13). The expression of IL-1β was elevated in moderate injury in both the 
ipsilateral and contralateral hippocampi and in the severely injured ipsilateral 
hippocampus relative to naïve. TNFα expression was elevated in ipsilateral hippocampi 
of both moderate and severe injury and in the contralateral hippocampus of severe injury 
relative to naïve. Interestingly, we also found increased levels of CXCL10 in both the 
moderately and severely injured ipsilateral hippocampi relative to naive. In conclusion, 
the expression of IL-1β, TNFα, and CXCL10 was elevated in at least the ipsilateral 
hippocampi after TBI and can be used as an outcome measure for future functional 
studies of inflammation-associated miRNAs.    
 
3.3 Discussion 
These studies addressed 3 major questions: 1) which anatomical regions are 
appropriate for studying the expression and function of inflammation-associated miRNAs 
after CCI? 2) Are inflammation-associated miRNAs increased by CCI? 3) What is the 
relationship between inflammation-assoicated molecules and pro-inflammatory 
cytokines?  
 By characterizing the pathophysiology of CCI in the mouse model we identified 
the hippocampus as an appropriate region for studying changes in inflammation-
associated miRNAs. The hippocampus showed evident neuropathology and robust glial 
activation without frank tissue loss or high levels apoptotic cell death. The inflammation-
associated miRNAs examined here all have known roles in apoptosis [182, 184, 195, 
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196]. Therefore, we wanted to avoid examining tissues with high amounts of apoptotic 
signaling after CCI. In CCI animals we found cortical tissue loss and TUNEL positive  
apoptotic cells concentrated in the lesion boundary zone of the cortex. These findings 
are in agreement with multiple studies describing apoptosis in cortical tissue after CCI 
[197, 198]. Alternatively, the hippocampus showed negligible tissue loss and very few 
apoptotic cells. We also wanted to ensure that the anatomical region studied showed 
robust glial activation. Immunohistochemisty revealed increases in both Iba1 and GFAP 
staining in the hippocampus suggesting that either anatomical region would be 
appropriate to study the inflammatory response after CCI. To study the complex 
interaction between neuroinflammation and neuronal injury and regeneration we wanted 
to examine a region where neuronal pathology was evident. We found that SMI-31, a 
marker of phosphorylated neurofilament was present in two distinct white matter tracts, 
the corpus callosum and hippocampal alveus [199]. Staining with MAP2 and 
synaptophysin was absent in the lesioned cortex, but was upregulated in both the 
cortices not directly involved in the lesion and in the hippocampus. This increase in 
important neuronal markers suggests a regenerative response to CCI. Based on these 
findings we directed further experiments in inflammation-associated miRNA after CCI 
towards the hippocampus.  
 Both qPCR and in situ hybridization showed increases in three out of the four 
inflammation-associated miRNAs examined in the hippocampus after CCI. Expression of 
miR-155, miR-21, and miR-223 were all increased in the ipsilateral hippocampi after 
CCI. Sustained eleveation of miR-155 was observed in the acute period 1, 3, and 7 days 
after TBI. Conversely, miR-21 showed increased expression in the sub acute phase (day 
7 and 14) by either pPCR or in situ. The expression of miR-223 showed a less sustained 
increase in the acute period. Somewhat surprisingly levels of miR-146 remained 
unchanged by CCI. In peripheral immune responses [120] and in microglia [200] miR- 
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Figure 1. Expression of cytokines, chemokines, and growth factors in the 
hippocampus after moderate and severe CCI. Levels of cytokines, chemokines, and 
growth factors in the ipsilateral (IPSI) and contralateral (CONTRA) hippocampus were 
measured 1, 3, 7, and 14 days after CCI by qPCR at 0.5-mm injury depth or 1.0-mm 
injury depth and in naïve animals and sham surgery controls. Data are expressed as fold 
change relative to naïve mice normalized to snRNA U6. The mean ± SEM from 3-4 
animals are shown. Statistical analysis was performed on ΔCt values using a two-way 
ANOVA, Bonferroni post-hoc tests were performed on each time point, *, P < .05; **, P < 
.01; ***, P < .001; relative to naïve.  
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146 participates in feedback inhibition, limiting the duration and magnitude of the 
immune response. Therefore, the lack of miR-146 could be a pathological feature of 
CCI.  
 Even though both qPCR and in situ hybridization identified the same general 
expression pattern, several differences between the regional and temporal expression of 
inflammation-associated miRNAs was found between these methods. One example 
being the detection of miR-155 in both sham and contralateral hemisphers. One possible 
explanation for this could be sampling differences between the two methods. The 
dilution of changes in miRNA levels near the injury site in RNA from the entire 
hippocampus might result in qPCR being a less sensitive measure of miRNA 
expression.  
 As expected, our CCI model showed striking increases in pro-inflammatory 
cytokines IL-1β, TNFα, and IL-6 in the injured hippocampi that peaked 1 day after injury. 
TNFα was elevated in craniotomy only sham controls and showed sustained elevation at 
3 days after injury, indicating that it is a sensitive indicator of neuronal injury and 
inflammation. The expression of inflammation-associated miRNAs showed high levels of 
correlation with the three pro-inflammatory cytokines. These data indicated a strong  
relationship between these two classes of molecules, however, the nature of this 
relationship cannot be determined by the studies described here.  
 To determine the ideal conditions for future studies of the function of 
inflammation-associated miRNAs in CCI, we examined levels of miRNAs in both 
moderate and severe CCI. While in moderate CCI only miR-155 was elevated relative to 
the contralateral hemisphere, in severe CCI increases in miR-21 and miR-223 were 
detected. Additionally, increases in three inflammatory signaling molecules, IL-1β, TNFα, 
and CXCL10 could also be detected 3 days after severe injury. Together these studies 
were designed to identify the ideal circumstances for studying the functional role of 
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inflammation-associated miRNAs in TBI. Based on our findings we will focus our efforts 
on studying the function of inflammation-associated miRNAs in the hippocampus 3 days 
after severe injury.  
 Another important finding of this work was the marked elevation of miR-155 
expression in the CCI model of TBI. Redell et al. also found that levels of miR-155 were 
elevated 24h after CCI [145]. However, no studies have examined the localization, 
association with inflammation, or function of miR-155 in TBI. Given the importance of 
miR-155 in other neurological conditions, further exploration of miR-155 function of TBI 
is warranted.  
 While miRNA-21 is the most studied miRNA in TBI, the late expression pattern 
and seemingly neuronal localization of miR-21 suggest that it may have additional roles 
besides regulating neuronal apoptosis, which occurs in the acute phase of injury. 
Several independent reports of miR-21 promoting neurite outgrowths may point to a role 
for miR-21 in the regenerative process after TBI [201-203].  
 The expression of miR-223 showed an acute increase after CCI in the ipsilateral 
hemisphere. Recently a report by Izumi et al. showed expression of miR-223 after spinal 
cord injury (SCI) that localized to neutrophils [204]. Given the acute increase and 
decrease of neutrophils in TBI lesions,[205] expression of miR-223 in neutrophils could 
explain the acute expression pattern seen for miR-223 in TBI.  
 
3.4 Summary: 
Several interesting inflammation-associated miRNAs were increased by TBI. Expression 
of miR-155, miR-21, and miR-223 were all elevated in ipsilateral hippocampi relative to 
contralateral hippocampi by both qPCR and in situ hybridization. Of the miRNA 
examined, miR-155 showed the largest and most consistent increase. Interestingly miR-
21 had a delayed expression pattern, suggesting that it may play a role the sub-acute 
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phase of injury. The roles of miR-155 in inflammatory signaling in the acute phase and 
miR-21 in regenerative phase of CCI warrant further study. Based on our findings the 
ideal conditions for studying the roles of inflammation-associated miRNAs are three days 
after CCI in the hippocampus.   
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Chapter 4: Function of miR-155 in the controlled cortical impact (CCI) model of TBI 
 
4.1 Background: 
 
Expression of inflammation-associated miR-155 was induced by TBI. Additionally, 
expression of miR-155 was highly correlated with pro-inflammatory cytokines. Based on 
the known roles of miR-155 in the peripheral immune response [121, 122, 206, 207] we 
hypothesized that miR-155 could regulate neuroinflammation after TBI. In vitro studies of 
miR-155 in microglia support a pro-inflammatory role in the brain [133]. However, in vivo 
studies are still lacking. In order to examine the function of miR-155 in TBI we obtained 
miR-155 knockout (KO) mice and induced TBI using a controlled cortical impact (CCI) 
model. Using a combination of RNA and protein analysis, histological characterization, 
and behavioral testing we compared TBI induced changes between miR-155 KOs and 
WT mice. 
 
4.2 Results: 
4.2.1 Validation of miR-155 KO by in situ hybridization 
Our previous studies showed increased miR-155 after CCI by both qPCR and in situ 
hybridization in wild-type mice. To examine it’s role in TBI we obtained miR-155 
knockout (KO) mice from the Jackson Laboratory. To confirm that expression of miR-155 
was absent from miR-155 KO mice and to localize miR-155 after severe injury we 
performed in situ hybridization on the brains of miR-155 KO and WT control mice 
sacrificed 3 days after CCI (Fig. 4.1). As observed previously in moderate injury, miR-
155 was detected in the hippocampus and cortex in the ipsilateral hemisphere after CCI 
and primarily localized to the nucleus. No staining was observed in miR-155 KOs 
confirming that miR-155 expression was absent in these animals.  
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Figure 4.1 
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Figure 4.1 Expression of miR-155 after CCI WT and miR-155 KO. Detection of miR-
155 expression (magenta) after CCI by fluorescence in situ hybridization performed on 
tissue sections from WT and miR-155 KO mice 3 days after 1.0-mm CCI. Nuclei are 
stained with DAPI (blue). Images are from the ipsilateral lesion boundary of the cortex 
and the dentate gyrus (DG) of the hippocampus. Original magnification 200x. 
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4.2.2 Ablation of miR-155 alters the expression of cytokines, chemokines and 
growth factors after CCI.  
In order to understand the function of miR-155 in regulating the immune response in TBI, 
we subjected miR-155 KOs and wild type mice to CCI. Three days after CCI, RNA was 
isolated from ipsilateral and contralateral hippocampi and levels of cytokines, 
chemokines, and growth factors were measured by qPCR (Fig. 4.2). No changes were 
found in naïve miR-155 KO compared to WT mice using two-way ANOVA followed by 
Bonferroni post-hoc tests. Changes were found between CCI injured miR-155 KO and 
wild type mice. Both type I and type II interferon (IFN) expression was altered. In the 
ipsilateral hemisphere IFN-β was reduced in miR-155 KOs. In the contralateral 
hemisphere IFN-γ was reduced in miR-155 KO mice compared to wild-type. 
Unexpectedly, there were no differences in the expression of IL-1β or TNFα, which are 
regulated by miR-155 in other systems [121, 192]. In our previous profiling experiments 
we had seen large increases in the expression of chemokine CXCL10. We again saw a 
large increase in CXCL10 expression due to TBI, which was significantly reduced in the 
ipsilateral hippocampi of miR-155 KO mice compared to WT. Additionally, we saw a 
decrease of brain-derived neurotropic factor (BDNF) in the contralateral hippocampus of 
miR-155 KO mice. The main findings of this work were the decreased expression of IFN-
β, IFN-γ, CXCL10 and BDNF in miR-155 KO hippocampi after CCI. CXCL10 is induced 
by both type I and type II IFN [208], and therefore the decrease in CXCL10 seen here 
may be secondary to the reduction in IFN.  
 
4.2.3 Regulation of SOCS1 by miR-155 in CCI.  
To further examine the changes in IFN signaling after CCI in miR-155 KO mice we 
examined the levels of known miR-155 target suppressor of cytokine signaling 1 
(SOCS1) [206]. IFN signaling relies on signal transducer and activator of transcription 1  
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Figure 4.2 
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Figure 4.2 Expression of cytokines, chemokines, and growth factors in the 
hippocampus after CCI in miR-155 KO and WT mice. Levels of cytokines, 
chemokines, and growth factors in the ipsilateral (IPSI) and contralateral (CONTRA) 
hippocampus were measured 3 days after CCI by qPCR at 1.0-mm injury depth and in 
naïve mice. Data are expressed as fold change relative to WT-naïve mice normalized to 
GAPDH. The mean ± SEM from 4 WT and 5 miR-155 KO mice are shown. Statistical 
analysis was performed on fold change values using a two-way ANOVA for each 
cytokine, Bonferroni post-hoc tests were performed on each time point, *, P < .05; **, P < 
.01; ***, P < .001.  
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(STAT1), which is inhibited by SOCS1 [209]. Therefore we hypothesized that removing 
miR-155 would increase levels of SOCS1, which in turn could decrease STAT1 
activation leading to a decreased response to IFN. In order to determine whether 
SOCS1 was in fact increased in miR-155 KO mice we measured levels of SOCS1 
protein and mRNA in miR-155 KO and WT ipsilateral hippocampi 3 days after CCI. 
There was no difference in SOCS1 protein level between miR-155 KO and WT 
hippocampi (Fig. 4.3). The lack of a change in SOCS1 protein levels could indicate that 
SOCS1 was not regulated by miR-155 in the brain after CCI. Alternatively the change in 
SOCS1 was not detectable because only a subset of cells had increased expression of 
miR-155 and corresponding reduction in SOCS1. If SOCS1 was decreased in a fraction 
of the total cells, the effect may have been diluted and immeasurable in hippocampal 
homogenate.  
 The expression of SOCS1 mRNA in the hippocampus after CCI was also 
measured. Surprisingly, the mRNA expression of SOCS1 was decreased in miR-155 KO 
mice (P = .028) (Fig. 4.4). Since SOCS1 is a target of miR-155; we hypothesized that its 
levels would increase in miR-155 KO hippocampi. The decreased mRNA levels, but 
unchanged protein levels could indicate compensatory effects. Alternatively, the effects 
could be cell type specific and unable to be detected in RNA or protein purified from 
tissue homogenates. There was a significant change in SOCS1 mRNA by condition (P < 
.001) with ipsilateral hippocampi showing a 2 fold increase in SOCS1 expression relative 
to naïve. This is the first report of increased SOCS1 expression in TBI and suggests that 
SOCS1 may be important for limiting the immune response after TBI.  
 
4.2.4 Increased microglial activation in miR-155 KO after CCI.  
Comparison of gene and protein expression between miR-155 KO and WT mice after 
CCI revealed changes in the IFN response. Several studies have shown that ectopic  
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Figure 4.3. Suppressor of cytokine signaling (SOCS1) is elevated in miR-155 KO 
mice. (A) Levels of SOCS1 were analyzed by SDS-PAGE and Western blot in WT (+) 
and miR-155 KO (-) mice 3 days after 1.0 mm CCI. (B) Level of SOCS 1 was quantified 
by densitometry and normalized to β-actin. The mean relative density ± SEM from 4 
animals are shown. Student’s t-test was used to determine significance. *, P = .042. 
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Figure 4.4 
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Figure 4.4 Expression of SOCS1 mRNA in the hippocampus after CCI in miR-155 
KO and WT mice. Levels of SOCS1 mRNA in the ipsilateral (IPSI) and contralateral 
(CONTRA) hippocampus were measured 3 days after CCI by qPCR at 1.0-mm injury 
depth and in naïve mice. Data are expressed as fold change relative to WT-naïve mice 
normalized to GAPDH. The mean ± SEM from 4 WT and 4 miR-155 KO mice are shown. 
Statistical analysis was performed on fold change values using a two-way ANOVA 
(condition P < .0001; genotype, P = .028). Bonferroni post-hoc tests were performed on 
each time point, but no significant changes were found. Student’s T-test between 
ipsilateral WT and miR-155 KO was significant **, P = .0058.  
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expression of miR-155 promotes microglial activation and cytokine production [210-213]. 
We hypothesized that microglial activation would be reduced in miR-155 KO mice. In 
order to characterize changes in microglial activation between miR-155 KO and WT 
mice we performed immunohistochemistry for microglial activation marker ionized 
calcium-binding adapter molecule 1 (Iba1) in the hippocampi after CCI. We hypothesized 
that increased SOCS1 in miR-155 KOs would reduce microglial activation. Surprisingly, 
we found the opposite effect (Fig. 4.5). Iba1 expression was increased in the ipsilateral 
hippocampus of miR-155 KOs relative to WT after CCI (P = .046). Increased expression 
of SOCS1 is discordant with an increase in microglial activation.  We speculate that 
SOCS1 is not the only target of miR-155 involved in the inflammatory response and that 
increased microglial activation could be related to other miR-155 targets.  
 
4.2.5 Neuronal localization of miR-155 after CCI. Surprisingly, microglial activation 
was increased after CCI in miR-155 KO mice. Additionally, we did not see changes in 
hippocampal SOCS1 protein after CCI. Interestingly, STAT1 can be activated in neurons 
after ischemic injury and contributes to cell death [214]. Also several reports have 
identified neuronal CXCL10 expression, which is also linked to neuronal cell death [215-
217]. To determine whether miR-155 plays a role in the neuronal regulation of STAT1 
and CXCL10, fluorescent in situ hybridization (FISH) was combined with 
immunohistochemistry (IHC) for neuronal marker MAP2 (Fig. 4.6) In the lesion boundary 
of the injured cortex we observed miR-155 staining in the nucleus of MAP2 positive 
cells. This indicated that neurons expressed miR-155 after CCI. We therefore proceeded 
to examine the role of miR-155 in neuronal cell death and degeneration.  
 
4.2.6 Apoptosis after CCI is unaffected by miR-155 KO 
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Figure 4.5  
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Figure 4.5 Iba1 staining is increased in the hippocampus of miR-155 KO mice after 
CCI. (A) Brains from WT (+) and miR-155 KO (-) mice were stained for Iba1 3 days after 
1.0-mm CCI. Representative images are shown. (B) The area of the hippocampus 
stained with Iba1 was quantified. The mean ± SEM from 5 WT and 6 miR-155 KO 
animals are shown. Student’s t-test was used to determine significance. *, P = .046. 
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Figure 4.6 
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Figure 4.6 Localization of miR-155 after CCI. Detection of miR-155 expression 
(magenta) after CCI by fluorescence in situ hybridization performed on tissue sections 
from WT mice 3 days after 1.0-mm CCI. Co-immunohistochemisty was performed for 
neuroanal marker MAP2 (green). Nuclei are stained with DAPI (blue). Images are from 
the ipsilateral lesion boundary of the cortex. Original magnification: 630x (bar = 20 µM). 
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Deletion of miR-155 in the KO mice caused decreased IFN response after CCL, but 
increased microglial activation. Aside from its role in inflammation miR-155 can regulate 
apoptosis [183]. To determine whether miR-155 ablation altered levels of apoptosis in 
the hippocampus after CCI, we measured total and cleaved caspase 3 by Western blot 
(Fig. 4.7). There were no changes in cleaved caspase 3 in the injured hippocampus 
between WT and miR-155 KO mice (P = .20). These data indicate that miR-155 does not 
alter levels of apoptosis in the hippocampus after CCI. As we had shown previously with 
TUNEL staining, there was very little apoptotic cell death in the hippocampus after CCI. 
It is possible that although apoptosis and thus cleaved caspase 3 levels were low in the 
hippocampi, measureable differences could be found closer to the lesion site.  
 
4.2.7 Neurodegeneration after CCI is unaffected by miR-155 deletion 
To examine the effect of miR-155 KO on neuronal degeneration after CCI we used 
fluorojade staining. Fluorojade is specific to degenerating neurons and can be used to 
quantify neurodegeneraton after CCI [218]. Three days after CCI brains from miR-155 
KO and WT mice were stained with fluorojade. Fluorojade positive cells in the cortex and 
hippocampus were counted. No changes were observed in fluorojade cell counts 
between genotypes in the hippocampus (P = .20) or cortex (P = .07) after CCI (Fig. 4.8). 
This indicates that miR-155 does not directly or indirectly influence neuronal 
degeneration 3 days after CCI.  
 
4.2.8 Motor function is impaired by CCI, but not altered by miR-155 deletion 
Deletion of miR-155 resulted in a reduced IFN response and increased microglial 
activity. To determine whether these changes have an affect on CCI outcome we 
performed accelerating rotarod testing. Accelerating rotarod is a common measure of 
motor dysfunction after CCI and in other models of TBI [95]. Animals of both genotypes  
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Figure 4.7 Cleaved-caspase 3 levels in the hippocampus do not change in miR-155 
KO after CCI. (A) Levels of caspase 3 were analyzed by SDS-PAGE and Western blot 
in WT (+) and miR-155 KO (-) mice 3 days after 1.0-mm CCI. (B) Cleaved-caspase 3 
and full-length caspase-3 was quantified by densitometry. The ration of cleaved to full-
length caspase 3 was multiplied by 100 to determine % cleaved caspase 3. The mean ± 
SEM from 4 animals are shown. Student’s t-test was used to determine significance P = 
.20. 
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Figure 4.8 
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Figure 4.8 Levels of neurodegeneration are similar between miR-155 KO and WT 
mice after CCI. (A) Degenerating neurons were stained with fluorojade (green) and 
DAPI (blue) 3 days after 1.0-mm CCI in the brains of WT and miR-155 KO mice. Images 
from the ipsilateral dentate gyrus (DG) and the lesion boundary of the cortex are shown. 
(B) Fluorojade cells were counted in three fields of the cortex, or in the DG from three 
slices between bregma -2.5 and -1.5. The mean ± SEM of total fluorojade cells in 5 WT 
and 6 miR-155 KO mice are shown. No significance was found by student’s t-test, DG (P 
= .20), cortex (P = .07). 
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were trained for 3 days prior to CCI procedure. There was no difference between groups 
in the baseline performance on the rotarod. CCI induced changes in rotarod 
performance were measured at 1, 3, 5 and 7 days post injury (Fig. 4.9). The effect of 
injury type was significant by two-way ANOVA (P < .0001), but no differences between 
genotype were found (P = .40). These data show that miR-155 does not play a critical 
role in motor dysfunction after CCI.  
 
4.2.9 Memory dysfunction in miR-155 KO and control mice after CCI 
No changes were found in CCI induced motor dysfunction between miR-155 KO and WT 
mice. Given that our previous studies had focused on the expression and function of 
miR-155 in the hippocampus after CCI, and that the hippocampus functions in memory 
formation and retention, we tested memory function in miR-155 KO and WT mice after 
CCI. To test memory function a novel object test was used. In this test an animal is 
exposed to identical two objects and allowed to explore them for 5 min. After a 3 hour 
interval one object was replaced with a novel, unfamiliar object. Again the mouse was 
given 5 min to explore these two objects. The time spent exploring the novel versus 
familiar object was determined. If the mouse did not recognize the familiar object, then it 
would spend equal time with both objects. Alternatively, if the mouse recognized the 
familiar object it would spend more time exploring the novel object. The outcome 
measure of the novel object test is the recognition index, a recognition index of .5 
indicates that there is no preference for the novel object. This is a standard test of 
mouse memory [219] and has been used to examine memory function in rodent models 
of TBI [220]. In this study, both genotypes showed no preference for the novel object in 
this test indicating memory impairment (Fig. 4.10). However, no differences were 
observed between the two genotypes (P = .29). This shows that ablation of miR-155 did 
not improve memory function. A floor effect was observed, since WT mice showed no  
	   	   	  116 
Figure 4.9 
 
  
	   	   	  117 
4.9 Motor function is similar in miR-155 KO and WT mice. Mice were trained on the 
rotarod apparatus for 3 days prior to CCI surgery the average latency to fall of 3 trials on 
the final day of training is shown as day -1. Rotarod testing began 1 day after 1.0 mm 
CCI and was repeated on days 3, 5, and 7 after surgery. The mean latency to fall ± SEM 
is shown. WT, n = 18, KO n = 20. Time after injury was significant by two-way ANOVA 
(P < .0001), but no effect of genotype was found (P = .40).    
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Figure 4.10  
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4.10 Cognitive function is similar in miR-155 KO and WT mice. Cognitive function 
was measured by novel object testing in miR-155 KO (KO) and wild type (WT) mice 11 
days after 1.0-mm CCI. The mouse was familiarized to two identical objects, after 3 
hours one of the familiar objects was replaced with a novel object. Exploration of the two 
objects was measured using Ethovision software (Noldus) and defined as the nose of 
the mouse within 2 cm of the object. The ratio time spent exploring the novel object to 
time spent exploring both objects is shown as the recognition index. A recognition index 
of .5 indicates no preference for the novel object. The mean ± SEM of WT (n = 18) and 
miR-155 KO (n = 20) are shown. No significance was found by student’s t-test, P = .29.   
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measurable preference for the novel object, we could not measure negative changes in 
memory function in miR-155 KO mice. In summary, no evidence was found for a 
difference in memory function between miR-155 KO and WT mice after CCI.  
 
4.2.9 Anxiety was decreased in miR-155 KO mice after CCI.  
As an additional measure of both motor activity and as a test for anxiety, open-field 
testing was performed. This test has been used to evaluate both motor activity [221] and 
anxiety [220] in TBI models. For open field testing a mouse was placed in an unfamiliar 
arena and allowed to explore it for 10 min. During this time the behavior was recorded 
and the overall distance traveled was measured. Using this outcome measure, there 
were no changes in overall distance moved between miR-155 KO and WT mice (P = 
.28)(Fig. 4.11A). This finding agreed with the results of the rotarod test (Fig. 4.9), which 
found no changes in motor function between the two groups. Another use of the open 
field test is measurement of anxiety in rodents [222]. As prey animals rodents prefer to 
avoid open spaces. The center of the open field is relatively exposed compared to the 
walls. To measure anxiety, the number of times the mouse entered the center quadrant 
was measured. Comparing the two genotypes using this measure we found an increase 
in center entries in miR-155 KO mice after TBI (P = .049)(Fig. 4.11B). This indicated that 
miR-155 KO mice had decreased anxiety compared to controls after CCI, without 
evident motor dysfunction.  
 
4.3 Discussion:  
In previous work we had identified that miR-155 was elevated in the hippocampus after 
CCI in mice. Due to its known role in inflammation and cytokine signaling, we 
investigated its function in CCI induced neuroinflammation. Changes were found in the 
levels of inflammatory cytokines and in glial activation in miR-155 KO mice compared to  
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Figure 4.11 
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4.11 Anxiety is reduced miR-155 KO compared to WT mice after CCI. Activity and 
anxiety was measured by novel object testing in miR-155 KO (KO) and wild type (WT) 
mice 10 days after 1.0-mm CCI. Each mouse was allowed to explore a open arena for 
10 min. (A) The overall movement over the 10 min interval was measured (B) The 
number of times each mouse entered the center quandrant was also measured. 
Movement of animals within the arena was recorded and movement and center 
frequency were calculated using Ethovision software (noldus) The mean ± SEM of WT 
(n = 18) an miR-155 KO (n = 20) are shown. Center frequency (P = .049), but not overall 
movement (P = .28), was significant by student’s t-test. *, P < .05. 
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controls after CCI.  In miR-155 KO mice levels of IFN-β and IFN-γ were reduced. 
Additionally, IFN induced chemokine CXCL10 was also reduced in miR-155 KO 
compared to WT mice. Together these findings showed an important role for miR-155 in 
the promotion of the IFN response. Interestingly, we also identified decreased BDNF 
expression in miR-155 KO mice. BDNF was predicted to be a miR-155 target through in 
silico methods [223]. But regulation of BDNF by miR-155 has not been reported in vitro 
or in vivo.  
We found that levels of protein SOCS1, an important negative regulator of IFN 
signaling, were unchanged in miR-155 KO mice. SOCS1 is a validated target of miR-155 
[206] that functions to inhibit STAT1, a key transcription factor for IFN signaling [209]. 
We expected to see decreased levels of SOCS1 in miR-155 KO mice, but detected no 
change in SOCS1 protein level in the injured hippocampi of miR-155 KO mice. 
Furthermore, there was an increase in SOCS1 mRNA in miR-155 KO mice. SOCS1 is a 
critical regulator of the immune response and deletion of SOCS1 is neonatal lethal [224]. 
Compensatory mechanisms could be responsible for decreasing SOCS1 mRNA and 
maintaining SOCS1 protein levels in miR-155 KO mice. Until this report, the effect of 
miR-155 ablation on SOCS1 or IFN signaling had not been investigated in the brain or in 
TBI. A handful of studies have highlighted a role for miR-155 in neuroinflammation. In 
experimental autoimmune encephalitis, a model of multiple sclerosis, mice lacking miR-
155 were resistant to the progression of this inflammatory disease, primarily through 
reducing T-cell mediated responses [126] Also, integrity of the BBB is diminished by 
miR-155 [225]. However, we are the first to identify changes in IFN and CXCL10 
expression in brain tissues from miR-155 KO mice.  
Normally expression of IFN cytokines and CXCL10 in the brain is very low. 
Interestingly, CXCL10 is strongly upregulated in both rodent models and human patients 
after TBI [176]. The expression of CXCL10 is found in clusters of cells in the brain of TBI 
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models that appear to be dendritic cells [226]. Interestingly, CXCL10 is strongly induced 
in viral infections of the brain [227]. For example CXCL10 is induced in neurons by West 
Nile virus infection [215] and in simian-human immunodeficiency virus encephalitis 
where it induces neuronal apoptosis [216]. These studies suggest a potential 
pathological role for CXCL10 in the brain.  
We found that after CCI miR-155 KO mice had an increase in Iba1 expression. 
This is counterintuitive based on in vitro studies suggesting miR-155 has a pro-
inflammatory response in microglia [210, 211]. It is unclear why we see an increased 
expression of Iba1 in miR-155 KO mice, but this could be due to differences in miRNA 
function between cell types. However by in situ hybridization we did not find an increase 
of miR-155 in microglia, rather it was in neurons. Interestingly, the induction of miR-155 
expression in neurons appeared to be largely nuclear.. While this is a unique finding, 
both Stat1 and CXCL10 are found in neurons and contribute to neuronal cell death [215-
217]. However, if these IFN induced molecules were neurotoxic, we would expect to see 
decreased neurotoxicity in miR-155 KO mice, where IFNs are decreased. However, our 
findings did not show any significant effects of miR-155 ablation on caspase 3 cleavage 
or degeneration measured by fluorojade, although we could be limited by group size or 
by the particular time points examined.  
We observed a decreased IFN response to CCI and increased microglial 
activation in miR-155 KO mice. We also found neuronal expression of miR-155, but no 
difference in apoptosis or neurodegeneration. To determine what the overall balance of 
these effects had on TBI outcomes, we performed behavioral testing. No changes were 
detected between miR-155 KO and WT mice in motor or cognitive function after CCI. 
Interestingly miR-155 KO mice showed reduced anxiety compared WT. Recently Fonken 
et al. identified reduced anxiety in miR-155 KO mice without TBI [228]. Future work 
should identify whether there is an interaction between miR-155 and TBI or whether 
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decreased anxiety is a function of genotype alone. The mechanism by which miR-155 
ablation relates to decreased anxiety is not clear. However, interferons are known to 
induce sickness behaviors including mood disturbances as is seen in patients being 
treated with high doses of IFNα for viral infections or cancers [229].  
 One scenario not addressed in these studies is the role of miR-155 in defense 
against pathogens. It has been proposed that the evolutionary advantage of stimulation 
of the immune response by tissue damage is to prevent infection by pathogens at the 
site of injury [230]. Recent reports have identified a critical role for miR-155 in the 
antiviral responses [129, 206]. One function of miR-155 and IFN induction could be to 
facilitate an appropriate immune response to potential infections in the damaged tissue. 
Studies of pathogen challenge in the context of TBI may be able to address this 
question.  
 
4.4 Summary: We have identified a critical role for miR-155 in regulating the interferon 
response to TBI. As part of the IFN response miR-155 regulates levels of CXCL10, a TBI 
induced chemokine. In contrast to decreased IFN response, we saw an increase in Iba1 
staining, suggesting increased microglial activation in miR-155 KO mice. Despite clear 
changes in the immune response to TBI, no changes were found in apoptosis or 
neurodegeneration in miR-155 KO mice. Similarly, miR-155 KO mice showed no 
changes in motor or cognitive function after CCI. One unexpected effect of miR-155 KO 
was that it reduced anxiety after CCI, which is consistent with IFN induced sickness 
behavior. Future studies should examine the link between TBI induced miR-155, 
neuroinflammation, and sickness behaviors.  
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Chapter 5: The role of miR-21 in neuronal function, injury, and repair 
 
5.1 Background: Previous studies have identified increased miR-21 in the sub-acute 
phase of CCI. Additionally, miR-21 is elevated in many neurological disorders (Table 
5.1). In vitro studies have proposed a role for miR-21 in neurite outgrowth [202], 
neuroprotection [151], and in neuronal dysfunction [231]. To characterize the role of 
miR-21 in the brain we obtained miR-21 KO mice. The study of miR-21 in the brain has 
so far focused on pathological states. However, whether or not miR-21 has a role in the 
function of the healthy nervous system has not been examined. The studies outlined 
here examine both the normal and pathological function of miR-21 in the brain.  
 
5.2 Results: 
5.2.1 Expression of miR-21 in the brain during development. 
Before examining the function of miR-21 in the brain, we set out to determine its 
expression during development. Levels of miR-21 were detected using qPCR and in situ 
hybridization. For qPCR experiments brains were removed from mice at embryonic day 
14 and 18, and at postnatal day 1, 8, and 14. Brains were homogenized and RNA 
extracted. There was a steady increase in miR-21 levels with increasing age (Fig 5.1). 
To address the function of miR-21 during development we measured miR-21 levels in 
differentiated and undifferentiated neuronal cells from various sources. Cultures of 
human neural progenitor cells (NPC) were grown in suspension creating neurospheres 
(Fig. 5.2A) then plated onto matrigel-coated dishes (Fig 5.2B). Neurosheres and 
dissociated NPCs showed the presence of SOX2 and Nestin, NPC markers [232]. 
Additionally, NPC could be differentiated into both astrocytes and neurons indicating that 
they were multipotent (Fig 5.2C).  
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Table 5.1. A list of neurological conditions that show increases in miR-21 expression. 
 
 
 A list of neurological conditions that show increases in miR-21 expression. Some fields were not 
addressed (NA) in all studies   
Condition Cell 
type/location 
Downstream effect Upstream regulation Citation 
Nerve injury  Primary 
sensory 
neurons 
Neuropathic pain IL-1B Sakai and 
Suzuki, 2013 
[233] 
Axotomy  Dorsal root 
ganglion 
neurons 
Targets Sprouty2 
Increasing axon growth 
Nerve transection Strickland et 
al., 2011 
[234] 
Spinal 
Chord injury 
(SCI) 
Astrocytes Reduces hypertrophy SCI in mouse Bhalala et 
al., 2012 
[141] 
Prion Exosomes 
from neurons 
NA Prion infection Bellingham 
et al., 2012 
[235] 
Stroke, 
Hypoxia,  
and 
ischemia 
Neurons and 
astrocytes 
NA Ischemia Ziu et al., 
2011 [236] 
Neurons in 
ischemic 
boundary  
Suppresses cell death in vitro 
after OGD by targeting 
FASLG 
Middle cerebral artery 
occlusion (MCAO) 
Buller et al., 
2010 [237] 
microglia Represses FasL Hypoxia Zhang et al., 
2012 [238] 
Brain tissue Negatively correlated with 
PDCD4 expression 
Embolic stroke mouse 
model 
Liu et al., 
2013 [239] 
Hippocampus Increased MMP9, possibly by 
targeting RECK 
Transient ischemia, 
MAPK/ERK signaling 
Deng et al., 
2013 [240] 
Ionizing 
radiation 
Hippocampal 
neurons 
Up regulation of EGFR  EGFR/Stat3 positive 
regulatory loop 
Shi et al., 
2012 [231, 
241] 
HIV 
encephalitis 
(HIVE) 
Hippocampal 
neurons 
Targets MEF2C  NMDA   Yelamanchili 
et al., 2010 
[231] 
Traumatic 
Brain injury 
(TBI) 
Hippocampus 
and cortex 
NA Rodent TBI Redell, 
Zhao, and 
Dash, 2011 
[242] 
Cerebral 
cortex 
NA Fluid-percussion injury Ping et al., 
2009 [144] 
Epilepsy Hippocampus NA Mesial temporal lobe 
epilepsy 
Peng et al., 
2013 [243] 
Multiple 
Sclerosis 
(MS) 
Active lesions NA Human MS patients, 
experimental autoimmune 
encephalitis (EAE) 
Lescher et 
al., 2012 
[244] 
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Figure 5.1  
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Figure 5.1 Expression of miR-21 increases during mouse development. Levels of 
miR-21 were measured by qPCR in mice at embryonic day 14 (E14), embryonic day 18 
(E18), postnatal day 1 (P1), postnatal day 8 (P8) and postnatal day 14 (P14). Expression 
of miR-21 was normalized to snRNA U6 and shown as fold change relative to E14. 
Shown is the mean ± SEM for two replicates.  
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Figure 5.2 
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Figure 5.2 Characterization of human neural progenitor cell (NPC) cultures. (A) 
NPCs were grown in suspension with growth factors FGF, EGF, and LIF. (B) For 
treatment with cytokines or inhibitors and for differentiation experiments NPC were 
plated onto matrigel coated plates. NPC were stained for markers SOX2 (red) and 
Nestin (green). (C) NPC were differentiated by withdrawl of growth factors. Differentiated 
cells showed both neuronal marker MAP2 (green) and astrocyte marker GFAP (green). 
Nuclei in all panels were stained with DAPI.  
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We found that in human neural progenitor cells (NPC) miR-21 levels were higher than in 
neurons from the same donor (Fig 5.3A) (P = .032). Similarly cultures of mouse NPC 
showed a trend towards higher levels of miR-21 than mouse neurons (P = .28), but 
levels of miR-21 were highly variable (Fig. 5.3B) In an attempt to find a more consistent 
model for studying miR-21 during neuronal differentiation, we measured miR-21 
expression in differentiated and undifferentiated SH-SY5Y human neuroblastoma cells 
(Fig. 5.3C). However, in contrast to primary neurons, miR-21 was higher in differentiated 
cells than in undifferentiated cells (P = .0051). This inconsistency between methods and 
model systems and in vitro and in vivo findings made it difficult to address any 
mechanistic questions related to miR-21 during development. The culture conditions of 
each of these differentiated and undifferentiated cell types varied greatly. Human NPC 
for example were grown with epidermal growth factor (EGF), fibroblast growth factor 
(FGF), and leukemia inhibitory factor (LIF). In contrast mouse NPC, which were grown in 
FGF, but not EGF of LIF. It is likely that these different culture conditions would influence 
the expression of miRNA-21. Due to the clear difference between human neurons and 
NPC, and the more translational nature of human primary cells future experiments were 
performed in human primary neurons and NPC.  
 
5.2.2 Induction of miR-21 by STAT3 acting growth factors and cytokines. 
Expression of miR-21 is induced in many types of neuronal injury, and some reports 
indicate this increased expression is in neurons [201, 233, 236]. To examine possible 
factors responsible for miR-21 induction in neurons after injury we treated primary 
human neurons with cytokines and growth factors. Rather than testing all cytokine 
families we focused on those that are induced by neuronal injury and signal through 
signal transducer and activator of transcription 3 (STAT3) STAT3 binds to  miR-21 
promoter through two validated binding sites [193]. This led us to focus on the   
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Figure 5.3 
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Figure 5.3 Expression of miR-21 in differentiated and undifferentiated neuronal 
cell types. Expression of miR-21 was measured by qPCR and normalized to snRNA U6. 
(A) miR-21 expression human NPC (nNPC) and human neurons (hNeu) from 4 donors 
shown as fold change from hNeu (P = .032). (B) miR-21 expression in mouse NPC 
(mNPC) and mouse neurons (mNeu) cultured from embryonic day 14 (E14) mice shown 
as fold change from mNeu (P = .28). (C) miR-21 expression in undifferentiated SH-SY5Y 
cells (Undiff) and SH-SY5Y cells differentiated (Diff) for 4 days with retinoic acid, shown 
as fold change from undiff (P = .0051). The mean fold change ± SEM is shown. 
Significance calculated by students T-test using fold change values, **, P < .01; ***, P < 
.001.    
	   	   	  135 
neurotrophic cytokines interleukin-6 (IL-6) and ciliary neurotrophic factor [245, 246]. Both 
IL-6 and CNTF are known to signal through STAT3 [247, 248] and have roles in 
neuronal injury [249, 250]. There are conflicting results regarding the expression of IL-6 
receptors in neurons, some reports show that soluble IL-6 receptor is necessary for IL-6 
mediated neuronal effects [251], while others report IL-6 receptor expression in neurons 
[252]. The expression of IL-6 receptor in cultured fetal human neurons has not been 
characterized, but in vivo fetal neurons do express at least modest amounts of IL-6 
receptor. To establish induction of STAT3 activation in human neurons with IL-6, 
neurons were treated with 10 ng/mL IL-6 and proteins purified from the cells 0, 15, and 
30, min after treatment. Sodium dodecyl sulfate poly acrylamide gel electrophoresis 
(SDS-PAGE) and Western blot analyses were used to measure levels of phosphorylated 
STAT3 (Fig 5.4). We found high levels of phosphorylated STAT3 at 30 min after IL-6 
stimulation in neuronal cultures thereby suggesting that these neurons do indeed 
express receptors for IL-6. To determine the relative ability of IL-6 and CNTF to stimulate 
P-STAT3, we treated human fetal neurons with IL-6 and CNTF for 30 min and measured 
P-STAT3 by Western blot (Fig 5.5). We found that relative to IL-6, CNTF stimulation 
resulted in higher levels of P-STAT3 and that this was consistent across 4 donors. 
Treatment with brain derived neurotrophic factor (BDNF) is not known to signal through 
STAT3 [253], and no P-STAT3 was observed after treatment of neurons with 10 ng/mL 
BDNF. To confirm the activation of STAT3 by CNTF in neuronal cultures 
immunohistochemistry was performed on neurons and 30 min after treatment with 10 
ng/mL CNTF. We also examined the localization of P-STAT3 in NPC post CNTF 
treatment. P-STAT3 by ws measured by immunocytochemistry. Interestingly, P-STAT3 
levels were high in both the untreated and CNTF treated NPC, but only induced in the 
CNTF treated neurons (Fig. 5.6). Additionally, P-STAT3 localized to the nuclei of cells 
confirmed with DAPI nuclear stain. These data showed that IL-6 and CNTF could induce  
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Figure 5.4 Induction of P-Stat3 by IL-6 in human fetal neurons. (A) Neurons were 
grown for 14 days in vitro then treated with 10 ng/mL of human IL-6 for 0, 15, or 30 min. 
Protein was purified from the cells and SDS-PAGE and Western blot analysis was used 
to detect levels of P-STAT3, Total STAT3, and actin loading control. The mean P-Stat3 ± 
SEM for 2 donors is shown.  
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Figure 5.5
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Figure 5.5 Induction of P-Stat3 by cytokines and neurotropic factors in human 
fetal neurons. (A) Neurons were grown for 14 days in vitro then treated with 10 ng/mL 
of human interleukin-6 (IL-6), brain derived neurotropic factor (BDNF), or ciliary 
neurotropic factor [246] for 30 min. Protein was purified from the cells and SDS-PAGE 
and Western blot analysis was used to detect levels of P-STAT3 and actin loading 
control. Samples from four individual donors are shown.    
	   	   	  140 
Figure 5.6 
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Figure 5.6 Nuclear localization of P-STAT3 after CNTF treatment in human NPC 
and neuronal cultures. (A) human neurons and (B) Neural progenitor cells (NPCs) 
were treated with 10 ng/mL cilliary neurotropic factor [246] for 30 min or no treatment 
(NT). Cells were fixed and stained with an antibody to P-STAT3 (green) and nuclear 
stain DAPI (blue). Staining was performed on cultures from 3 donors and representative 
images are shown.   
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phosphorylation of STAT3 in human fetal neuronal cultures, but that the levels of P-
STAT3 were constitutively high in NPC.  
Given that we saw induction of STAT3 phosphorylation in neurons after IL-6 and 
CNTF treatment, we then measured downstream induction of miR-21 expression. 
Neurons were treated with IL-6 and CNTF for 24 hours and levels of miR-21 were 
measured by qPCR. We found that both IL-6 and CNTF induced miR-21 expression in 
neurons (P < .05) (Fig 5.7A). Pri-miRNA is the transcriptional product of the miRNA 
gene, pri-miRNA is cleaved by Drosha in the nucleus into pre-miRNA-21, which is further 
processed by Dicer into the mature miR-21. To determine if pri-miR-21 was 
transcriptionally activated, levels of pri-miR-21 were measured after IL-6 and CNTF 
treatment in neurons. No change was found in pri-miR-21 expression after IL-6 or CNTF 
treatment (P = .92)(Fig. 5.7). These data suggest that either miR-21 is regulated at the 
processing level or that changes in pri-miRNA occur before the 24 h time point 
examined. Overall, these studies showed that both CNTF and IL-6 could induce 
phosphorylation of STAT3 and miR-21 expression. 
 STAT3 acting cytokines IL-6 and CNTF induced miR-21 expression in human 
neurons. Additionally miR-21 levels were higher in NPC that have constitutive STAT3 
activation. These data suggest a potential link between STAT3 activation and miR-21 
expression. To determine if STAT3 is essential for induction of miR-21 in neurons we 
used stattic, a STAT3 inhibitor that targets the SH2 domain [254]. Treatment of neurons 
with 1 µM stattic 30 min prior to CNTF treatment did not reduce miR-21 expression (P = 
.18) (Fig. 5.8A). Similarly, treatment of NPC with Stattic (2.5 µM) or Jak1 (0.6 nM) 
inhibitor did not reduce miR-21 expression (P = .58)(Fig. 5.8B). These findings thus 
suggest that miR-21 induction by CNTF is not dependent on STAT3 activation. Future 
studies should focus on alternative signaling pathways for miR-21 induction.  
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Figure 5.7 
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5.8 IL-6 and CNTF induce miR-21, but not pri-miR-21 expression in human 
neurons. Human neurons were treated with 10 ng/mL CNTF or IL-6, 24 hours later cells 
were harvested for RNA isolation. (A) Expression of miR-21 was measured by qPCR 
and normalized to snRNA U6. (B) Expression of pri-miR-21 was also measured by 
qPCR, but normalized to GAPDH. The mean fold change relative to no treatment (NT) ± 
SEM is shown. One-way repeated measures ANOVA was used to calculate significance 
based on ΔCt values. No change in pri-miRNA expression was found (P = .92), *, P < 
.05 relative to NT.  
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Figure 5.8 
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5.8 Inhibitors of JAK1 and STAT3 do not inhibit miR-21 expression. (A) Human 
neurons were treated with 1 µM stattic 30 min prior to addition of 10 ng/mL CNTF, 24 
hours later cells were harvested for RNA isolation. (B) Human NPC were treated with 2.5 
µM stattic or 0.6 nM JAK1 inhibitor for 48 hours. Expression of miR-21 was measured by 
qPCR and normalized to snRNA U6, shown as fold change relative to no treatment (NT). 
The mean ± SEM is shown. No significance was found by 1-way repeated measures 
ANOVA (neurons, P = .18; NPC, P = .58).  
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5.2.3 Protein expression of miR-21 targets in the brains of miR-21 knockout mice  
To further examine the role of miR-21 in neuronal function and injury we acquired miR-
21 KO mice. These mice are viable and fertile and have changes in apoptotic cell death 
in cancer models [164]. Before performing function studies of miR-21 in the brain we 
measured levels of miR-21 targets in the hippocampi of miR-21 KO mice compared to 
controls. We chose to examine levels of miR-21 target Phosphatase and tensin homolog 
(PTEN) a negative regulator of the Akt pathway [255]. In the brain PTEN regulates 
plasticity [256] and deletion of PTEN causes seizures and ataxia [257]. Hippocampi were 
dissected from miR-21 KO, heterozygous and WT mice, and protein homogenates 
analyzed by Western blot analyses. No changes in PTEN levels were observed in the 
brains of heterozygous or homozygous knockout mice relative to WT (Fig. 5.9A). 
Additionally, there were no changes in phosphorylated Akt (Fig. 5.9B). These data 
indicate that miR-21 is not essential for PTEN regulation in 5-week old hippocampi.  
 
5.2.4. Neuronal function measured by long-term potentiation (LTP) is normal in 
miR-21 KO mice    
Our previous studies had shown that increased miR-21 expression in neurons can lead 
to dysregulation of potassium channel currents [231]. No other studies on neuronal 
function had been performed on miR-21 KO mice. To determine whether miR-21 KOs 
showed changes in neuronal function we performed long-term potentiation (LTP) 
recordings on miR-21 KO and WT hippocampi. LTP is a correlate for learning and 
memory and a measure of complex neuronal function. To record LTP a stimulating 
electrode is placed in the Shaffer collateral and a recording electrode is placed in the 
CA1 subfield of the hippocampus. A stimulus is sent through the Shaffer collateral and 
the excitatory post-synaptic potential is measured in the stratum radiatum of the CA1. 
After a baseline response is recorded a high frequency stimulus is administered to the   
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Figure 5.9 Levels of known miR-21 targets are unchanged in miR-21 KO mice. 
Hippocampi were dissected from 5-week old miR-21 KO (KO), Heterozygous mice 
(HET) and wild type (WT) mice. Protein was purified and SDS-PAGE and Western blot 
were used to detect levels of miR-21 targets and activation of downstream pathways. (A) 
Levels of miR-21 target phosphatase and tensin homolog (PTEN) and actin loading 
control. (B) Levels of P-Akt and total Akt, a pathway inhibited by PTEN. N = 3.  
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Shaffer collateral. This induces an increased responsiveness to subsequent stimuli 
known as the post-tetanus potentiation (PTP). After a few min the PTP is diminished, but 
the potentiation is still elevated above baseline. This elevation is referred to as LTP. 
Measurement of LTP in miR-21 KO and WT mice litter mates showed no differences (Fig 
5.10). This result indicates that miR-21 KO neurons are still capable of functioning in the 
context of LTP.  
 
5.2.5 Susceptibility to excitotoxicity does not change in miR-21 KO neurons 
Several studies have identified a neuroprotective role for miR-21 [237, 258, 259]. To 
determine whether miR-21 knockout neurons showed any change in neuronal cell death 
we used an in vitro model of excitotoxicity. Excitotoxicity is related to several 
neurological conditions [260]. Excitotoxicity is caused by increased levels of excitatory 
amino acids, which bind to neurotransmitter receptors. The N-methyl D-aspartate 
(NMDA) receptor is thought to primarily contribute to excitotoxicity due to its calcium 
permeability [260]. In vitro models of excitotoxicity use NMDA to stimulate NMDA 
channels and cause delayed calcium-induced cell death. To measure differences in 
susceptibility to excitotoxicity in miR-21 KO neurons we cultured neurons from postnatal 
day 0 mouse pups and treated them with NMDA after 14 days in culture. P0 neurons 
were exposed to varying concentrations of NMDA for 30 min, followed by removal of 
NMDA and replacement of conditioned neuronal media. Cell death was then measured 
by increases in lactate dehydrogenase [176] release and alamar blue assay. Lactate 
dehydrogenase is released from dying cells and is a common measure of cell death. 
Alamar blue is a redox indicator of cell viability that can be used to asses neuronal 
viability [261]. In both the LDH and alamar blue assays we found a significant effect of 
NMDA concentration (P = .013 for alamar blue assay and P = .0028 for LDH assay), but 
no changes between miR-21 KO and WT neurons at any of the tested concentrations of  
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Figure 5.10 
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Fig. 5.10 Long-term potentiation is normal in miR-21 KO mice. Hippocampal slices 
from 4-6 week old miR-21 KO and WT littermates were bathed in oxygenated artificial 
CSF for one hour before recordings were made. Stimulation of the Shaffer collateral was 
used to elicit field excitatory postsynaptic potentials (fEPSP) recorded from the CA1 
subfield in the stratum radiatum. A 20 min baseline was recorded before high frequency 
stimulation (HFS, 100 Hz, 500 ms) fEPSP was recorded for an additional 40 min to 
measure long-term potentiation. Recordings from WT slices = 7, animals = 3, KO slices 
= 7, animals = 4). Shown is the mean initial slope of the EPSP ± SEM.   
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NMDA (P = .90 for alamar blue assay and P = .91 for LDH)(Fig. 5.11). This result was 
rather unexpected considering multiple reports of the neuroprotective role of miR-21. We 
cannot rule out a potential role for miR-21 in neuroprotection, but we were not able to 
measure it in this system. Compensatory mechanisms are one possible explanation for 
the lack of observed changes in neuroprotection. Another explanation is that miR-21 
levels are too low to observe changes without induction. In previous experiments we 
identified CNTF as an inducer of miR-21 expression. CNTF is secreted by astrocytes 
after CNS damage [262]. Therefore it is possible that in a complex multicellular 
environment during neuronal injury miR-21 could have an effect on neuronal survival.  
 
5.2.6 Ablation of miR-21 does not affect neurological severity score after CCI.  
In order to examine the function of miR-21 in a multicellular context of neuronal injury we 
used a CCI model of TBI.  In previous studies miR-21 was elevated at 3 days after 
severe (1.0 mm) CCI. To examine what effect miR-21 ablation had on neuronal survival 
and TBI outcome, CCI was performed on miR-21 KO and WT mice and evaluated by 
behavioral testing and histology. For these experiments 2 month-old miR-21 KO and WT 
mice were given a severe brain injury (1.0 mm depth). Neurological severity score was 
measured 3 days after CCI. The maximum score on the NSS is 10, a higher score 
indicates increased neurological impairment. A list of measures used for NSS testing is 
included in table 2. Using this gross measure of neurological function we found no 
changes between miR-21 KO mice and WT after CCI (P = .28) (Fig. 5.12) We used both 
male and female mice for this test and found no difference between genders (P = .60), 
or genotype (P = .25), or interaction between the variables (P = .44) by two-way ANOVA. 
Given that there was no difference between gender we examined NSS outcome of miR-
21 KO vs. WT by student’s T-test  
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Figure 5.11 
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Figure 5.11 No change in neurotoxicity after NMDA treatment in miR-21 KO 
neurons. Neurons were cultured from postnatal day 0 mice and grown for 13 days in 
vitro. On the 13th day neuronal media was removed and cells were treated with indicated 
concentrations of N-Methyl-D-aspartic acid (NMDA) for 30 min in artificial CSF. After 
treatment conditioned media was returned and cell death was measured 24 hours later 
by LDH and alamar blue assays. (A) Shown is the mean % cytotoxicity ± SEM measured 
by LDH assay and (B) Mean % Viability ± SEM was determined using alamar blue 
assay. Significance was calculated using two-way ANOVA. NMDA concentration was 
significant (P = .013 for alamar blue assay and P = .0028 for LDH assay), but no effect 
of genotype was found (P = .90 for alamar blue assay and P = .91 for LDH). 
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Figure 5.12 
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Figure 5.12. Neurological severity score [87] testing of WT and miR-21KO mice. 
The severity of injury 3 days after severe (1.0 mm) CCI was measured by NSS testing in 
miR-21 KO and WT mice. The maximum score possible is 10, with a higher score 
indicating higher severity. WT and miR-21KO mice were injured at 7-9 weeks old. WT, 
males = 8, females = 9; KO, males = 13, females = 9. (A) No significant difference was 
found by two-way ANOVA, (genotype, P = .25; gender, P = .60, interaction P = .44). The 
mean neurological severity score ± SEM is shown. (B) Combining male and female 
values gave no significance by student’s T-test, P = .28. 
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and also found no significant change (P = .28) We were not able to detect a difference in 
NSS outcome in miR-21 KO mice. The NSS is a relatively basic outcome measure, 
possibly more thorough outcome assessment could detect changes between miR-21 KO 
and WT.   
 
5.2.7 Neurodegeneration after CCI is unaffected by miR-21 KO 
To examine to importance of miR-21 in CCI mediated neuronal degeneration we used 
fluorojade C (FJC) staining. FJC is specific to degenerating neurons and can be used to 
measure neurdegeneration after TBI in rodent models [218]. One-mm CCI was 
administered to miR-21 KO and WT mice, then sacrificed the mice at 3 days post injury. 
FJC staining was performed and FJC positive cells were counted. Again, there were no 
measurable change between miR-21 KO and WT mice (cortex, P = .74; hippocampus, P 
= .34)(Fig. 5.13). These data suggest that even in a complex multicellular model of 
neural injury, miR-21 KO mice do not show changes in neuronal degeneration. This 
finding again points to a possible compensatory mechanism in miR-21 KO mice.  
  
5.2.8 Creation of miR-21 conditional knockout mice  
In order to address the potential compensatory mechanisms found in miR-21 KO a 
conditional miR-21 KO was created. This mouse was designed to be inducible by a 
AAV-CRE system or through tissue specific expression of CRE. Functionally this means 
that cultured cells or tissues of live animals could be transduced with a viral vector 
expressing CRE recombinase, alternatively CRE can be expressed under tissue specific 
promoters. CRE would cause recombination at LoxP sites on either side of the miR-21 
stem loop deleting the gene (Fig. 5.14). The initial steps of the mouse generation were 
performed by Mike McManus at the University of California San Francisco [263]. First a 
targeting vector was designed to insert a FRT site, lacZ gene, loxP site, Neomycin  
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Table 5.2 Neurological severity score parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Failure to complete each task in the allotted time was given a score of 1 for a maximum 
of 10 [87]. 
Task Score 
Exit circle within 3 min 1 
Presence of seeking behavior 1 
Monoparesis/hemiparesis 1 
Strait walk 1 
Startle reflex 1 
Beam balancing for 10 sec 1 
Beam walking 3 cm width in 3 min  1 
Beam walking 2 cm width in 3 min 1 
Beam walking 1 cm width in 3 min 1 
Round stick balancing 1 
Total Possible 10 
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Figure 5.13 Levels of neurodegeneration are similar between miR-21 KO and WT 
mice after CCI. Degenerating neurons were stained with fluorojade (green) and DAPI 
(blue) 3 days after 1.0-mm CCI in the brains of WT and miR-21 KO mice. (A) Fluorojade 
cells were counted in three fields of the cortex, or (B) in the DG from three slices 
between bregma -2.5 and -1.5. The mean ± SEM of total fluorojade cells are shown, WT, 
n = 4 and miR-21 KO, n = 5 (C) Representative images from the ipsilateral dentate gyrus 
(DG) and the lesion boundary of the cortex are shown. No significance was found by 
student’s t-test, DG (P = .74), cortex (P = .34). 
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cassette, FRT site, and final loxP site (FRT-lacZ-loxP-Neo-FRT-loxP) upstream of the 
miR-21 stem loop with an additional loxP site downstream. This construct was 
electroporated into embryonic stem cells to generate chimeric mice. These mice were 
then crossed with other strains to generate the colony. Mice containing the targeted 
allele were donated to Jackson laboratories. We obtained mice heterozygous for the 
targeted allele from Jackson laboratories. This construct is referred to as a knock out-
first system as the LacZ and neomycin cassettes disrupt the expression of the gene. 
Once the LacZ and Neomycin cassettes are removed by Flp recombinase the target 
gene is expressed. Recombination with Cre recombinase removes the gene creating a 
true knockout. In this strain homozygosity for the targeted allele was lethal either 
embryonically or perinatally. The ratios of each genotype from a heterozygous cross to 
reach weaning age were homozygous 0/18 heterozygous 12/18 and wild type 6/18. 
Deletion of the miR-21 stem loop in another mouse strain (background 129S and 
C57Bl6) was not fatal and was used for our previous studies. However, the large 
neomycin/lacZ cassette likely interfered with the expression of the miR-21 host gene 
TMEM49 which codes for the vacuole membrane protein 1 (VMP1), which is essential 
for autophagy and other cellular processes [264]. Therefore heterozygous mice were 
bred to a Flp recombinase expressing strain to create a floxed miR-21 allele where the 
gene is flanked on either end by a LoxP site. The recombined allele was no longer 
homozygous lethal and mice homozygous for the floxed allele were generated. Floxed 
miR-21 mice can be used for in vitro or in vivo conditional deletion of the miR-21 gene. 
These mice could be breed with strains expressing Cre recombinase under tissue 
specific promoters to generate tissue specific strains [265, 266]. Alternatively neurotropic 
AAV serotypes expressing Cre recombinase could be injected to ablate miR-21 in 
neurons after development [267].  
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Figure 5.14 
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Figure 5.14 Generation of conditional miR-21 KO mice. (A) A (FRT-lacZ-loxP-Neo-
FRT-loxP) cassette was inserted upstream of the miR-21 stem loop followed by an 
additional FRT site. Approximate location of FRT recombination sites (red triangles) and 
loxP recombination sites (blue triangles) are shown. (B) Crossing with a Flp 
recombinase expressing strain removes the LacZ and neomycin cassette leaving a 
floxed miR-21 stem-loop. (C) Introduction of CRE recombinase by germline or viral 
transduction produces a knock-out allele.  
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5.3 Discussion 
Expression of miR-21 increases during development and can be induced by STAT3 
dependent neurotrophic factors IL-6 and CNTF. Examination of the hippocampi of miR-
21 KO mice revealed no changes in target PTEN or downstream phosphorylation of Akt. 
Additionally, miR-21 KO mice showed no changes in long-term potentiation indicating 
that neuronal function in these mice was intact. Despite the proposed neuroprotective 
properties of miR-21 [152, 237, 238, 258], we saw no changes in NMDA excitotoxicity in 
cultured miR-21 KO hippocampal neurons compared to WT. Additionally, we observed 
no changes in neurodegeneration measured by FJC in the brains of miR-21 KO mice vs. 
controls. There was also no difference in functional outcomes between the genotypes 
after CCI as measured by the NSS.  
 It is difficult to reconcile the evidence of a neuroprotective role for miR-21 
reported by multiple independent labs with the results of these studies. One possible 
explanation is that compensatory mechanisms could be at play. Patrick et al. reported a 
similar finding in miR-21 KO mice in the field of cardiology [268]. Despite multiple reports 
by several groups that miR-21 mediated a hypertropic response in the heart [269], 
Patrick et al reported no change in cardiac function in miR-21 KO mice. To address 
these concerns we have generated a mouse carrying a floxed miR-21 allele that could 
be used in the future for conditional deletion of miR-21 by either tissue specific or AAV 
mediated CRE recombinase expression.   
 One significant finding of these studies was the ability CNTF to induce miR-21 in 
human neurons. CNTF is critical for neuronal survival and regeneration [250, 270, 271]. 
Clinical trials targeting CNTF have been done in ALS patients and in retinal 
degeneration. In the ALS trial CNTF did not produce significant improvements and in 
many cases dosing was limited by adverse effects such as anorexia, weight loss, and 
cough [246]. However, studies in retinal degenerative diseases with CNTF producing 
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explants have not shown toxicity [272]. As therapeutic use of CNTF poses several 
challenges, identifying the importance of miR-21 for the down-stream effects of CNTF 
could lead to a novel therapeutic target for neuroprotection and regeneration.  
 
5.4 Summary: 
CNTF induces P-Stat3 and miR-21 in human neurons. Lack of neuronal phenotype in 
miR-21 KO mice suggests that compensatory mechanisms  could be involved. To 
address this issue a mouse strain with a floxed miR-21 allele was generated. This 
mouse can be combined with various modes of CRE delivery to make a conditional 
knockout for the study of miR-21 in the brain or in other systems.  
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Chapter 6: Traumatic brain injury increases levels of miR-21 in extracellular 
vesicles: implications for neuroinflammation 
 
6.1 Background: 
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide and 
current treatment strategies are limited [4, 6, 61]. The damage caused by a TBI can be 
divided into the instantaneous primary mechanical injury and delayed secondary injury, 
which includes inflammation, neurochemical changes, and mitochondrial dysfunction 
[21]. A robust inflammatory response is seen post-TBI, including migration and activation 
of resident glia and recruitment of peripheral immune cells to the injury site [28]. As in 
other types of injury, cell-cell communication is critical for regulating the immune 
response in TBI. Although there is a wide body of research examining the roles of cell-
cell mediators such as cytokines and chemokines in TBI [273], the short duration of 
action, along with the complex and pleiotropic nature of these molecules make them 
difficult drug targets [21]. In recent years several important studies have found that 
extracellular vesicles (EVs) can influence cell-cell communication significantly [274-276]. 
EVs are membrane-derived vesicles that include vesicles that originate from the plasma 
membrane, exosomes derived from multi-vesicular bodies, and apoptotic bodies. These 
EVs serve as shuttles for cellular components between cells, carrying proteins, 
metabolites, lipids, mRNA, and microRNA (miRNA) [277].  EV mRNA and miRNA can 
function within the recipient cell to alter protein expression [275, 278]. Recent studies 
also show that miRNA carried within extracellular vesicles can trigger inflammatory 
responses and neuronal damage through pattern-recognition receptors (PRRs) [276]. 
While several experiments have shown effects of EV associated miRNAs (EV-miRNAs) 
on cells in culture, less is known about how the miRNA content of EVs is altered in 
disease conditions and whether or not EV-miRNA has important pathophysiological 
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roles. No studies so far have characterized EVs in the TBI brain. The goal of this study 
was to investigate changes in EV microRNA after a TBI. To accomplish this we 
quantified levels of miRNA in EVs from mice 7 days after a TBI using next-generation 
sequencing. Furthermore, in situ hybridization was performed to analyze the expression 
of miRNA in the brain.  
 
6.2 Results: 
6.2.1 Characterization of CCI. While the CCI model is commonly used in TBI research, 
the histopathology and behavioral deficits can vary dramatically with injury depth, 
species, strain, and age, as well as choice of controls. We chose a 1.0 mm depth to 
model severe injury.  While a craniotomy only (without TBI) control is used by some in 
the TBI field, it is associated with inflammation [185, 186]. To avoid neuroinflammation 
caused by craniotomy, and to better control for peripheral injury and inflammation we 
used a peripheral injury control where an animals were given anesthesia, analgesia, and 
a scalp incision. 
Rotorod testing was then used to examine motor and vestibular function, as 
abnormalities are found after CCI [95]. Before surgery animals were trained on the 
accelerating rotarod apparatus for three trials a day for 3 days. On the last day of 
training there was no difference in latency to fall between the groups randomly selected 
for CCI and sham surgery (Fig 6.1A). Animals were tested daily beginning one day after 
surgery. CCI impaired motor function 1, 2, and 3 days after injury, by day 4 post injury 
motor function recovered to the level of control. Peripheral injury controls did not show a 
decrease in motor function after sham surgery. Since rotorod deficits were resolved at 7 
days after CCI, subsequent studies were performed at this time point. 
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Luxol fast blue staining was then performed In order to characterize the lesion 
site morphology and white matter damage 7 days after CCI or sham surgery (Fig. 6.1B). 
Sham animals showed no evident neuropathology, however CCI induced cortical and  
hippocampal tissue loss on the injured side and enlargement of the lateral ventricle. 
Disruption of white matter tracts was clearly observable. The corpus callosum was 
disrupted and the fimbria was deformed.  
 Glial activation is a well-recognized component of TBI pathophysiology [279]. To 
examine the extent of glial activation at 7 days after CCI, tissues were stained for GFAP 
and Iba1, markers of astrocytes and microglia respectively (Fig. 6.1C). Levels of GFAP 
and Iba1 are both up-regulated when glial activation occurs. As expected, staining for 
GFAP and Iba1 increased after TBI. In addition microglial morphology shifted from 
ramified, resting microglia to a bushy, activated state in the injured hemisphere 
compared to sham controls. Activated microglia were also observed in the contralateral 
cortex after CCI, but to a lesser extent. 
Overall, both motor impairment and neuropathology are consistent with 
descriptions of CCI by other groups. No changes in motor function or glial activation 
were seen in peripheral injury sham controls. Importantly, while motor deficits are 
resolved, glial activation is prominent at 7 days after injury, we chose this time point to 
examine the role of EV miRNA in TBI induced neuroinflammation.  
 
6.2.2 Isolation and characterization of EV after CCI. EVs were isolated from pooled 
brain tissue using differential centrifugation on a sucrose gradient. Transmission electron 
microscopy [24] was used to characterize vesicle size (Fig. 6.2). EVs isolated from 
mouse brain showed a heterogeneous sized population of EVs. Intact vesicles were 
present indicated by the characteristic “cup shape” created by the pooling of negative  
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Figure 6.1 
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Figure 6.1 Characterization of CCI model. (A) Motor function in the week after CCI 
measured by rotarod. Sham controls and CCI mice were tested 3 times per day and 
trained for three days prior to injury. The average time to fall of the final training day is 
shown as time 0. The average time to fall of three trials for each day after injury is 
shown. Day 1 corresponds to 1 day after CCI. The mean ± SEM from 15 animals are 
shown. A two way ANOVA was used to determine statistical significance. *, P < .001. (B) 
Histology performed on mice 7 days after injury or sham surgery. Shown are 
representative images of three replicates. Luxol fast blue and cresyl violet staining of 
myelin (blue) and Nissl substance (purple) showing gross histology of the lesion, 
indicated by an asterisk, after CCI compared to the normal anatomy of the sham surgery 
control. (C) Iba-1 and GFAP immunohisochemisty (IHC) staining for microglia and 
astrocytes respectively in the left hemisphere of sham controls (SHAM), and the 
ipsilateral (IPSI) and contralateral (CONTRA) hemisphere of animals after CCI (TBI), 
lesion cavity indicated by an asterisk. Original magnification 10 x (bars = 100 µM), and 
40 x (bars = 25 µM). 
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stain on top of the intact vesicle [277]. These data indicate that intact, heterogeneous 
EVs were isolated from mouse brain.  
 
6.2.3 Sequencing of EV-miRNA after CCI. Recent evidence has shown that EV-miRNA 
can induce inflammation and neuronal damage [177, 276, 280, 281]. Therefore, 
understanding changes in EV-miRNAs after CCI is relevant to TBI pathology. To quantify 
EV-miRNAs, EVs were isolated from the left and right hemispheres of animals 7 days 
after CCI or sham surgery. Then miRNAs were purified from the EVs and sequenced. 
Brains from four conditions were used for this purpose: TBI ipsilateral (left) hemisphere, 
TBI contralateral (right) hemisphere, sham left hemisphere and sham right hemisphere. 
A heat map of all differentially expressed miRNA genes (P < 0.05 by ANOVA) is shown 
in Fig. 6.3A. Generally miRNAs clustered into those that increased or decreased in both 
the ipsilateral and contralateral hemispheres and those that increased only in the 
ipsilateral hemisphere. The largest number of differentially expressed miRNAs (59) was 
found in the ipsilateral hemisphere from TBI relative to the corresponding sham 
hemisphere, followed by the TBI ipsilateral vs. contralateral hemisphere (46). Only 7 
differentially expressed genes were common between the ipsilateral and contralateral 
hippocampi (Fig. 6.3B). Together this indicates that the ipsilateral hemisphere shows the 
most distinct set of differentially expressed EV miRNAs, as would be expected 
considering the unilateral nature of the injury and glial activation seen by 
immunohistochemistry. To focus further examination, we calculated log2 values for 
differentially expressed miRNAs and set a threshold of |log2| = 0.5. Based on these 
criteria we identified 5 differentially expressed genes, 4 up-regulated and 1 down-
regulated in the ipsilateral hemisphere (Fig. 6.3C). Levels of miR-212 were decreased in 
the ipsilateral hemisphere relative to corresponding sham and contralateral 
hemispheres. In contrast, miR-7b, miR-7a, and miR-21 levels were all increased in the  
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Figure 6.2 
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Figure 6.2 Characterization of EVs from brain tissue. Transmission electron 
microscopy of brain derived EVs showing a heterogeneous population of vesicles.  
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ipsilateral hemisphere compared to the corresponding sham hemisphere. Uniquely, miR-
146 was increased bilaterally in both the ipsilateral and contralateral hemispheres 
compared to sham. Of all the differentially expressed EV-miRNAs, miR-21 showed the  
largest increase after CCI. Average counts for differentially expressed miRNAs are 
shown in Table 6.1.The sequences in Table 6.2 show differentially expressed miRNAs. 
Three of the five miRNAs have GU rich sequences that are known to mediate TLR7/8 
responses [282]. In summary, CCI induced changes in miRNAs associated with EVs, 
particularly in the ipsilateral hemisphere.  
 
6.2.4 Localization of miR-21 expression after CCI. Injury significantly increased EV-
miR-21 in brain tissue. As homogenized brain tissue was used to isolate EVs, which cell 
types secrete miR-21 into EVs could not be determined. To investigate the cell-type 
specific expression of miR-21 after CCI we performed combined immunofluorescence 
and in situ hybridization. Images were taken in the parietal cortex adjacent to the lesion, 
or lesion boundary. Expression of miR-21 was higher in CCI animals than in the sham 
control (Fig. 6.4), which is in agreement with other reports [145, 152, 283].  Co-staining 
with MAP2, a cell-type specific marker for neurons, showed co-localization with miR-21, 
indicating that miR-21 is highly expressed in neuronal cell bodies. In contrast, miR-21 
expression did not co-localize with microglial marker Iba-1, suggesting that microglia are 
not the primary source of EV-miR-21. However, activated microglia were found in 
immediately adjacent to the miR-21 positive neurons in the lesion boundary. While this 
staining cannot prove that the origin of EV-miR-21 is neuronal, it strongly suggests that 
the up-regulation in EV-miR-21 is due to an increased expression of miR-21 in neurons.  
 
6.3 Discussion 
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Figure 6.3 
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Figure 6.3 Sequencing of EV miRNAs after CCI. (A) Heat map and hierarchical 
clustering depicting all differentially expressed miRNAs (P < .05 by ANOVA). (B) Venn 
diagram showing differentially expressed miRNAs in ipsilateral (IPSI) vs. sham left and 
contralateral (CONTRA) vs. sham right. Significance was determined by T-test P <.05 
(B). (C) MiRNAs that increase or decrease in the ipsilateral hemisphere (IPSI) relative to 
controls (log2 > .5) (C). Log2 values for the contralateral hemisphere (CONTRA) are also 
shown. The mean ± SEM from 3 replicates are shown. A one-way ANOVA was used to 
determine statistical significance. *, P < .05; **, P < .01; ***, P < .001. 
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The major finding of this study is that TBI induces changes in EV associated miRNAs in 
a rodent CCI model. Through miRNA sequencing, we found that miR-21, miR-146, miR-
7a, and miR-7b all increased in the injured hemisphere relative to sham surgery control, 
while miR-212 expression decreased. Of these miRNAs, miR-21 showed the largest fold  
change. Localization of miR-21 expression through in situ hybridization was found 
overwhelmingly in MAP2 expressing neurons in the lesion boundary, suggesting that EV 
miR-21 could be neuronal in origin and might mediate neuron-glia signaling.  
 
This is the first study to profile changes in brain EV-miRNA after TBI. Several previous 
studies have identified changes in miRNA expression in brains from TBI models [144-
149]. Of these studies 3 reported a significant increase in miR-21 relative to controls 
[144, 145, 148]. Generally, literature on miR-21 in TBI supports a neuroprotective role for 
miR-21. Treatment with a miR-21 mimic improved disease outcomes in rats after CCI 
[152]. Also, overexpression of miR-21 reduces neurotoxicity in an in vitro, stretch model 
of TBI through miR-21 targeting of PTEN [284]. Increasingly, miR-21 is recognized as a 
important molecule in neuronal injury [285]. The neuroprotective and regenerative 
effects of miR-21 have been observed in models of stroke [237], axotomy [234], and 
neurodegeneration [259]. Additionally, miR-21 has roles in glial responses to injury. In 
spinal chord injury miR-21 reduces hypertrophy of astrocytes, reducing glial scar 
formation [141], whereas in experimental stroke, miR-21 targets FasL in microglia 
reducing microglia-mediated neuronal death [238]. Despite the potential benefits of miR-
21 expression in neuronal injury, there are also drawbacks. For example, in HIV 
associated neurocognitive disorders elevated expression of miR-21 contributes to 
neuronal dysfunction by increasing potassium channel activity and targeting MEF2C, an 
important neuronal transcription factor [231]. Elevated miR-21 also contributes to 
neuropathic pain in nerve injury [233]. Nevertheless, this yin-yang role of miR-21 makes  
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Table 6.1. 
 
     IPSI/ 
miRNA IPSI CONTRA SHAM L SHAM R SHAM L Log2 
miR-21a-5p 9,283 ± 3,860 6,610 ± 2,736 3,275 ± 295 4,179 ± 618 2.8 1.5 
miR-146a-5p 3,648 ± 413 3,707 ± 1,067 2,042 ± 318 2,163 ± 444 1.8 .84 
miR-7a-5p 11,393 ± 1,411 9,631 ± 1,313 7,057 ± 1,115 8,330 ± 910 1.6 .69 
miR-7b-5p 8,582 ± 1,411 8,067 ± 932 5,764 ± 642 6,827 ± 1,176 1.5 .57 
miR-212-5 2,988 ± 666 4,745 ± 594 4,229 ± 115 4,380 ± 931 .71 -.50 
 
Sequencing counts of miRNAs significantly increased in the ipsilateral hemisphere (P < 
.05 with |log2 IPSA/Sham L)| > .5), average counts ± SD for three replicates, each 
pooled from 3 animals. 
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Table 6.2 
 
miRNA    Sequence    
miR-21a-5p            UAGCUUAUCAGACUGAUGUUGA 
miR-146a-5p  UGAGAACUGAAUUCCAUGGGUU 
miR-7a-5p  UGGAAGACUAGUGAUUUUGUUGU 
miR-7b-5p  UGGAAGACUUGUGAUUUUGUUGU 
miR-212-5p  ACCUUGGCUCUAGACUGCUUACU 
 
Sequences of miRNAs significantly increased in the ipsilateral hemisphere (P < .05 with 
|log2| > .5). GU rich sequences shown in bold. 
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Figure 6.4 
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Figure 6.4 Localization of miR-21 expression after CCI. Expression of miR-21 was 
visualized by combined in situ hybridization and immunofluorescence. Staining for miR-
21 (magenta) and cell-type markers (green), MAP2 and Iba1 were used to identify 
neurons and microglia respectively. Nuclei are stained with DAPI (blue). Original 
magnification 63 x (bars = 100 µm), location of insets marked with an asterisk. Staining 
was performed in duplicate and representative images are shown. 
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it an interesting target of study in neuronal injury and inflammation. Here, for the first 
time we have identified that miR-21 can also be associated with EVs in TBI. 
In this study we profiled EV-miRNAs from the brain tissues of CCI injured mice. 
Previously, Patz et al also characterized EV-miRNAs after TBI, but in the cerebrospinal 
fluid (CSF) of patients [286]. Our miRNA sequencing did not recapitulate the miRNA 
profile found in this previous study. This difference could be due to several factors, such 
as the use of CSF vs. brain tissue, and patients versus a controlled experimental model. 
Outside of the TBI field, profiling of EV-miRNA from neurons and brain tissue has been 
performed. Interestingly, exosomes secreted by prion-infected neurons show higher 
levels of miR-21 than exosomes from uninfected neurons in vitro [235]. This supports the 
theory that neurons increase the release of miR-21 in EV as a response to stress. Our 
group and others have studied the role of miRNAs in exosomes or extracellular vesicles 
in HIV-associated neurocognitive disorders (HAND), conditions strongly linked with 
neuroinflammation [287]. One study indicated that comorbid HIV infection and opiate 
abuse can increase miR-29 packaging in brain EV, which in turn downregulates the 
important neuroprotective molecule PDGF [288]. Another study showed that in HAND, 
EV miR-21 is increased and mediates neurotoxicity by binding to TLR7 and causing 
necroptosis [177]. As more groups profile miRNA signatures of EVs, a clearer picture will 
form of which miRNAs are common to neuronal injury or inflammation and which are 
specific to disease state.  
The release of miRNAs in EVs is thought to have two possible effects on target 
cells. The first mechanism occurs when the EV either fuses with the cell membrane or 
endosomal membrane to release its contents into the cytosol [278]. Mature miRNAs in 
the cytosol can bind to target mRNAs and decrease their translation [274]. The second 
mechanism of EV miRNA action is through binding of pattern recognition receptors in the 
endosomal compartment, primarily toll-like receptor 7/8 (TLR7/8) [276]. TLR7/8 
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recognizes ssRNA, and elicits an antiviral response as part of the innate response to 
viral pathogens[289]. Several groups have reported that miRNAs with EV can stimulate 
TLR7/8, but the outcome of miRNA binding to TLR7/8 is highly dependent on cell type. 
In immune cells, such as macrophage and microglia, TLR7/8 binding elicits a pro-
inflammatory response, including secretion of TNFα [276]. Alternatively, TLR7/8 binding 
in neurons is toxic and can lead to cell death or synaptic loss [177, 280, 281]. The 
binding of miRNAs to TLR7/8 is dependent on GU rich sequences [282], as miR-21 has 
such a GU rich sequence it is a strong stimulator of TLR7/8 [177, 276, 280]. Recent 
studies have identified EV miR-21 specifically as both pro-inflammatory [276] and 
neurotoxic [281]. Our studies on SIV encephalitis showed that not only was miR-21 
elevated in EV from encephalitic brains, but also that EV miR-21 induced necroptosis in 
neurons through TLR7 [177]. Therefore, the increase of EV-miR-21 reported in this study 
has important pathophysiological implications for TBI. Whether miR-21 in EV leads to 
translational regulation or TLR7/8 stimulation in recipient cells after TBI is not addressed 
in this study and will be an important question for future research.  
Aside from miR-21, we identified 3 other miRNAs with increased levels in EVs, 
miR-146, miR-7a, and miR-7b. Increased expression of total brain miR-146a was 
reported Lei et al. in a CCI model of TBI [144]. Interestingly our previous studies in SIV 
encephalitis also found increases in EV miR-146 [177]. It is known that inflammatory 
stimuli such as LPS induce miR-146 [290]. Interestingly, knockout studies in mice have 
proven miR-146 to be an important anti-inflammatory miRNA [291]. Even more 
importantly miR-146 within exosomes can act functionally to reduce inflammation in 
recipient cells [292]. Therefore, it is possible that in TBI miR-146 within exosomes could 
reduce neuroinflammation. Relatively little is known about miR-7a and b compared to 
miR-146 and miR-21. However, some in vitro data suggest miR-7 can be 
neuroprotective [293]. The expression of miR-7 is relatively brain specific [294]. 
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Interestingly miR-7a and b both contain a GU rich element identical to that found in miR-
21 (UGUUG) indicating that they may also be ligands for TLR7/8 (6.2). We found one 
miRNA, miR-212, down regulated in EV after TBI. Down-regulation of miR-212 has been 
found in several brain diseases [295]. These include anencephaly [296], schizophrenia 
[297], and Alzheimer’s disease [298]. Together these studies hint that deregulation of 
miR-212 may be pathological in the brain.  
 
6.4 Summary: In conclusion we report here the first miRNA profile of brain exosomes in 
TBI. Differential expression of 5 miRNAs was found between EVs from CCI injured brain 
vs. uninjured controls. Of the differentially expressed miRNAs, miR-21 showed the 
highest increase in EVs of the injured brain. Interestingly, increased levels of miR-21 
were found in neurons of the injury boundary zone near reactive microglia. This work 
shows that TBI induces changes in EV miRNA, which likely has important consequences 
for cell-cell signaling and the disease process in TBI.  
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Chapter 7: Behavioral phenotyping of mice in the chronic phase of TBI 
 
7.1. Background:  
Survivors of TBI experience a variety of chronic symptoms that can range from motor 
and cognitive disability to neuropsychiatic dysfunction. Current pre-clinical modeling of 
TBI in rodents generally fails to address these chronic outcomes of TBI. To improve 
translational efficacy, a better understanding of the chronic phenotype of rodent models 
of TBI is needed. Additionally, the pathophysiology that causes neuropsychiatric 
conditions after TBI is unknown. Animal modeling of neuropsychiatric changes after TBI 
could provide a mechanistic understanding of these disorders. In order to investigate 
changes in long-term behavioral outcomes we chose a highly utilized model of TBI, the 
controlled cortical impact (CCI) model. Four experimental groups naïve, craniotomy only, 
moderate and severe CCI, were tested using a battery of motor, cognitive, and 
neuropsychiatric behavioral measures.  
 
7.2 Results: 
7.2.1 Motor function 2 months after CCI is normal 
To evaluate motor and vestibular function in the chronic phase of CCI we performed 
accelerating rotarod testing. Rotarod testing is a common measure of TBI induced 
deficits in rodent models [95, 170]. The accelerating rotarod utilizes a rotating cylinder as 
a treadmill. Mice were placed on the rod, the speed of rotation was steadily increased 
until the mouse fell, activating a weight based sensor below the rod. The latency to fall 
was then recorded. Mice were tested three times a day for three days and the trials 
averaged for each day. There were no differences between groups in rotarod 
performance indicating that motor function was not impaired 2 months after CCI (Fig 
7.1).  
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Figure 7.1 
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Figure 7.1 Motor testing 2 months after CCI. Motor and vestibular functions were 
tested by accelerating rotarod on three consecutive days in naïve, craniotomy only 
(Sham), moderate (0.5 mm) and severe (1.0 mm) CCI. Latency to fall was recorded by 
weight-based sensors. The average of three trials was reported for each day. The mean 
± SEM is shown, n = 8 per group. No significance by condition was found by two way 
ANOVA (P .40), however the day of testing was significant (P < .0001).  
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7.2.2 Memory is not impaired 2 months after CCI  
To evaluate memory function 2 months after CCI we performed novel object testing. 
Novel object testing is an ethological test of memory function [219] and has been used to 
evaluate animal models of TBI [299, 300]. Mice were first familiarized to two identical 
objects then after an interval of three hours one object was replaced with a novel, 
unfamiliar object. The mouse was then returned to the arena and recorded for 5 min. 
The time spent exploring each object was measured and a recognition index was 
calculated. The recognition index is a ratio of the time spent with the novel object to the 
time spent exploring both objects. A recognition index of .5 means that there was no 
preference for the novel object. Using this memory test no differences were found 
between the four groups (Fig. 7.2). All groups showed a recognition index greater than .6 
indicating a preference for the novel object. These data indicate that 2 months after 
injury mice do not have deficits in memory function. 
 
7.2.3 Evidence of hyperactivity 2 months after CCI  
The open field test is both a measure of overall motor function and activity and a 
measure of anxiety [301]. Mice were placed in an unfamiliar 49 cm x 49 cm arena and 
behavior was recorded for 20 min. Both moderately (.5 mm) and severely (1.0 mm) 
injured mice traveled a greater distance than naïve mice and severely injured mice 
traveled more than craniotomy only sham controls (Fig 7.3A). Similarly both moderately 
and severely injured mice had increased velocity in the open field test relative to naïve 
controls (Fig. 7.3C). The open field test can also be used to measure anxiety, to do this 
the percent time spent in the center quadrant is calculated. Injured mice and controls 
showed no changes in anxiety by this test (Fig. 7.3B). In summary, injured mice showed 
increased activity and velocity in the open field test.  
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Figure 7.2 
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Figure 7.2 Normal memory function months after CCI. Memory was tested by novel 
object recognition in naïve, craniotomy only (Sham), moderate (0.5 mm) and severe (1.0 
mm) CCI. The mouse was familiarized to two identical objects, after 3 hours one of the 
familiar objects was replaced with a novel object. Exploration of the two objects was 
measured using Ethovision software (Noldus) and defined as the nose of the mouse 
within 2 cm of the object. The ratio of time spent exploring the novel object to time spent 
exploring both objects is shown as the recognition index. A recognition index of .5 
indicates no preference for the novel object. The mean ± SEM is shown, n = 8 per group. 
No significance was found by one way ANOVA (P = .53).   
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Figure 7.3 
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Figure 7.3 Increased activity in injured mice 2 months after CCI. Activity and anxiety 
were tested by novel object recognition in naïve, craniotomy only (Sham), moderate (0.5 
mm) and severe (1.0 mm) CCI two months after injury.  Each mouse was allowed to 
explore an open arena for 20 min. (A) The overall movement over the 20 min interval (B) 
The % time each mouse spent in the center quandrant. (C) The velocity over the 20 min 
interval. Movement of animals within the arena was recorded and movement and center 
frequency were calculated using Ethovision software (noldus) The mean ± SEM of each 
group are shown, n = 8. Overall movement (P = .0017), but not % time in center (P = 
.52), was significant by one-way ANOVA. *, P < .05; **, P < .01 from naïve. #, P < .05 
from sham.   
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7.2.4 Injured mice are disinhibited 2 months after CCI 
In order to investigate the anxiety-like phenotype of injured mice, elevated zero maze 
testing was performed. In this modified version of an elevated plus maze mice were 
recorded while they explore the open, exposed arms and the closed, protected arms 
[302]. Over the 6 min recording period the time spent in the closed arms and the number 
of entries into the closed arms was determined. Interestingly severely injured mice spent 
significantly more time in the open arms (Fig. 7.4). No changes were observed in exits 
from closed arms. The increased time spent in the open arms by severely injured mice 
suggests decreased anxiety or disinhibition.  
 
7.2.5 Lack of depressive phenotype 2 months after CCI  
Depressive-like behavior in mice can be measured by the tail suspension test [303, 304]. 
Mice were suspended from a metal rod by the tail 30 cm off the counter. The time spent 
immobile vs. the time spent struggling was scored by a blinded observer. An increase in 
time spent immobile is a marker of depressive-like behavior in mice. No changes were 
observed between the four experimental groups in time spent immobile (Fig. 7.5). Based 
on this measure we did not observe depressive-like behavior in mice 2 months after CCI.  
 
7.2.6 Sociality in mice 2 months after CCI  
To measure subtle changes in social interaction between injured mice and non-injured 
controls we performed a social interaction test [305]. Experimental mice were placed in a 
clean cage with fresh bedding. Immediately after placing the experimental animal in the 
cage, a second non-experimental size matched con-specific was placed in the same 
cage. The two mice were allowed to interact for 20 min while being recorded. A blinded 
observer scored the time spent in proximity and scored several pro-social and 
aggressive behaviors performed by the experimental animal. We found no changes in  
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Figure 7.4 
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Figure 7.4 Disinhibition in injured mice 2 months after CCI. Anxiety was tested in 
naïve, craniotomy only (Sham), moderate (0.5 mm) and severe (1.0 mm) CCI two 
months after injury using an elevated zero maze. (A) The duration of time spent in the 
open arms in seconds (B) The number of times all four paws exited the closed arms.  
Movement of animals within the elevated zero maze was recorded and time spent in the 
closed arms was calculated using Ethovision software (noldus) The mean ± SEM of 
each group are shown, n = 8. No differences were seen in the number of exits from 
closed arms by one way ANOVA (P = .065). *, P < .05 from naïve. 
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Figure 7.5 
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Figure 7.5 Lack of depression-like phenotype in injured mice 2 months after CCI. 
Depression was tested in naïve, craniotomy only (Sham), moderate (0.5 mm) and 
severe (1.0 mm) CCI two months after injury using a tail suspension test. Time spent 
immobile was scored. The mean ± SEM of each group are shown, n = 8. No significance 
was found by one-way ANOVA (P = .93).  
  
	   	   	  199 
any of the observed behaviors (Fig. 7.6). There was a trend towards increased 
aggressive behaviors in severely injured mice, but there was high variability between 
individual mice.  
 
7.2.7 No difference in hyperactivity or disinhibition at 6 months after CCI 
At 2 months after CCI, injured mice showed increased activity and increased time spent 
in the open arms of the elevated zero maze (EZM). To determine whether measured 
changes in hyperacitivity and disinhibition persisted these tests were repeated at 6 
months after CCI. At this time point no changes were observed between groups in 
movement, velocity, or time spent in the center quadrant as measured by the open field 
test (Fig. 7.7). Similarly we found no difference between groups in the elevated zero 
maze (Fig. 7.8). These data suggest that the hyperactive and disinhibited phenotype of 
injured mice at 2 months after injury does not persist to 6 months after injury.  
 
7.3 Discussion 
The main finding of this work was disinhibition and hyperactivity in mice 2 months after 
CCI. Increased levels of movement and velocity were observed in both moderate and 
severely injured mice relative to controls indicating increased exploratory behavior. 
Additionally, severely injured mice spent more time in the open arms of an elevated zero 
maze, indicating disinhibition.  
 Several other groups have observed hyperactivity or increased exploratory 
behavior in rodent models of TBI. Increased activity was found in a CCI model [306], and 
diffuse axonal injury models [307, 308] as well as models of mild TBI [262, 309]. A few 
studies have also found decreased activity, but this was either during the acute phase 
when motor impairment is still a confounding factor [310] or in very severe injury [299].  
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Figure 7.6 
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Figure 7.6 Sociality 2 months after TBI. Sociality was measured 2 months after TBI by 
a social interaction test with a weight-matched male conspecific. Naïve, craniotomy only 
(Sham), moderate (0.5 mm) and severe (1.0 mm) CCI were tested 2 months after injury. 
Time spent in proximity (A) was evaluated as well as frequency of various (B) pro-social 
and (C) aggressive behaviors performed by the experimental animal. The mean ± SEM 
of each group are shown n = 8 per group. No significance was found by one-way for any 
of the recorded behaviors or for proximity (P = .20).  
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Figure 7.7 
 
  
M
ov
em
en
t (
cm
)
Na
ive
 
Sh
am
 
0.5
 m
m
1.0
 m
m
0
5000
10000
15000
#
**
**
Ti
m
e 
in
 C
en
te
r (
%
)  
Na
ive
 
Sh
am
 
0.5
 m
m
1.0
 m
m
0
5
10
15
Ve
lo
ci
ty
 (c
m
/s
)
Na
ive
 
Sh
am
 
0.5
 m
m
1.0
 m
m
0
2
4
6
8
10
**
*
Na
ive
 
Sh
am
 
0.5
 m
m
1.0
 m
m
0
5000
10000
15000
M
ov
em
en
t (
cm
)
Na
ive
 
Sh
am
 
0.5
 m
m
1.0
 m
m
0
5
10
15
Ti
m
e 
in
 C
en
te
r (
%
)  
Ve
lo
ci
ty
 (c
m
/s
)
Na
ive
 
Sh
am
 
0.5
 m
m
1.0
 m
m
0
2
4
6
8
10
2 month 5 month 
A 
B 
C 
	   	   	  203 
Figure 7.7 No change in activity in injured mice 6 months after CCI. Activity and 
anxiety were tested by novel object recognition in naïve, craniotomy only (Sham), 
moderate (0.5 mm) and severe (1.0 mm) CCI six months after injury.  Each mouse was 
allowed to explore an open arena for 20 min. (A) The overall movement over the 20 min 
interval (B) The % time each mouse spent in the center quandrant. (C) The velocity over 
the 20 min interval. Movement of animals within the arena was recorded and movement 
and center frequency were calculated using Ethovision software (noldus) The mean ± 
SEM of each group are shown, n = 8. None of the parameters were significantly different 
by one-way ANOVA (Movement, P = .331; % in center, P =  .62).  
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Figure 7.8 
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Figure 7.8 No change in anxiety 6 months after CCI. Anxiety was tested in naïve, 
craniotomy only (Sham), moderate (0.5 mm) and severe (1.0 mm) CCI six months after 
injury using an elevated zero maze. (A) The duration of time spent in the open arms in 
seconds (B) The number of times all four paws exited the closed arms.  Movement of 
animals within the elevated zero maze was recorded and time spent in the closed arms 
was calculated using Ethovision software (noldus) The mean ± SEM of each group are 
shown, n = 8. No differences were seen in the number of exits from closed arms by one-
way ANOVA (Open arm duration, P = .070; exits from closed arms, P = .51).  
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Impulsivity and disinhibition are seen in human patients after TBI and are 
typically related to orbitofrontal injuries, but can also be related to injuries of the limbic 
system or the circuitry connecting these regions [68, 311]. To date, investigations into 
impulsivity or disinhibition in rodent models of TBI have been limited. Crane et al. 
showed deficits in impulse control using a stop-signal reaction time (SSRT) task after 
CCI injury to the medial prefrontal cortex, but this phenotype only persisted for 8 days 
post injury [312]. Bondi et al. showed changes in a CCI model using an attentional set-
shifting task, which measures executive functioning 4-weeks post injury [313]. In contrast 
to the EZM used in this study, both of these tests require complex training and testing 
paradigms that would be difficult to employ as part of a standard pre-clinical battery. 
However, they are more accurate and sensitive tests of impulse control than the EZM.  
The results of EZM testing or the closely related elevated plus maze (EPM) have 
rendered mixed results, some indicating disinhibition others anxiety [314]. Siopi et al. 
detected an increased number of head dippings after a closed-head, weight-drop injury 
model suggesting mild disinhibition 3.5 weeks after injury [315]. Washington et al. 
showed time spent in the open arms of the EPM 21 days after CCI was increased 
irrespective of injury severity [194]. Conversely Shultz et al. showed increased anxiety in 
a repeated fluid percussion injury model [316]. This diversity of findings on anxiety-like 
behaviors in pre-clinical models of TBI highlights the importance of injury model, 
species, and timing of behavioral testing on outcomes.  
There is a paucity of studies of TBI associated aggression in pre-clinical models. 
One study gave mice a TBI during adolescence then found development of an 
aggressive phenotype in adulthood [317]. The social-interaction test performed here is 
designed to limit aggressive behavior. This is done by the use of a size matched 
conspecific and a clean cage. Therefore it is surprising that we detected any aggressive 
behaviors. The increase in aggressive behaviors shown here, though highly variable, is 
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intriguing. There are much more sensitive tests of aggression in rodents, such as the 
resident-intruder test, which uses a smaller test animal in the experimental animal’s 
home cage. Also studies of aggression in rodents typically use strains prone to 
aggressive behavior. Performing testing of TBI models using both more sensitive testing 
and more appropriate strains and species would likely provide better modeling of TBI 
induced aggression. Further studies on TBI induced aggression could provide a new 
avenue to study the link between brain injury and aggression and develop improved 
treatment strategies.  
 
7.4 Summary: Taken as a whole these findings suggest a hyperactive and disinhibited 
phenotype of CCI mice in the chronic phase. Disinhibition or impulsivity is a well-
recognized feature of human TBI and can be associated with aggression [68]. 
Additionally, recent reports have linked TBI to increased risk of attention-deficit 
hyperactivity disorder in children [318] and adults [73]. This study shows that the CCI 
can model some of the long-term consequences of TBI. Future studies exploring the 
neuroanatomical and neurochemical correlates of these changes would further our 
understanding of TBI associated deficits and inform treatment strategies for TBI 
associated neuropsychiatric disorders.  
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Chapter 8: Conclusions 
 
Traumatic brain injury (TBI) is a disorder of interest and importance. While improved 
trauma care has improved survival from severe TBI, no treatment has led to improved 
outcomes [7]. Recently, miRNAs have emerged as modulators of neuroinflammation and 
injury [319]. While the roles of miRNAs in peripheral inflammation and injury are 
increasingly well defined [109], in the context of the brain far less is known. Beginning to 
define the expression and function of these inflammation-associated miRNAs in TBI was 
the goal of this work.  
To identify miRNA important to TBI induced neuroinflammation we used a mouse 
controlled cortical impact (CCI) model of TBI. We identified miR-155 as an inflammation-
associated miRNA that increased after CCI. Studies on miR-155 KO mice after CCI 
revealed altered cytokine and chemokine expression as well as increased microglial 
activation. However, we also identified several non-canonical roles for inflammation-
associated miRNA after CCI. Expression of both miR-155 and miR-21 was localized to 
neurons after CCI. Additionally the expression of miR-155 showed a nuclear expression 
pattern, suggesting it may have functions outside of traditional mRNA silencing. In other 
studies, we profiled miRNAs found in extracellular vesicles (EV) after CCI. We found 
changes in levels of EV-assoicated miRNAs, including increased levels of 3 miRNAs 
with GU rich sequences. GU rich sequences are important for TLR7/8 stimulation 
suggesting that these miRNAs could act as damage associated molecular patterns 
(DAMPS) in the context of CCI. Here we report that miRNA not only show altered 
expression, but also have functional roles in CCI. While miRNA do regulate inflammation 
in the context of CCI, they also have non-canonical roles both in neuronal nuclei and 
extracellular vesicles. Future work should focus not only on the ability of miRNA to 
silence target transcripts, but also consider a broader repertoire of functions for miRNAs 
in CNS inflammation and injury.  
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 We began by characterizing the pathology of the CCI model to identify promising 
anatomical regions to study the immune response after TBI, focusing on the injured 
cortex and underlying hippocampus. We found frank tissue loss and apoptotic cell death 
in the injured cortex, but not the hippocampus. However we found increased expression 
of glial markers Iba1 and GFAP in both the injured cortex and the ipsilateral 
hippocampus. Additionally, neuropathology was evident in both the cortex and 
hippocampus on the injured side, shown by damage-associated markers in 
neurofilaments, white mater degeneration, and accumulation of neuronal markers MAP2 
and synaptophysin. Therefore, we chose to study expression and function of 
inflammation-associated miRNAs in the hippocampus.  
 A panel of inflammation-associated miRNAs was chosen based on known roles 
in inflammation and identification by at least one miRNA profiling experiment in TBI 
models. The temporal expression of these miRNAs was measured over the acute and 
sub-acute phases of CCI using qPCR. Distinct temporal profiles were found for all the 
miRNAs examined. Expression of miR-155 was elevated in the acute phase up to 7 days 
after CCI, conversely miR-21 was only elevated in the sub-acute phase at 14 days after 
injury. Interestingly, miR-223 only showed a limited, acute expression. Given that miR-
223 is highly linked to neutrophils, we hypothesize that the expression of miR-223 in the 
brain may be linked to invading neutrophils, which show a similar pattern of acute 
response to TBI as found in spinal cord injury. Expression of miR-223 in neutrophils 
could explain the acute expression pattern seen for miR-223 in TBI, but would need 
verification in future studies. Surprisingly, miR-146 did not show a significant increase in 
TBI. Expression of miR-146 is induced by NF-κB and important to for inflammation 
resolution in the periphery through feedback inhibition [120]. The lack of miR-146 
induction could be pathological in TBI, leading to a prolonged and damaging 
inflammatory response.  
	   	   	  210 
To further characterize expression of miR-155, miR-21, and miR-223 we 
performed fluorescent in situ hybridization (FISH), which confirmed our qPCR findings. 
Interestingly the expression pattern of miR-155 was primarily nuclear. While at one time, 
nuclear expression was thought to indicate inactivity of miRNA, new studies are finding 
unique roles for nuclear miRNA in regulation of gene expression [105]. The expression 
pattern of miR-21 was also of interest. 7 days after injury miR-21 expression was found 
in regions of the hippocampus primarily composed of neuronal cell bodies and 
processes. In later experiments using combined immunofluorescence and FISH, we 
confirmed neuronal localization of miR-21. 
To identify which miRNAs were most associated with inflammation we measured 
levels of pro-inflammatory miRNA after CCI and correlated their expression with 
inflammation-associated miRNAs. In contrast to the expression of inflammation-
associated miRNAs, pro-inflammatory cytokines IL-6, TNFα, and IL-1β all peaked 1 day 
after injury. Although nearly all combinations of cytokines and miRNAs showed 
significant correlation, the association between miR-155 and IL-1β was the strongest. 
These studies were performed using a moderate CCI, 0.5 mm injury depth. To 
determine whether increasing injury severity would increase expression of inflammation-
associated miRNAs and cytokines we compared naïve, sham, moderate (0.5 mm), and 
severe (1.0 mm) injuries three days after injury. Severely injured mice had more robust 
expression of inflammation-associated miRNAs and cytokines 3 days after CCI. In 
addition, we increased the panel of inflammatory mediators examined to include 
additional cytokines, chemokines, and growth factors. Using this extended panel, we 
found IL-1β, TNFα, and chemokine CXCL10 to be strongly induced 3 days after CCI.  
To examine the role of miR-155 in TBI we acquired miR-155 KO mice. After CCI 
miR-155 KO mice showed no measurable motor or cognitive deficits in the acute and 
sub-acute time frames after CCI. Additionally, no changes in hippocampal apoptosis or 
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neurodegeneration were found between miR-155 KO and WT mice. However, we did 
find decreased interferon (IFN) expression in miR-155 KO mice after TBI, including 
decreased levels of IFN regulated chemokine CXCL10. We also found a decrease in 
anxiety after CCI in miR-155 KO mice relative to WT mice. The link between IFNs and 
mood disorders is well established, and patients administered IFNs show sickness 
behavior and mood disorders [229]. Together these data suggest that miR-155 affects 
the IFN response, and we speculate that this may alter mood disruptions after TBI. The 
mechanisms by which regulates IFN and CXCL10 expression is unknown. While we find 
miR-155 in neurons, the source of IFN and CXCL10 are unknown. Others have found 
that small populations of invading peripheral immune cells express CXCL10 in TBI, in 
clusters that appear to be dendritic cells [226]. 
Suppressor of cytokine signaling 1 (SOCS1) is a known target of miR-155 [206] 
and a negative regulator of the IFN response [209]. Therefore, in miR-155 KO mice we 
hypothesized that SOCS1 levels would be increased, leading to the observed decrease 
in IFN signaling. However the levels of SOCS1 in hippocampal homogenate were 
unchanged at the protein level. Still we note that while there were no changes in the 
hippocampus as a whole, levels in individual cells may still be altered. Expression of 
SOCS1 mRNA was decreased slightly but significantly in miR-155 KO mice, the 
opposite of what would be expected if miR-155 targeted SOCS1 mRNA in a cell type 
expressing both molecules. Thus it is unlikely that alterations in SOCS1 play a role, at 
least on the level of the whole hippocampus  
We also found in the miR-155 KO mice subjected to TBI there was an increase in 
Iba1 expression indicating increased microglial activation. Other groups have shown that 
miR-155 is pro-inflammatory in microglia and that reducing miR-155 leads to decreased 
levels of microglial marker CD11b, interpreted as decreased microglia activation [210]. 
Our findings suggest an opposite role for miR-155 in microglial activation after TBI, since 
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in fact, increased microglial activation was observed in miR-155 KO mice. Therefore it is 
possible that miR-155 does play a role in the microglial response, but in a different 
manner depending on the biological and pathological setting..  
To further explore the role of miR-155 in TBI we examined the cell-type specific 
localization of miR-155 in the brain after CCI. We found that miR-155 was highly 
expressed in neuronal nuclei. Whether this expression is linked to the observed changes 
in IFN and CXCL10 expression or anxiety remains to be determined. In viral infections of 
the brain CXCL10 is expressed in neurons [215, 216]. This suggests the possibility that 
miR-155 regulates expression of CXCL10 in neurons after CCI. However, nuclear 
expression is often associated with non-cannonical functions of miRNAs [320]. Future 
studies should address the role of nuclear miR-155 expression in neurons.  
We have discovered that miR-155 regulates the IFN response after TBI including 
TBI induced chemokine CXCL10. We have also shown that miR-155 contributes to 
anxiety after TBI, likely through the IFN response. Further studies are needed to 
determine the exact mechanism of miR-155 regulation of the IFN response and which 
cell types are responsible.  
Another miRNA of interest is miR-21. Increased expression of miR-21 has been 
seen in many types of neuronal injury [321], and we detected miR-21 in the sub-acute 
phase of CCI. Due to the various roles of miR-21 in neurons we characterized its 
expression in development, induction by neurotrophic cytokines, and role in neuronal 
function. The expression of miR-21 in the brain increases during development in mice 
from embryonic day 14 to postnatal day 14. However, different neuronal model systems 
had divergent expression patterns during differentiation. Expression in was higher in 
cultured human NPC than human neurons, but no change was found in mouse NPC and 
neurons, and conversely differentiated SH-SY5Y neuroblastoma cells showed higher 
expression of miR-21 than undifferentiated cells. To study the induction of miR-21 we 
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used cultured human neurons. We found that neurotrophic cytokines IL-6 and CNTF 
could induce miR-21. Additionally, we showed that IL-6 could stimulate STAT3 activation 
in human neurons, though not with the same magnitude as CNTF. The expression of IL-
6 receptor in neurons depends highly on neuronal type and species. Novel findings 
include the discovery that IL-6 treatment of fetal human neurons can induce STAT3 
signaling. Another novel finding is the induction of miR-21 in human neurons and to that 
miR-21 is induced by IL-6 and CNTF. Inhibitors of the Jak-Stat pathway did not inhibit 
miR-21 expression and levels of primary miR-21 were not elevated after treatment with 
IL-6 and CNTF. Future studies should examine alternative mechanisms of miR-21 
induction by neurotrophic cytokines. Even though the mechanism is not understood, the 
induction of miR-21 by these neurotrophic cytokines may explain why so many types of 
neuronal injury increase miR-21 expression.  
The function of miR-21 in the healthy brain is unknown. Previous data from our 
lab indicated that pathologically increased miR-21 could alter potassium currents in 
neurons [231]. However, we found that long-term potentiation, a correlate of learning 
and memory was not altered in miR-21 KO mice. Additionally, miR-21 targets PTEN and 
downstream phosphorylation of Akt were not changed in miR-21 KO mice. Together we 
could not identify a role for miR-21 in normal neuronal function. To determine whether 
miR-21 was neuroprotective in the context of injury, we utilized an in vitro model of 
excitotoxicity. Again, we did not detect any differences between miR-21 KO and WT 
neurons. Finally, we tested the importance of miR-21 in TBI by administering CCI to 
miR-21 KO mice and controls. We found no differences in function or in neuronal 
degeneration in miR-21 KO and WT mice. It is possible that miR-21 may play a role in 
neuronal development and neuroprotection, but that miR-21 KO during development 
induces compensatory mechanisms. To address this issue in the future we developed a 
mouse strain with a floxed miR-21 allele. In this stain two LoxP sites surround the miR-
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21 stem loop. Cre recombinase can cause recombination at these LoxP sites resulting in 
gene deletion. Therefore to induce conditional deletion of the miR-21 gene, Cre can be 
introduced virally or through a tissue specific promoter. These mice can be used to 
further study the role of miR-21 in neuronal development and injury.  
While miRNA are known to regulate gene expression in the cell, new evidence 
shows that miRNA may also be transferred between cells in extracellular vesicles (EVs). 
EVs containing miRNA can affect the recipient cell by decreasing mRNA expression in 
the cytosol [278] or binding to PRRs in the endocytic compartment [276]. In immune 
cells TLR7/8 recognizes viral RNA and miRNA and produces an inflammatory response 
[289]. Neurons also express TLR7/8 and activation of this receptor can be neurotoxic 
[177]. We isolated EVs from brains 7 days after CCI to examine the changes in EV-
associated miRNA (EV-miRNA). Small RNA sequencing showed changes in the EV-
miRNA profile after CCI. We found that miR-21, miR-146, miR-7a and miR-7b were 
elevated in EVs after CCI. One miRNA, miR-212 was down regulated. Three of the 
differentially expressed miRNA contain GU rich sequences that mediate TLR7/8 binding 
[282]. Of the differentially expressed miRNAs miR-21 showed the largest change. In situ 
hybridization combined with immunofluorescence, localized miR-21 to neurons near the 
lesion boundary. We also found reactive microglia adjacent to miR-21 expressing 
neurons suggesting that EV-associated miR-21 may be important for neuron-glia 
communication in TBI. While EV-miRNA can elicit immune responses [276] and 
neurotoxicity [177] in vitro and several studies have shown that EV-miRNA are altered in 
neurological disease [177, 288], the overall effect of this mechanism on disease 
pathology is still unclear. TBI may serve as a useful model to study the importance of 
EV-miRNA signaling through TLR7/8 on neuroinflammation.  
Neuropsychiatric dysfunction is a common consequence of TBI [66, 322, 323]. 
However, mechanisms of long-term dysfunction in TBI patients are unclear. One 
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difficulty in performing these types of mechanistic studies is the lack of a defined 
neuropsychiatric phenotype of mice in the chronic phase of TBI. Here we used a battery 
of neuropsychological tests to determine the phenotype of mice in the chronic phase of 
TBI. We found no evidence of motor or cognitive dysfunction, but did detect hyperactivity 
and disinhibition at 2 months after CCI, primarily in severely injured mice. Disinhibition is 
classically found in frontal lobe injuries [68]. Given that the lesion in our model primarily 
involves the parietal cortex and underlying hippocampus, how this injury induces 
disinhibition is unclear. A recent report identified a high degree of long-range inputs to 
the prefrontal cortex in mouse [324]. It is possible that diffuse axonal injury may disrupt 
these inputs. We currently have studies in progress to elucidate the pathological 
correlates to these behavioral changes. These studies will examine the presence of 
neuroinflammation in the prefrontal cortex after CCI using immunohistochemistry and 
determine CCI changes in connectivity using diffusion tensor (DT) magnetic resonance 
imaging (MRI) and tractography.  
In conclusion, this work has furthered the understanding of miRNA expression 
and function in TBI. While study of miRNAs in peripheral inflammation and injury has 
focused on regulation of cytokine signaling and immune cell function, we have found 
multi-faceted roles for miRNAs in brain injury. Changes in cytokine, chemokine, and glial 
activation were observed in miR-155 KO mice indicating that miRNAs are involved in 
neuroinflammation after TBI. Additionally, neuronal, nuclear, and EV-associated miRNAs 
were identified highlighting non-canonical roles for inflammation-associated miRNAs in 
TBI. Finally, we have identified disinhibition and hyperactivity in the chronic phase of 
CCI. Together these studies suggest an important role for miRNA in TBI and 
neuroinflammation. Based on this work we have identified several topics of interest for 
future studies of TBI: 1) The roles of inflammation-associated miRNAs in neurons, 
including the function of miR-155 in neuronal nuclei 2) The mechanistic link between 
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miR-155 expression, IFN expression, and anxiety after TBI 3) The effect of changes in 
EV-miRNA expression after TBI, especially in TLR7/8 activation and 4) The pathological 
correlates of disinhibition and hyperactivity in the chronic phase of the CCI mouse 
model. 
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